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Cynthia A. Morgan 
 
IDENTIFICATION AND CHARACTERIZATION OF SMALL MOLECULE 
INHIBITORS OF ALDEHYDE DEHYDROGENASE 1A1 
 
The human genome encodes 19 members of the aldehyde dehydrogenase (ALDH) 
superfamily, critical enzymes involved in the metabolism of aldehyde substrates. A major 
function of the ALDH1A subfamily is the oxidation of retinaldehyde to retinoic acid, a 
key regulator of numerous cell growth and differentiation pathways. ALDH1A1 has been 
identified as a biomarker for both normal stem cells and cancer stem cells. Small 
molecule probes are needed to better understand the role of this enzyme in both normal 
and disease states. However, there are no commercially available, small molecules that 
selectively inhibit ALDH1A1. Our goal is to identify and characterize small molecule 
inhibitors of ALDH1A1 as chemical tools and as potential therapeutics. To better 
understand the basis for selective inhibition of ALDH1A1, we characterized N,N-
diethylaminobenzaldehyde (DEAB) which is a commonly used inhibitor of ALDH1A1 
and purported to be selective. DEAB serves as the negative control for the Aldefluor 
assay widely utilized to identify stem cells. Rather than being a selective inhibitor for 
ALDH1A1, we found that DEAB is a slow substrate for multiple ALDH isoenzymes, and 
depending on the rate of turnover, DEAB behaves as either a traditional substrate or as an 
inhibitor. Due to its very slow turnover, DEAB is a potent inhibitor of ALDH1A1 with 
respect to propionaldehyde oxidation, but it is not a good candidate for the development 
of selective ALDH1A1 inhibitors because of its promiscuity. Next, to discover novel 
 vii 
 
selective inhibitors, we used an in vitro, high-throughput screen of 64,000 compounds to 
identify 256 hits that either activate or inhibit ALDH1A1 activity. We have characterized 
two structural classes of compounds, CM026 and CM037, using enzyme kinetics and X-
ray crystallographic structural data. Both classes contained potent and selective inhibitors 
for ALDH1A1. Structural studies of ALDH1A1 with CM026 showed that CM026 binds 
at the active site, and its selectivity is achieved by a single residue substitution. 
Importantly, CM037 selectively inhibits proliferation of ALDH+ ovarian cancer cells. 
The discovery of these two selective classes of ALDH1A1 inhibitors may be useful in 
delineating the role of ALDH1A1 in biological processes and may seed the development 
of new chemotherapeutic agents.       
 
Thomas D. Hurley, Ph.D., Chairman 
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I. Introduction 
A. Aldehydes 
Aldehydes are organic compounds with the general formula 
RCHO, with CHO representing a terminal carbonyl group 
and the R group ranging from a hydrogen atom to complex 
organic compounds (Figure 1). They are found extensively 
in the environment and are products of numerous biological 
pathways. Although small reserves of aldehydes exist 
naturally, such as the production of formaldehyde from the photochemical oxidation of 
methane in the atmosphere, most exogenous sources of aldehydes have an anthropogenic 
origin. Motor vehicle exhaust is a leading contributor, releasing formaldehyde, 
acetaldehyde, and acrolein as well as other carbonyls, plus hydrocarbons that can undergo 
photochemical oxidation to aldehydes. Aldehydes are used or released in a variety of 
industrial applications, including the production of plastics and resins, and in agriculture 
as both a preservative in animal feed and fumigant for pest control. The indoor 
environment is estimated to have a 4- to 10-fold higher level of aldehydes than outdoor 
air, with cigarette smoke, furniture, paints, cleaning agents, and cooking fumes all 
contributing to the aldehyde load
1
. Aldehydes, such as citral, acetaldehyde, and 
benzaldehyde, are found naturally or added to foods and beverages. A number of drugs 
are metabolized via an aldehyde intermediate, including ethanol, the cancer drug 
cyclophosphamide
2,3
, the sedative chloral hydrate
4
, and the reverse transcriptase inhibitor 
Abacavir
5
. Endogenously, lipid peroxidation, the oxidative degradation of membrane 
lipids, is estimated to produce over 200 aldehydes, including 4-hydroxynonenal (4-HNE) 
and malondialdehyde (MDA)
6
. Aldehydes are also produced during both amino acid and 
carbohydrate metabolism, generating glyceraldehyde, glycolaldehyde, methylglyoxal, 
and glutamic-γ-semialdehyde. Common sources of aldehydes are summarized in Table 1. 
 
Aldehydes play vital roles in normal biological processes. The retinaldehyde 11-cis-
retinal binds the protein opsin, forming the photoreceptor rhodopsin that is critical for 
animal vision
7
. Retinaldehydes are also the precursors to retinoic acids, with both 
substrate and product serving as ligands of the retinoic acid and/or retinoic-X receptors 
 
Figure 1: Aldehyde 
 
 
 2 
 
(RAR and RXR), transcription factors that are critical for cellular growth and 
differentiation pathways
8
. Glyceraldehyde-3-phosphate is an intermediate in glycolysis 
and gluconeogenesis, as well as in photosynthesis, serving as a vital component of 
cellular energy homeostasis
7
.  
 
Although aldehydes are critical for biological functions, the electrophilic carbonyl group 
is highly reactive, and aldehydes are capable of forming adducts with various cellular 
components including proteins, nucleic acids, and glutathione (GSH), leading to 
dysfunction and cell death. Unlike reactive oxygen and nitrogen species, aldehydes have 
relatively long lifespans, and they can be transported or diffuse to sites far removed from 
where they are produced. Protein carbonylation is the formation of a covalent adduct 
between an aldehyde and a protein involving either a Schiff base formation via the ε-
amino of lysine or a Michael addition to cysteine, histidine, or lysine (Figure 2)
9,10
. 
Moderate carbonylation can be processed by the cell, but as the load of carbonylated 
proteins increases, they can aggregate and resist proteolysis, leading to protein 
dysfunction, cell death, and ultimately contribute to disease progression
11
. Protein 
carbonylation is elevated during oxidative stress, a process that generates numerous toxic 
aldehydes, and is associated with many diseases including rheumatoid arthritis, 
cardiovascular disease, Parkinson’s disease, and Alzheimer’s disease. Aldehydes and 
Table 1: Common sources of exogenously and endogenously produced aldehydes. 
Exogenous Source Aldehyde  
  Foods & Beverages   Benzaldehyde, crotonaldehyde, acrolein, acetaldehyde 
  Combustion   Formaldehyde, acetaldehyde, acrolein 
  Cigarettes   γ-3-Pyridyl-γ-methylaminobutyraldehyde, formaldehyde 
    
Endogenous Source Aldehyde 
  Lipid peroxidation   4-hydroxynonenal, malondialdehyde, hexanal 
  Vitamin A metabolism   Retinaldehyde 
  Dopamine catabolism   3,4-Dihydroxyphenylacetaldehyde 
  Corticosteroid catabolism   21-Dehydrocorticosteroids 
  Proline biosynthesis   Glutamic- γ-semialdehyde 
  Sorbitol metabolism   Glycolaldehyde, glyceraldehyde, glyoxal 
  Putrescine catabolism   γ-amino butyraldehyde 
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other carbonyls have been shown to inactivate glutathione reductase, glutathione 
peroxidase, and glutathione transferases, increasing cellular oxidative stress
1
. Aldehydes 
can also form adducts with DNA, leading to DNA-DNA and DNA-protein crosslinks, 
mutagenesis, chromosomal aberrations and other DNA damage (Figure 3)
12
. Cellular 
defense mechanisms exist to minimize damage, and mutations in these repair pathways 
have been linked to increased cancer rates
12,13
.  
 
 
Figure 2: Protein carbonylation. 
Formation of a covalent adduct between an aldehyde and a protein. Lipid peroxidation 
produces numerous aldehydes, including  4-HNE, which is capable of forming 
adducts, most often on histidine, lysine, and cysteine residue of the protein (modified 
from Curtis et al
9
 and Ross et al
10
). 
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Due to the cytotoxic nature of aldehydes, their detoxification is critical for cellular 
homeostasis. To decrease the aldehyde burden in a cell, aldehydes are reduced to an 
alcohol, oxidized to an acid, or eliminated via the antioxidant glutathione. The main 
aldehyde reduction enzyme systems are alcohol dehydrogenases and aldo-keto 
reductases, while the main aldehyde oxidation enzyme systems are aldehyde/xanthine 
oxidase and aldehyde dehydrogenase (Figure 4). Alcohol dehydrogenases catalyze the 
reversible reduction of aldehydes and ketones to an alcohol, with the direction heavily 
dependent on the NAD
+
 to NADH ratio; given the 500:1 ratio of NAD
+
 to NADH 
commonly found in cells, the oxidation of an alcohol to a carbonyl is the dominant 
reaction
14,15
. The aldo-keto reductase superfamily also catalyzes the reversible reduction 
of a carbonyl to its corresponding alcohol, and this superfamily plays a large role in the 
removal of reactive aldehydes and other carbonyl-containing organic compounds
16
. 
Aldehyde and xanthine oxidase metabolize a variety of aromatic and heterocyclic 
aldehydes to their corresponding carboxylic acid
17
. The aldehyde dehydrogenase 
superfamily catalyzes the irreversible, NAD(P)
+
-dependent oxidation of an aldehyde to 
its corresponding carboxylic acid or ester CoA
18
. Finally, reactive aldehydes are also 
eliminated via conjugation to the tripeptide glutathione
19
. Although all these pathways 
contribute to reducing the cellular aldehyde burden, the aldehyde dehydrogenase 
superfamily is capable of oxidizing a wide-variety of aldehyde substrates, both aliphatic 
and aromatic, and plays a critical role in both the cellular protection from reactive 
aldehydes and the generation of biologically important compounds. 
 
Figure 3: Aldehyde-induced DNA damage (modified from Brooks et al 
12
). 
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B. The Aldehyde Dehydrogenase Superfamily 
Members of the aldehyde dehydrogenases (ALDH) superfamily of enzymes are found in 
all three taxonomic domains, Archaea, Eubacteria, and Eukarya, indicating that this 
superfamily of proteins plays a critical evolutionary role
20
. The Ninth International 
Symposium on Enzymology and Molecular Biology of Carbonyl Metabolism established 
a standardized gene nomenclature system for the ALDH superfamily based on divergent 
evolution and amino acid identity (Figure 5)
21
. Members of the same ALDH family have 
more than 40% protein sequence identity, while members of the same subfamily have 
more than 60% protein sequence identity. A nomenclature exception has been made for 
ALDH2, an enzyme involved in ethanol metabolism with an immense presence in the 
literature record. ALDH2’s longstanding name has been grandfathered in despite its 
amino acid sequence placing it in the ALDH1A subfamily. Currently the eukaryotic 
ALDH superfamily has 24 families, with 11 families represented in the human genome
22
. 
The human genome contains at least 19 ALDH genes, most of which catalyze the 
 
Figure 4: Aldehyde detoxication enzymes. 
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NAD(P)
+
-dependent oxidation of a wide 
variety of endogenous and exogenous 
aldehydes to their carboxylic acids. ALDHs 
differ in their tissue distribution, subcellular 
location, structure, and substrate preference. 
They are found in numerous subcellular 
locations, including the cytoplasm, 
mitochondria, endoplasmic reticulum, and the 
nucleus. ALDHs are critical enzymes in 
biological functions, as well as in the defense 
against toxic aldehydes
23
. Through their role in aldehyde oxidation, ALDHs are involved 
in the synthesis of a number of key molecules, including retinoic acid, betaine, and 
tetrahydrofolate, as well as the removal of toxic aldehydes. A second enzymatic role for 
ALDHs is the hydrolysis of esters, although the physiological importance of its esterase 
activity is not well understood
24
. Some members of the ALDH superfamily have 
functions removed from an enzymatic role. ALDHs in ocular tissue act as crystallins, 
structural proteins capable of protecting the eye by absorbing ultraviolet radiation, while 
others serve as binding proteins for hormones and other small molecules
6
. A summary of 
the 19 human ALDH proteins is shown in Table 2. 
 
Due to their involvement in a variety of physiological processes, mutations in human 
ALDH genes have been linked to a number of diseases (Table 2). The ALDH1A 
subfamily of proteins, via their production of retinoic acid, is critical during 
embryogenesis, and mutations in this subfamily have been associated with congenital 
heart disease and spina bifida
6,25
. As crystallin proteins, ALDH1A1 and ALDH3A1 
protect ocular tissue from reactive oxygen species and absorb damaging UV 
radiation
26,27
. ALDH1A1
-/-
 and ALDH3A1
-/-
 single knockout mice as well as the 
ALDH1A1
-/-
 / ALDH3A1
-/-
 double knockout mice had premature cataract formation
28
. 
ALDH2 plays a major role in the detoxication of aldehydes in response to ischemia and 
of acetaldehyde during ethanol metabolism
6
. Mutations in the ALDH2 gene can lead to 
alcohol flushing syndrome following alcohol consumption due to elevated blood 
 
Figure 5: ALDH Nomenclature 
Members of the same family have 
>40% protein sequence identity; 
members of the same subfamily share 
> 60% identity. 
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acetaldehyde levels
29
. ALDH1A1 and ALDH2 are both involved in dopamine 
metabolism, a neurotransmitter linked to Parkinson’s disease30 and drugs of addiction31. 
It is common for mutations in ALDH genes to result in neurological defects. Mutations in 
the ALDH5A1 gene, the last step in the metabolism of the neurotransmitter GABA, are 
responsible for the autosomal recessive disorder γ-hydroxybutyric aciduria, marked by 
neurological and cognitive defects
32
. ALDH3A2, is involved in the oxidation of fatty 
alcohols to fatty acids, and mutations in this gene are associated with Sjӧgren-Larsson 
syndrome, an autosomal recessive disorder that causes skin, eye, and neurological 
problems
33
. ALDH4A1 is involved in proline degradation and mutations cause type II 
hyperprolinemia, marked by mental retardation and seizures
34
. ALDH18A1 is important 
for proline and arginine synthesis, with mutations resulting in low levels of these critical 
amino acids, characterized by metabolic and neurological disorders, including 
hypoprolinemia
35
. Several ALDH isoenzymes (ALDH1A1, ALDH1A2, ALDH1A3, 
ALDH1L1, ALDH2, ALDH3A1, ALDH4A1, and ALDH7A1) have been associated with 
cancer, and over-expression of ALDHs in cancer cells is linked to poor prognosis and an 
increased resistance to certain cancer drugs, including cyclophosphamide, that utilize 
ALDHs for drug metabolism
3,6
. In mammals and fish, ALDH16A1 is unique as the active 
site lacks key catalytic residues, rendering this enzyme inactive with respect to aldehyde 
oxidation; however, ALDH16A1 may function as a binding protein and has been linked 
to gout
36
. 
 
The primary function of almost all ALDHs is the oxidization of a wide range of 
aldehydes to their corresponding carboxylic acid or to CoA esters utilizing the cofactor 
NAD(P)
+
. However, early sequence alignment of 145 ALDHs indicated only a limited 
number of residues are conserved in catalytically active enzymes, including the catalytic 
cysteine and residues involved in cofactor binding
37
. Using the mature ALDH2 sequence 
as reference, Cys302 is the active site nucleophile
38
 while Glu268 acts as a general 
base
39
. The basic mechanism of the reaction catalyzed by ALDHs is shown in Figure 6A. 
The aldehyde oxidation mechanism starts with binding of the cofactor NAD(P)
+
 and 
concludes with release of the reduced cofactor, but there are differences in the rate-
limiting step among the different ALDH enzymes. For example, the rate-limiting step for 
 8 
 
A. Aldehyde oxidation     B. Ester hydrolysis 
 
Figure 6: Mechanisms of aldehyde oxidation and ester hydrolysis of ALDH. 
A) Aldehyde oxidation occurs in five steps: 1. catalytic cysteine (Cys302) activated by 
water-mediated proton abstraction by glutamate (Glu268), 2. nucleophilic attack on 
the carbonyl carbon of the aldehyde by the thiolate group of Cys, 3. formation of a 
tetrahedral thiohemiacetal intermediate and hydride transfer to the cofactor NAD(P)
+
, 
4. Glu activates a water molecule that attacks the carbonyl carbon of the thioester-
enzyme complex, 5. formation of tetrahedral intermediate that rearranges to release 
the carboxylic acid, release of cofactor, and regeneration of activated enzyme by 
binding cofactor. B) Ester hydrolysis is proposed to use the same active site residues 
but not require the NAD(P)
+
 cofactor. 1. Cys
 
is activated by water-mediated proton 
abstraction by Glu, 2.  thiolate group of Cys attacks the carbonyl carbon of the ester 
substrate forming an oxyanion intermediate, 3. rearrangement of intermediate results 
in cleavage and release of an alcohol, 4. Glu
268
 activates a water molecule that attacks 
the carbonyl carbon of the thioester-enzyme complex, 5. formation of tetrahedral 
intermediate that rearranges to release the carboxylic acid product and activated 
enzyme with activated cysteine. For step 1 in both reactions, the cysteine may be 
activated by glutamate directly rather than via an activated water. 
 
 
the ALDH1A subfamily is cofactor dissociation, deacylation for ALDH2, and hydride 
transfer for ALDH3A1
40-42
. Many ALDHs also possess an NAD(P)
+
-independent esterase 
activity
24
, and this esterase activity is proposed to use the same active site as 
dehydrogenase activity (Figure 6B)
43
.  
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The structure of mammalian ALDHs are similar, functioning as multimers, with each 
subunit containing a catalytic domain, a cofactor binding domain, and an oligomerization 
domain (Figure 7)
23
. The global structural similarities support identical active site 
residues whose contributions to aldehyde oxidation are well established. The first crystal 
structure of an ALDH was determined in 1997 for rat ALDH3A1, a homodimer (PDB 
Code 1AD3)
44
, with the structure of the first homotetramer solved shortly afterwards for 
bovine ALDH2 (PDB Code 1AG8)
45
. The first human structure was determined in 1999 
(PDB Code ICW3)
46
. To date, the structures of seven human ALDHs have been 
determined (ALDH2, ALDH3A1, ALDH3A2, ALDH4A1, ALDH5A1, ALDH7A1, and 
ALDH18A1). The enzyme’s active site is in a tunnel that is supported by monomer 
oligomerization, with the cofactor binding site at one end of the tunnel and the substrate 
binding site at the other end of the tunnel. Despite similarities in structure and function, 
the isoenzymes of the ALDH family of proteins have evolved to recognize different 
spectrums of aldehyde substrates due to differences in the size and shape of their 
respective substrate binding sites
23,47
.  
 
 
A.                                                                 B. 
 
Figure 7: Ribbon diagram of the ALDH2 monomer and homotetramer. 
A) Monomer showing the cofactor in green, the substrate crotonaldehyde in blue, and 
the active site Cys-302 in red (PDB Code 1O01). B) ALDH2 homotetramer with each 
monomer a different color (PDB Code 3N80). 
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C. Aldehyde Dehydrogenase 1A1  
ALDH1A1 (retinaldehyde dehydrogenase 1, RALDH1) is a highly conserved, cytosolic 
homotetramer (~55 kDa monomers) that is constitutively expressed in numerous tissues, 
including brain, liver, kidneys, adipose, eye lens and retina. ALDH1A1 homologs are 
present in most vertebrae species analyzed, but are absent in Zebra fish and other fishes 
in the teleost lineage
20
. A key role of ALDH1A1 is the oxidation of retinal 
(retinaldehyde) to retinoic acid (RA), forming transcriptional regulators critical for 
normal cell growth and differentiation
48
. Both the substrate (retinal) and product (RA) are 
important for normal biological processes, including vision, cellular differentiation, and 
immune function
6
. Other aldehydes oxidized by ALDH1A1 include acetaldehyde during 
ethanol metabolism, 3,4-dihydroxyphenylacetaldehyde (DOPAL) in dopamine 
metabolism, and (±)-4-hydroxy-2E-nonenal (HNE), a toxic by-product of oxidative 
stress. ALDH1A1 also has non-catalytic roles, functioning as structural proteins in eye 
tissue and as a binding protein for various compounds
22
. In mammalian eye tissue, 
ALDH1A1, along with other ALDHs, act as corneal and lens crystallins
49
. In this 
capacity, ALDH1A1 contributes to the transparent and refractive properties of eye tissue, 
as well as protecting the tissue from ultraviolet radiation damage
22,50
. As a binding 
protein, ALDH1A1 functions as an androgen-, thyroid hormone-, and cholesterol-binding 
protein and is also capable of interacting with such drugs as quinolone, daunorubicin, and 
flavopiridol
22,51,52
. ALDH1A1 shares greater than 70% sequence identity to both 
ALDH1A2 and ALDH1A3 (RALDH2 and RALDH3, respectively) and both also convert 
retinal to RA, but their roles may be more confined to embryogenesis and stem cell 
development
53,54
. ALDH1A1 knockout mice are viable, but ALDH1A2 and ALDH1A3 
knockout mice are embryonic or perinatal lethal, respectively, with ALDH1A2
-/-
 
characterized by heart defects and death at midgestation, and ALDH1A3
-/-
 characterized 
by nasal and ocular defects, leading to respiratory failure shortly after birth
55
. ALDH1A1 
can catalyze the oxidation of multiple retinal isomers (all-trans-, 9-cis-, and 13-cis-reinal) 
with Km values ranging from 2 – 6 µM
56
. Both ALDH1A2 and ALDH1A3 prefer the all-
trans isomer, but can catalyze the oxidation of the cis-isomers
6
. A fourth retinaldehyde 
dehydrogenase, ALDH8A1, shares only 40% protein sequence identity with ALDH1A1 
and prefers 9-cis-retinal
57
. The resulting retinoic acid products, as well as other retinoids, 
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act as ligands for the retinoic acid and retinoic X receptors (RAR and RXR, respectively). 
RAR and RXR are members of the nuclear hormone receptor superfamily, ligand-
activated gene regulatory proteins (Figure 8)
58
. The retinoid signaling molecule enters the 
target cell, binds to the receptor, and activates it. Next, the ligand-receptor complex binds 
to a specific DNA sequence, the retinoic acid response element (RARE), in the promoter 
region of a gene, regulating its expression and affecting cellular phenotype. RAR and 
RXR act as homo- and heterodimers both with other RARs and RXRs as well as other 
nuclear receptors, including thyroid hormone receptors, peroxisomal proliferator 
activated receptors (PPAR), and glucocorticoid receptors, enabling great diversity and 
complexity in the signaling process
59
. Retinoid metabolism and signaling via their 
nuclear receptors are involved in such fundamental biological processes as 
embryogenesis, cell cycle control, cell growth and differentiation as well as cellular 
energy balance. Dysregulation of these functions have been linked to obesity, diabetes, 
cardiovascular disease, and cancer plus fetal abnormalities and birth defects
29,59
. 
Although no SNPs in the coding sequence of ALDH1A1 have been associated with a 
disease phenotype, the National Center for Biotechnology Information (NCBI) AceView 
 
Figure 8: ALDH in the retinoic acid signaling pathway. 
Retinol is oxidized by retinol dehydrogenases (RDH) to retinal, which is oxidized to 
retinoic acid (RA) by the human ALDH isoenzymes ALDH1A1, ALDH1A2, 
ALDH1A3, and ALDH8A1. RA diffuses into the nucleus, activates transcription 
factors (RAR, RXR), and initiates transcription of RARE-containing genes. 
Depending on cellular environment, gene products can lead to differentiation, 
apoptosis, cell cycle arrest, or other cellular outcomes (modified from Marcato et al
58
). 
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states that there are at least 13 splice variants of ALDH1A1, 5 probable alternative 
promoter sequences, along with various alternative post-translational modifications sites 
for polyadenylation, acetylation, methylation, phosphorylation, and ubiquitination
60
. 
Polymorphisms in the promoter regions have been linked to alcoholism
61,62
. Other 
diseases have been associated with ALDH1A1 dysregulation, resulting in either too little 
or too much enzyme, but not to any specific polymorphisms in the gene itself. This 
dysregulation of ALDH1A1 can result in the disruption of various cellular differentiation 
pathways due to the enzyme’s role in retinoid metabolism. Competition between the 
oxidation of distinct substrates for ALDH1A1 can also contribute to disease states. As an 
aldehyde detoxification enzyme, ALDH1A1 is critical for minimizing cellular damage 
from toxic aldehydes, and a reduction in enzyme activity levels could increase the 
aldehyde burden in the cell. In addition, ALDH1A1 is involved in the metabolism of 
different cancer chemotherapeutic agents, and overexpression is correlated with increased 
drug resistance and poorer prognosis
3,63
. ALDH1A1 is involved in the metabolism of 
various neurotransmitters, including dopamine, with lowered ALDH1A1 expression 
potentially leading to the build-up of neurotoxic aldehyde intermediates, including 3,4-
dihydroxyphenylacetaldehyde (DOPAL). As will be discussed below, three disorders that 
have been linked to ALDH1A1 dysregulation are Parkinson’s disease, cancer, and 
obesity. 
 
D. ALDH1A1 and Parkinson’s disease 
Parkinson’s disease (PD) is a neurodegenerative disorder that affects millions worldwide. 
Hallmark symptoms of PD include tremors, muscle rigidity, movement and gait 
abnormalities, with pathological features including the intracellular aggregation of α-
synuclein (Lewy bodies) and the loss of dopaminergic neurons in the substantia nigra
64
. 
Clinical signs of PD typically do not appear until over 50% of neurons and 80% of 
striatal dopamine have been lost
65,66
. The neurotransmitter dopamine is primarily found in 
the central nervous system within two midbrain regions, the substantia nigra and the 
ventral tegmental area, as well as in the hypothalamus
67
. Dopamine is synthesized in two 
steps from the essential amino acid tyrosine. Following re-uptake into a neuron, the first 
step in dopamine catabolism is the production of the aldehyde 3,4-
 15 
 
dihydroxyphenylacetaldehyde (DOPAL) via the enzyme monoamine oxidase (Figure 9). 
Most DOPAL is oxidized via an ALDH to the carboxylic acid 3,4-dihydroxyphenylacetic 
acid (DOPAC), but it can also be reduced to the alcohol 3,4-dihydroxyphenylethanol 
(DOPET). Since the 1960s, PD has been treated primarily with the dopamine precursor 
levodopa (ʟ-DOPA), managing symptoms by increasing the levels of dopamine in the 
brain but not halting the progression of the disease. Short-term side effects following 
levodopa treatment, including nausea and vomiting, are linked to dopamine’s role in the 
peripheral nervous system, while long-term side effects, such as involuntary movements, 
are likely the result of fluctuations in the body’s response to the drug after years of 
treatment
68,69
. Down-regulation of both ALDH1A1 mRNA and protein has been reported 
in PD
70-72
, and although DOPAL is a substrate for ALDH1A1, it is also a covalent 
inhibitor of the enzyme
67,73
. DOPAL has been shown to be cytotoxic in multiple in vitro 
and in vivo experiments, with toxicity likely due to protein adduction, isoquinoline 
formation, and free-radical generation
67
. Low levels of enzyme combined with substrate-
induced inhibition of the remaining enzyme would lead to the accumulation of the 
neurotoxic DOPAL. Both ALDH1A1 and ALDH2 are involved in dopamine metabolism 
in the brain and double knockout mice (ALDH1A1
-/-
 x ALDH2
-/-
) have elevated levels of 
the neurotoxic aldehydes DOPAL and 4-HNE, have loss of dopaminergic neurons in the 
substantia nigra, and have age-dependent deficits in motor performance
74
. Therefore, a 
deficit in ALDH activity, specifically ALDH1A1 activity in the substantia nigra, may 
lead to the accumulation of neurotoxic aldehydes and ultimately the cell death seen in PD 
and possibly other neurodegenerative disorders. Activators of ALDH1A1 activity could 
 
Figure 9: Dopamine synthesis and inactivation. 
DOPA = 3,4-dihydroxyphenylalanine; DOPAL = 3,4-dihydroxyphenylacetaldehyde; 
DOPAC = 3,4-dihydroxyphenylacetic acid; DOPET = 3,4-dihydroxyphenylethanol. 
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be useful in halting disease progression by either reducing the levels of DOPAL and other 
toxic aldehydes or by protecting ALDH1A1 from covalent modifications and inhibition 
by these aldehydes, as seen with the ALDH2 activator Alda-1
75
.  
 
E. ALDH1A1 and Cancer 
Over 20 years ago, cytosolic ALDH (ALDH1) was shown to be elevated in 
hematopoietic stem cells (HSC) and could be used for HSC isolation
76,77
. The first cancer 
stem cells (CSC) were identified in 1994 for acute myeloid leukemia
78
 and nearly a 
decade later, CSCs in solid tumors were discovered
79
. Since then, CSC have been 
identified in a number of cancers, and these sub-populations of tumor cells have critical 
roles in self-renewal, tumorigenesis, and differentiation
80
. Prior to the discovery of CSC, 
cancer was thought to consist of a heterogeneous collection of cells, each capable of 
mutating and initiating a new tumor. With the discovery of CSC, the classic stochastic 
model of cancer was partially replaced with a more hierarchical model. In the hierarchical 
model for cancer, a small subset of cells are capable of extensive proliferation, while the 
vast majority of cells in a cancer population are differentiated and have a more limited 
capacity to spread and form tumors
78
. Unfortunately most therapies still take a stochastic 
approach to curing cancer, targeting all cells equally and potentially shrinking tumor size 
in the short-term but allowing CSC to survive and regenerate the cancer
81
. Therefore 
targeting CSC may offer a better outcome in the quest to eradicate tumors. Expression 
profiles to determine what genes are up- or down-regulated in stem cells offer potential 
drug targets for CSC, with various ALDHs having altered expression levels. The roles of 
ALDH1A1 and other ALDH isoenzymes in stem cells are not well understood. In mice, 
Aldh1a1 is expressed in HSC and in neural crest stem cells, but the enzyme is not 
required for function in either hematopoietic or nervous system stem cells; mice deficient 
in Aldh1a1 developed normally, were fertile, and had normal lifespans
82
.  However, the 
mouse genome contains an additional ALDH1A gene, Aldh1a7, compared to humans that 
could compensate for the loss of Aldh1A1 function
20
. The role of the ALDH1A 
subfamily members is at least partially due to their involvement in retinoic acid synthesis, 
as various retinoids, including RA, effect cellular differentiation. All-trans retinoic acid 
(ATRA) in combination with vitamin D3 induces differentiation followed by cell cycle 
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arrest in various leukemia cells and as such has been used as an anti-leukemia agent
83
. 
Inhibition of ALDH via diethylaminobenzaldehyde (DEAB) expands HSC populations 
by delaying the G0G1 transition
84
, but this effect is reversed upon addition of ATRA, 
indicating that the role of ALDHs in RA production is important for HSC 
differentiation
85
. RA has been shown to induce apoptosis and differentiation in a number 
of human cancer cell models, including oral cancer
86
, non-small cell lung cancer
87
, and 
liver cancer
88
. The Wnt signaling pathway was first identified as contributing to cancers 
over a decade before the discovery of CSC, and this pathway is characterized by 
activation of the transcription factor β-catenin89. Mutations in the β-catenin gene itself 
(CTNNb1) typically diminish β-catenin degradation and have been linked to numerous 
cancers including colorectal, liver, kidney, ovarian, prostate, and thyroid cancers
89
. 
Targeting and disrupting the Wnt signaling pathway may serve as a potential treatment 
avenue. Recently, niclosamide, an FDA-approved treatment for tapeworm infections, has 
been shown to have anti-cancer properties. As an anti-helminthic, niclosamide is 
proposed to function by uncoupling oxidative phosphorylation in the tapeworm
90
. As an 
anti-cancer agent, niclosamide inhibits the Wnt pathway and decreases β-catenin levels, 
along with other signaling cascades
91
. Although initially identified as a candidate for 
glioblastoma therapy, ovarian cancer cells are particularly sensitive to niclosamide 
treatment
92
. 
 
First demonstrated in a breast cancer model, in vitro assays of mammary stem cells have 
shown that they form spheroids, or mammospheres, which are rich in progenitor cells and 
have metastatic capacity
93,94
. These spheroid cells are rich in ALDH1A1 enzyme activity 
and have been associated with earlier metastasis and poorer clinical outcome in breast 
cancer
95
. Similar spheroid formation of stem cells has been seen in other cancers, 
including cervical, prostate, and ovarian cancers
96-98
. Accounting for over half of deaths, 
ovarian cancer is the most lethal of the gynecological cancers, resulting in nearly 15,000 
deaths in the United States in 2011
99,100
. With most patients initially diagnosed in an 
advanced stage and a reoccurrence rate of 80% following treatment, the 5-year survival 
rate is only 30%
94
. The ability of ovarian cancer (OC) to form spheroids may facilitate 
metastases and enable the cancer to survive chemotherapy
101
. Similar to mammospheres, 
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OC spheroids also have elevated ALDH1A1 enzyme activity, with OC spheroids having 
up-regulation of both ALDH1A1 and β-catenin transcription, but not elevated 
transcription of similar ALDHs linked to cancer, including ALDH1A2, ALDH1A3, 
ALDH2, and ALDH3A1
101
. The ALDH1A1 gene is a direct target of the transcription 
factor β-catenin, and continuous propagation of OC spheroids results in increasing levels 
of both ALDH1A1 expression and overall up-regulation of the Wnt signaling pathway 
from generation to generation of spheroids
101
. The role of ALDH1A1 in spheroid 
formation is not known, but ALDH1A1 could represent a potential target for drug 
development to minimize cancer metastasis.  
 
As reviewed in Marcato et al, cancer stem cells are often resistant to various 
chemotherapeutic agents, including daunorubicin, mitoxantrone, temozolomide, 
carboplatin, paclitaxel, and cyclophosphamide, enabling cancer recurrence
3,58,63,102,103
. As 
with normal stem cells, CSC are typically in a quiescent state and are not good targets for 
drugs aimed at fast-growing cells
104
. Increased transporter activity designed to remove 
drugs from cells and increased DNA repair proteins are also both seen in CSC, 
decreasing their sensitivity to a drug
58
. In most cases, the role of ALDH1A1 in cancer is 
not well understood. However, it is known that this enzyme, along with ALDH3A1, 
metabolizes certain chemotherapeutic agents, including cyclophosphamide, to a less toxic 
metabolite that can be cleared by the cancer cell, resulting in decreased sensitivity and the 
need for higher drug dosages
3
. Increases in ALDH expression, particularly ALDH1A1 
and ALDH3A1, have been linked to drug resistance in various leukemia cell lines due to 
inactivation via these enzymes
105
. After progressive rounds of chemotherapy, targeting 
CSC becomes more difficult as resistance is enhanced. Small molecules that target and 
inhibit ALDH1A1 activity would be useful as adjuvant therapy for minimizing cancer 
chemo-resistance. ALDH3A1 inhibitors have been shown to increase sensitivity to 
mafosphamide, a cyclophosphamide analog that is metabolized by ALDH1A1 and/or 
ALDH3A1, in cancer cell lines over-expressing ALDH3A1
106,107
. Far less clear is why 
ALDH1A1 is overexpressed in stem cells in general, and what roles ALDH1A1 plays in 
maintaining stem cells, self-protection, enhancing metastases, and other phenotypes 
associated with stem cells and various cancers. Small molecule, chemical probes that 
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either activate or inhibit ALDH1A1 would be helpful in deciphering the function of the 
protein and may be developed further as possible therapeutics. As seen with niclosamide, 
targeting and disrupting the Wnt signaling pathway, including ALDH1A1 expression, 
may serve as a potential treatment avenue
91,108
.  
 
F. ALDH1A1 and Obesity 
A second differentiation pathway regulated by retinoids is adipogenesis. Adipogenesis is 
the formation of adipocytes, or fat cells, from precursor stem cells. There are two main 
types of adipose tissue: white adipose tissue (WAT) and brown adipose tissue (BAT). 
The main function of WAT is the storage of energy as triglycerides, but WAT is also 
involved in endocrine function, producing adipocyte-derived secreted proteins, 
adipokines, involved in normal and disease states, including cardiovascular and metabolic 
disorders
109
. BAT is heavily innervated, rich in mitochondria and uses energy to produce 
heat via thermogenesis by uncoupling the mitochondrial proton gradient from ATP 
synthesis
110
. Although BAT is known to be critical for maintaining body temperature in 
newborns and small mammals, until recently it was not thought to be present in adult 
humans; its role in adults is not well understood but may be important in energy 
homeostasis
111-113
. Both types of adipose tissues arise from mesenchymal stem cells, 
which are also able to differentiate into myocytes, chondrocytes, and osteocytes. As 
reviewed in Cristancho et al, differentiation occurs in two phases, commitment and 
terminal differentiation
114
. In the commitment phase, pluripotent stem cells are converted 
to pre-adipocytes, cells indistinguishable morphologically from their precursor yet unable 
to differentiate into anything other than adipocytes; commitment to BAT or WAT 
lineages occurs during this first phase of differentiation. During the terminal 
differentiation phase, pre-adipocytes become mature, functioning adipocytes
114
. The role 
of adipogenesis in obesity is not well understood; animals fed high fat diets for extended 
periods first exhibit an increase in adipocyte cell size followed by an increase in 
adipocyte cell number
115,116
, while rodent models of obesity have increased cell size, 
increased cell number, or both
117
. In rodents, ALDH1A1 is expressed in adipose tissue, 
and mice lacking this gene are resistant to both diet-induced obesity and insulin 
resistance
118
. The ALDH1A1 substrate itself, retinaldehyde, decreased transcription of 
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adipogenesis genes in cell models of adipogenesis; in vivo, retinaldehyde decreased fat 
levels and increased insulin sensitivity in an obese mouse model, both indicating that 
retinaldehyde may act as a signaling metabolite inhibiting adipogenesis
118
. ALDH1A1
-/-
 
mice also had increased body temperature and metabolic rate, plus increased expression 
of uncoupling protein 1 (Ucp1) and other BAT markers; these results indicate a change in 
energy expenditure and suggest a possible shift of WAT to more BAT-like 
characteristics
118,119
. BAT is metabolically active, uses energy to generate heat, and is 
associated with lower body weight, and a shift from WAT to BAT may reduce 
obesity
110,119
. The ALDH1A1 product, retinoic acid, also has an effect on adipogenesis. 
RA treatment of obese mice caused both weight loss and increased insulin sensitivity 
while increasing expression of RAR and other genes
120
. RAR targets a wide variety of 
both pro- and anti-apoptotic and cell cycle genes depending on the relative levels of other 
proteins in the cell. In vitro studies have shown that, compared to other vitamin-A 
metabolizing enzymes used to produce RA, the major enzyme expressed during 
adipogenesis is ALDH1A1, and adipocytes deficient in ALDH1A1 have impaired 
adipogenesis
121. Retinaldehyde, the substrate of ALDH1A1, is an inhibitor of PPARγ, a 
transcription factor considered the master regulator of adipogenesis
118
. In a negative 
feedback loop, RA itself may inhibit ALDH1A1 expression
121
. These results indicate that 
ALDH1A1 may serve as a target for the development of small molecule modulators that 
could serve both as tools to better understand adipogenesis and as potential therapeutics 
in the treatment of obesity and related metabolic disorders. 
 
G. The Aldefluor Assay 
The controlled regulation of stem cells is critical for normal cell growth and 
differentiation. In the last few decades, the development of the cancer stem cell 
hypothesis has increased the urgency to acquire tools to aid in the study of stem cells. As 
with HSC, ALDH’s have been identified as possible biomarkers for numerous CSC122,123. 
A commonly used method to identify and isolate stem cells is via the Aldefluor Assay 
(Stemcell Technologies, Inc.) that measures ALDH activity in live cells (Figure 10). This 
assay takes advantage of the conversion of the ALDH substrate BODIPY- 
aminoacetaldehyde (BAAA) to the charged product BODIPY-aminoacetate, which 
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accumulates in cells and enhances their 
fluorescence. The level of fluorescence 
corresponds to the amount of ALDH 
activity present in the cell. An inhibitor of 
ALDH activity, N,N-diethylamino-
benzaldehyde (DEAB), is supplied as a 
negative control for this assay. DEAB was 
developed as a reversible, competitive 
inhibitor of ALDH enzymes to replace 
more toxic, irreversible inhibitors like 
disulfiram. At the time of its development 
in the 1980s, DEAB was found to be a 
potent inhibitor of cytosolic ALDH 
(ALDH1) but not mitochondrial ALDH (ALDH2)
124
. Consequently, the Aldefluor Assay 
was thought to identify cellular ALDH1A1 activity, suggesting that this isoenzyme was 
responsible for the vast majority of ALDH activity seen in stem cells. However, recent 
studies have reported that DEAB inhibits other ALDH isoenzymes; therefore, the 
Aldefluor Assay will detect stem cells with high levels of other ALDH isoenzyme 
activity, including ALDH1A2, ALDH1A3, and ALDH2
125-127
. Therefore, ALDH-positive 
cells identified via the Aldefluor Assay could contain high levels of one or multiple 
ALDH isoenzymes, and additional assays are needed to determine which isoenzymes are 
specifically responsible for the elevated ALDH activity. ALDH activity is still an 
excellent biomarker for multiple normal and cancer stem cell lines, and the Aldefluor 
Assay is a simple and reliable test for the identification and isolation of these stem cells. 
However, better control inhibitors, particularly selective inhibitors for each of the ALDH 
isoenzymes, would aid in understanding which isoenzyme(s) is contributing to the high 
ALDH activity seen in a particular stem cell. At this time, there are no selective inhibitors 
for the majority of ALDH isoenzymes, including ALDH1A1.  
 
 
Figure 10: The Aldefluor Assay.  
Flow cytometry assay that identifies stem 
cells based on ALDH activity. In the cell, 
ALDH converts BAAA to BAA, trapping 
the fluorescent molecule in the cell. 
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H. ALDH1A1 Activators and Inhibitors 
The initial focus on the development of ALDH inhibitors was centered on ALDH2 and 
the development of anti-alcohol (antidipsotropic) therapies due to the enzyme’s role in 
the detoxification of acetaldehyde following alcohol consumption. A single 
polymorphism in ALDH2 (ALDH2*2) results in reduced acetaldehyde metabolism and 
causes alcohol flushing syndrome. Found in close to 50% of the East Asian population, 
the ALDH2*2 mutation induces unpleasant side effects, including nausea and erythema, 
after drinking alcohol, and therefore these populations exhibit lower incidences of 
alcoholism
128
. By targeting and inhibiting ALDH2, antidipsotropic drugs like daidzin and 
disulfiram (Antabuse) cause unpleasant side effects following alcohol consumption and 
discourage users from seeking alcohol. Daidzin is a naturally occurring isoflavone 
derived from the kudzu plant (Pueraria lobata). Although it inhibits both ALDH1A1 and 
ALDH2, based on IC50 values, it is 100 times more potent for ALDH2, and daidzin 
analogs are being developed to better target ALDH2
23
. On the other hand, disulfiram is a 
potent inhibitor of both ALDH1A1 and ALDH2 and has been used as an antidipsotropic 
for alcoholism and as a treatment for cocaine addiction, likely due to the role of ALDHs 
in dopamine metabolism
31
. Disulfiram is also being evaluated for anti-cancer activity 
resulting from increasing sensitivity to other anti-cancer drugs inactivated by ALDHs as 
well as by inducing apoptosis
23,129-131
. Citral is a naturally occurring α,β-unsaturated 
aldehyde found in herbs and citrus fruits that is capable of inhibiting a number of ALDH 
isoenzymes and likely inhibits by acting as a slow substrate, therefore appearing as an 
inhibitor for faster substrates
23
. Rodents administered citral have reduced weight gain, 
lower fasting glucose, and a higher metabolic rate compared to controls, supporting the 
ALDH1A1
-/-
 knockout mice observation that ALDH1A1 may contribute to obesity and 
other metabolic disorders
132,133
. DEAB, the control inhibitor used in the Aldefluor Assay, 
is also an aldehyde and likely inhibits by binding at the active site as a substrate that is 
turned over slowly
127
. Although the effects of disulfiram, citral, and DEAB show promise 
in targeting ALDH, their ability to inhibit multiple ALDH1/2 family members minimizes 
their effectiveness as chemical tools, while increasing the likelihood of off-target effects 
when used as chemotherapeutics. Certain biocides, including the antifungal benomyl and 
various thiocarbamate herbicides, such as molinate, pebulate, and triallate, also inhibit 
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various ALDHs, either directly or via biotransformation following exposure
23,134
. 
Gossypol is a naturally occurring aldehyde that is more selective for ALDH3A1 
compared to members of the ALDH1/2 family
23
. Although traditionally used in Chinese 
medicine as a male contraceptive, its anti-tumor properties are now being studied. 
Gossypol is not only non-selective compared to other ALDH isoenzymes, it also inhibits 
other NAD(P)
+
-dependent oxidation enzymes, including aldose reductases and lactate 
dehydrogenases, and therefore likely interacts with these enzymes at the cofactor binding 
site
23,135
. Using in vitro high throughput screens (HTS), more selective ALDH3A1 
inhibitors have been recently developed to sensitize ALDH3A1-positive cancer cells to 
oxazaphosphorines
106,107,136
. Similar to ALDH3A1, ALDH1A1 is upregulated in multiple 
cancers, contributing to drug resistance, and therefore inhibitors of ALDH1A1 could 
increase cancer cell sensitivity to various cancer chemotherapeutics. In a similar manner 
to ALDH3A1, HTS have been used to find ALDH2 inhibitors, but achieving selectivity 
for ALDH2 compared  to other ALDH enzymes has been more difficult
136,137
. In addition 
to drug metabolism, ALDH1A1 likely contributes to cancer stem cell maintenance and/or 
differentiation, and small molecule modulators would aid in better understanding of this 
enzyme in disease progression as well as serving as possible chemotherapies. The use of 
RNA interference to silence ALDH1A activity leads to cell cycle arrest, apoptosis, 
decreased cell viability, and decreased tumorigenesis in human melanoma stem cells
138
. 
These results indicate that the ALDH1A subfamily represents an excellent therapeutic 
target for the development of small molecule inhibitors. 
 
There are very few small molecule activators of ALDHs, and the discovery of small 
molecule enzyme activators, in general, lags far behind inhibitor development
139
. Alda-1 
activates ALDH2 and also prevents enzyme inactivation by various toxic aldehyde 
substrates, including 4-HNE, offering additional protection from oxidative stress
75
. Alda-
1 also activates the ALDH2*2 enzyme, acting as a chemical chaperone to restore function 
to an otherwise inactive mutant
75,140
. Alda-1 may also activate ALDH1A1 activity 
following DOPAL-induced inactivation of the enzyme
141
. Similar to inhibitors, enzyme 
activators can serve as useful tools to decipher the role of an enzyme in various 
physiological processes. Activators also can have therapeutic value. Alda-1 has been 
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shown to reduce ischemic damage to the heart following myocardial infarction
75
.  Human 
exposure to pesticides has been linked to Parkinson’s disease, and the fungicide benomyl 
has been shown to inhibit ALDH activity, resulting in the build-up of neurotoxic 
aldehydes, the death of dopaminergic neurons, and the development of Parkinson’s 
disease
142
. Since down-regulation of both ALDH1A1 mRNA and protein has been 
reported in PD and a substantial decrease in dopaminergic neurons is needed before 
manifestation of symptoms, activators of ALDH1A1 could halt or significantly delay the 
development of PD
65,66,70-72
.  
 
The development of compounds that selectively target ALDH1A1 has proven to be 
difficult as the ALDH superfamily of enzymes shares many common structural and 
mechanistic features. These members generally function as homodimers or 
homotetramers, with the monomers containing three structural domains: a catalytic 
domain, a cofactor binding domain, and an oligomerization domain. The NAD(P)
+
 
binding domain is a Rossmann-fold, a nucleotide binding site that consists of two sets of 
parallel beta sheets and alpha helices. The Rossmann-fold is found in the NAD(P)
+
 
binding domains of multiple dehydrogenase families, including ALDHs, lactate 
dehydrogenases, alcohol dehydrogenases, and glyceraldehyde-3-phosphate 
dehydrogenase
140,143,144
. There are differences in the Rossmann fold between ALDH and 
other oxidoreductases that could be exploited for the development of small molecule 
modulators of various ALDH isoenzymes compared to other NAD(P)
+
-binding enzyme 
families
44
. However, there exists much more structural similarity in the NAD(P)
+
- 
binding site for ALDH family members, and the development of selective modulators 
that target this site may be much more difficult. Despite similarities in structure and 
function, as well as some overlap in substrate preferences, the isoenzymes of the ALDH 
family of proteins have evolved different aldehyde binding sites due to substitutions of 
the residues lining their respective substrate binding tunnels
23,47
. Therefore, the substrate 
binding site or an allosteric site away from the active site would serve as better sites for 
targeting. The human ALDH1/2 family is a particularly difficult challenge for inhibitor 
development since it contains the highest number of family members at seven 
(ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, ALDH1L1, ALDH1L2, and ALDH2). 
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Compounds such as diethylaminobenzaldehyde (DEAB) and disulfiram are potent 
inhibitors of ALDH1A1, with IC50’s in the nM range, but both also inhibit ALDH2
23,126
. 
DEAB is also a relatively potent inhibitor for other ALDH1/2 family members, but is a 
robust substrate for ALDH3A1
126,127
. DEAB  is of particular interest due to its use as a 
control in the Aldefluor Assay, and further analysis is warranted to better understand the 
various effects of DEAB on the different ALDH isoenzymes, from potent inhibitor to 
excellent substrate. In addition, selective ALDH1A1 modulators are needed to better 
understand this enzyme’s role in both normal and disease states. An in vitro high 
throughput screen (HTS) is a common method of discovering novel, small molecule 
modulators for a particular enzyme. Typically, the rate of aldehyde oxidation by ALDHs 
is studied by monitoring the formation of NADH at 340 nm on a spectrophotometer 
(molar extinction coefficient of 6220 M
-1
 cm
-1
) (Figure 11A). However, this approach is 
not ideal for the screening assay as it is common for compounds in the libraries to absorb 
light in the same wavelength range as NADH and lead to interference in the analytical 
approach. Therefore, another assay design is needed for an ALDH1A1 HTS. One 
 
Figure 11: Reactions used to discover ALDH1A1 modulators.  
A) NAD
+
-dependent aldehyde oxidation reaction monitored formation of NADH at 
340 nm. B) HTS used an NAD
+
-independent esterase reaction that monitored the 
formation of p-nitrophenol at 405 nm. 
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possibility is to couple aldehyde oxidation to a second reaction that can be monitored by 
either fluorescence or UV/Vis spectrophotometry. For example, the dehydrogenase 
activity of ALDH2 was coupled to the NADH-dependent reduction of resazurin to 
resorufin to discover Alda-1, a novel activator of ALDH2
75
. As ALDH1A1 can also 
function as an esterase, another approach would be to use the inherent esterase activity of 
ALDH1A1 to identify modulators. The ALDH1A1 ester substrate para-
nitrophenylacetate (pNPA) is hydrolyzed to p-nitrophenol, which absorbs light at 405 nm 
and can be monitored spectrophotometrically, with minimal interference from library 
compounds (Figure 11B). Site-directed mutagenesis studies on ALDH2 have shown that 
Cys-302 is the essential nucleophile for both the dehydrogenase and the esterase reaction, 
with Glu-268 acting as the general base to activate Cys-302
38,39
. The proposed catalytic 
steps for both the dehydrogenase and esterase reactions have been recently reviewed
23
 
and are shown in Figure 6, although minor details still need to be resolved, including the 
roles of second sphere residues in assisting proton transfer to solvent
145,146
. The use of 
common active site residues for the two reactions makes it likely that modulators of the 
esterase reaction would also modulate aldehyde oxidation activity. In support of this 
hypothesis, the ALDH2 activator Alda-1 activates both the esterase and dehydrogenase 
activity of the enzyme, and daidzin inhibits both reactions
75,140,147
. An additional 
advantage of the esterase reaction is that it does not require the cofactor NAD
+
, and so 
allows the screen to be less influenced by compounds binding to this site. Small 
molecules that alter ALDH1A1’s esterase activity can be further analyzed using steady-
state kinetics, protein X-ray crystallography, and cell culture studies to determine the 
compound’s effect on the aldehyde oxidation activity of ALDH1A1 and other ALDH 
superfamily members, their mechanism of action, and ultimately determine their 
usefulness as both chemical tools and chemotherapeutics.  
 
I. Hypothesis and Approach 
Due to differences in the structure and function of human ALDH1A1 isoenzyme, we 
hypothesize that small molecules can be identified that selectively modulate the activity 
of ALDH1A1 compared to other members of the ALDH superfamily. Comparisons of the 
active sites of sheep ALDH1A1 and human ALDH2 and ALDH3A1 illustrate that there 
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are sufficient differences to support the development of inhibitors specific for each 
enzyme (Figure 12). The substrate binding site of sheep ALDH1A1 (PDB 1BXS)
148,149
 
has a large, somewhat linear active site, while human ALDH2 (PDB 1O02)
150
 has a more 
narrow, linear active site. In contrast, human ALDH3A1 (PDB 3SZA)
137
 has a large, bent 
active site. 
 
ALDH1A1 has been linked to both normal and diseased states. ALDH1A1 is one of four 
retinaldehyde dehydrogenases that produce retinoic acid, a key transcription regulator in 
a number of cell growth and differentiation pathways. Up-regulation of the gene and 
increased protein levels are seen in both normal and cancer stem cells. Increased 
ALDH1A1 protein levels are often correlated with increased drug resistance, more 
aggressive tumors, and poorer prognosis. Rodent studies using either gene knockout or 
non-selective inhibition indicate that ALDH1A1 is involved in adipogenesis and obesity. 
Down-regulation of the enzyme is observed in Parkinson’s disease, with build-up of toxic 
substrates of ALDH1A1 possibly contributing to PD development. Therefore, ALDH1A1 
is a potential target for drug therapy. However, the specific role ALDH1A1 is playing in 
many of these biological processes and disease states is unclear. Is ALDH1A1 
functioning via retinaldehyde metabolism, another aldehyde substrate, or is it a 
completely different function of the enzyme? What contribution does ALDH1A1 play 
compared to other aldehyde dehydrogenases, especially the other retinaldehyde 
dehydrogenases? The discovery of small molecules that selectively activate or inhibit 
A. ALDH1A1                 B. ALDH2             C. ALDH3A1 
 
Figure 12: Comparison of the active sites of three ALDH isoenzymes.  
The surface rendition of the active site, with the cysteine shown in red and the 
cofactor binding site orientated to the right of the cysteine. A) Sheep ALDH1A1 (PDB 
1BXS); B) Human ALDH2 (PDB 1O02); C) Human ALDH3A1 (PDB 3SZA).  
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ALDH1A1 aldehyde oxidation activity but have little to no effect on other ALDHs could 
serve as chemical tools to better delineate the biological function(s) this enzyme has in 
both normal and disease states. With better understanding of the physiological processes 
involved, it is possible to accurately determine potential targets for drug development, 
maximizing therapeutic benefits while minimizing side effects (Figure 13)
151
.  
 
With the knowledge that ALDH1A1 is involved in a number of biological pathways, our 
goal was to characterize small molecule inhibitors of ALDH1A1 that can serve as 
chemical tools to decipher the specific function of this protein. At this time, there are no 
commercially available selective inhibitors of ALDH1A1 and therefore no chemical tools 
capable of distinguishing the role of ALDH1A1 compared to a number of structurally and 
functionally similar ALDH isoenzymes. Although RNAi can enable specific knockdown 
of each of the ALDH isoenzymes, small molecule probes do offer some advantages. First, 
a good modulator (activator or inhibitor) will modify the enzymatic activity of a protein 
but have little to no effect on other functions of that protein. Second, activation or 
inhibition by small molecules is dose dependent and often reversible, enabling a high 
level of control for the pathway of interest. Finally, enzyme activation studies are not 
possible using RNAi. Ideally, chemical probes and RNAi should complement each other, 
possibly revealing any off-target effects of the compound and/or nonenzymatic roles of 
the protein of interest. 
 
We took two approaches to develop selective activators and inhibitors of ALDH1A1:     
1. the use of a nonselective inhibitor as a scaffold to develop more selective inhibitors, 
 
Figure 13: Small molecule discovery.  
Approach to the discovery of small molecules as chemical tools for scientific 
discovery and for drug development. The steps in the blue boxes were performed as 
part of this project (modified from Lipinski et al
151
). 
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and 2. the discovery of novel compounds from a high throughput screen. To accomplish 
our goal, first we characterized DEAB, a commonly used, commercially available, non-
selective inhibitor of ALDH1A1 and proposed a mechanism of action for its varied effect 
amongst the ALDH isoenzymes, from a pseudo-covalent inhibitor to a rapid substrate. By 
determining why it behaves differently within the active sites of different ALDHs, 
chemical modification to DEAB could produce more selective inhibitors of ALDH 
isoenzymes. Second, we used X-ray crystallographic studies to determine the structure of 
human ALDH1A1, enabling comparisons between other human ALDHs and identifying 
potential sites that can be exploited for compound selectivity. Finally, an in vitro esterase 
high-throughput screen was developed to identify novel activators and inhibitors of 
ALDH1A1. Compounds identified in the HTS were characterized using steady-state 
enzyme kinetics and X-ray crystallographic studies. Ideally, the knowledge gained from 
the discovery of these compounds will enable the development of new medicines to treat 
disease.  
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II. Materials and Methods 
A. Materials  
Chemicals and reagents used for protein expression and purification, enzyme kinetics, 
and X-ray crystallography were purchased from Sigma Aldrich (St. Louis, MO), unless 
otherwise noted. Compounds were purchased from ChemDiv Corporation (San Diego, 
CA) and through the Indiana University Chemical Synthesis Core. Dithiothreitol (DTT) 
was purchased from GoldBio (St. Louis, MO). Primers for site-directed mutagenesis and 
sequencing were purchased through Integrated DNA Technologies (Coralville, IA). 
Sitting drop plates for crystallography were purchased from Charles Supper Co (Natick, 
MA). Sequencing was performed by the Department of Biochemistry and Molecular 
Biology, Indiana University School of Medicine. 
 
B. Methods 
1. Production of ALDH Isoenzymes 
The full-length cDNA for human ALDH1A1 was generously provided by Dr. Henry 
Weiner, Purdue University in a pT7-7 vector
152
 and used to transform E. coli. BL21 
(DE3) cells. The general protocol for expression and purification of ALDH1A1 has been 
published before and is similar to ALDH2
136,152
. Specifically, a single transformed BL21 
colony was first grown in 10 mL 2XTY broth containing 100 µg/mL ampicillin (TY-
Amp) for 8 – 10 hours at 37°C with shaking. Next, 5 mL of this starter culture was used 
to inoculate 100 mL TY-Amp and grown overnight at 37°C with shaking. For large-scale 
preparations (8L), 8 x 1L TY-Amp in baffled 2L flasks were inoculated with 5 mL of the 
overnight culture and incubated at 37°C with shaking at 200 rpm. When the culture 
reached an optical density at 600 nm (OD600) of 0.6 to 0.8, isopropyl-β-D-
thiogalactopyranoside (IPTG) was added to a final concentration of 500 µM. IPTG is 
used to induce large quantities of ALDH1A1 protein expression via the T7 promoter on 
the plasmid
153
. Cultures were incubated overnight at 16°C with shaking at 200 rpm 
before harvesting. The cells were centrifuged to remove broth, and the pellets flash 
frozen in liquid nitrogen and stored at -80°C. For ALDH expression and purification, all 
buffers contained dithiothreitol (DTT), which helps maintain cysteine residues in their 
reduced state (-SH), and were sparged with helium to remove dissolved oxygen. 
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Combined, sparging and DTT minimized oxidation of active site cysteine residues. The 
cell pellets were thawed slowly in a cold water slurry and resuspended in lysis buffer 
(Table 3). Cells were lysed via three passages through a microfluidizer (DivTech 
Equipment). Cell lysate was clarified via centrifugation at 35,000 rpm for 30 minutes at 
4°C (Beckman-Coulter Optima L-90K Ultracentrifuge, Ti-45 Rotor). The clarified lysate 
was dialyzed into two 4L changes of lysis buffer at 4°C, each at least 5 hours. Next, the 
lysate was loaded onto a DEAE-Sepharose column and protein eluted with a gradient of 0 
to 250 mM NaCl (DEAE Elute Buffer, Table 3) with most elution occurring at 
approximately 100 mM NaCl. The eluted fractions from the DEAE-Sepharose column 
were analyzed by SDS gel to confirm the presence of protein (Figure 14). Fractions 
containing protein were pooled and loaded onto a 4-hydroxyacetophenone (4-HAP) 
affinity column and eluted in a single step with approximately 75 mL of 10 mM 4-HAP 
elute buffer (Table 3, Figure 14). The protein was dialyzed exhaustively into three 4L 
changes of 10 mM sodium ACES, pH 6.6 with 1 mM DTT at 4°C, each at least 5 hours. 
Protein was concentrated to 5 – 10 mg/mL using Amicon Ultra Centrifugal Devices 
(Millipore Corp, Bedford, MA). Prior to storage, protein concentration was measured 
using the BioRad Protein Assay (BioRad Laboratories, Hercules, CA), and its aldehyde 
oxidation activity  determined using saturating amounts of propionaldehyde and NAD
+
. 
An 8L preparation generated 150 – 200 mg ALDH1A1 protein. The majority of the 
protein was concentrated to 5 – 8 mg/mL, distributed into 100 – 200 µL aliquots, flash 
Table 3: Solutions used in the preparation of ALDH1A1 protein. 
 Lysis Buffer DEAE Elute Buffer HAP Elute Buffer 
Sodium Phosphate,    
NaH2PO4 
10 mM, pH 7.0 10 mM, pH 7.0 20 mM, pH 7.5 
EDTA 2 mM 2 mM 1 mM 
Benzamidine 1 mM 1 mM --- 
DTT 1 mM 1 mM 1 mM 
NaCl --- 250 mM 50 mM 
4-HAP --- --- 10 mM 
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frozen in liquid nitrogen, and stored at -80°C. ALDH1A1 for crystallization was stored at 
-20°C in a 50% (v/v) solution with glycerol to minimize degradation and lose of activity; 
prior to use it was dialyzed into three 4L changes of 10 mM sodium ACES, pH 6.6 with 1 
mM DTT at 4°C, each for at least 5 hours.  
 
The ALDH1A1 cDNA contained a known A-to-G SNP at position 72928972 on 
chromosome 9 (NCBI rs1049981) resulting in an Asn-to-Ser missense mutation at 
protein position 121
152
. This SNP has been found in a small percentage of the HapMap-
CEU population representing Utah residents with Northern and Western European 
ancestry, but there is no known clinical significance to the mutation. ALDH1A1 N121S 
was active and behaved similar to ALDH1A1 WT. ALDH1A1 WT protein was used for 
all aldehyde oxidation assays and X-ray crystallography, unless otherwise noted. The full 
length cDNA for human ALDH4A1 and ALDH5A1 were generously provided by Dr. 
Daria Mochly-Rosen. ALDH1L1 (10-formyltetrahydrofolate dehydrogenase) consists of 
three domains: an N-terminus hydrolase domain, an intermediate linker domain, and the 
C-terminus ALDH domain
154
. The carboxyl terminus of rat ALDH1L1 was generously 
 
Figure 14: ALDH1A1 protein purification. 
Representative SDS-PAGE gels of WT ALDH1A1 protein expression and 
purification. From the DEAE column, 50 mM NaCl fractions 1 and 2, plus 100 mM 
NaCl fractions 1 – 5 were pooled and loaded on to the HAP column.  
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provided by Dr. Sergey Krupenko in the pRSET expression plasmid. ALDH1L1 was 
expressed and purified as previously described for ALDH3A1
136
 with the following 
modifications: 1) the medium contained 100 µg/mL ampicillin, 2) cells were lysed via 3 
passages through a microfluidizer (DivTech Equipment), and 3) a single passage on a 
nickel-NTA column was used for purification, without the second Q-sepharose column 
used to purify ALDH3A1. Protein used for kinetics was flash frozen in liquid nitrogen 
and stored at -80°C. ALDH1A2, ALDH1A3, ALDH1B1, ALDH2, and ALDH3A1 were 
produced and purified as previously described
107,136,155
. ALDH3A1 was purified and 
provided by Dr. Bibek Parajuli; ALDH1A2, ALDH1A3, ALDH1B1, and the mutant 
ALDH1A1 G458N were purified and provided by Lanmin Zhai; ALDH4A1 and 
ALDH5A1 were purified and provided by Cameron Buchman similar to the purification 
of ALDH1L1.  
 
2. Generation of wild-type ALDH1A1 and the G458N mutant 
The QuikChange site-directed mutagenesis protocol was used to make point mutations. 
First, wtALDH1A1 was generated from the Weiner N121S polymorphism. Wild-type 
ALDH1A1 was constructed using the forward primer 5'- CTC TAT TCC AAT GCA 
TAT CTG AAT GAT TTA GCA GGC TGC ATC -3' and its complement. A point 
mutation of wtALDH1A1 was performed to produce the G458N mutant. ALDH1A1 
G458N mutants were constructed using the forward primer 5’-GTG GGT GAA TTG 
CTA TAA CGT GGT AAG TGC CCAG-3’ and its complement. This G458N mutant 
was purified in the same way as other ALDH1A1 proteins (WT, N121S), but the yield 
was approximately 10% the yield of WT. G458N was stored at 2-mg/mL and 8-mg/mL 
at -80˚C. Kinetic experiments for G458N were performed in the same manner as WT 
protein. 
 
3. X-ray crystallography 
ALDH1A1 protein used for crystallization was stored at -20°C in a 50%(v/v) glycerol 
solution. Prior to use, the protein was dialyzed against three 4L changes of 10 mM 
sodium ACES, pH 6.6 and 1 mM dithiothreitol at 4°C, each for at least 5 hrs. Hampton 
Research (Laguna Niguel, CA) screens, in particular their Index and Additive Screens, 
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were used to help determine appropriate crystallization conditions for the human 
ALDH1A1 protein. Other than the Hampton Research screens and the compounds used 
for co-crystallization or soaks, all solutions (buffers, NAD
+
/NADH, and protein) were 
sterile-filtered thru a 0.2 µm or 0.45 µm membrane to remove any particulate matter. 
Crystallization conditions were determine using a sitting drop method by mixing 2 µL of 
the protein solution (4 mg/mL) with 2 µL of crystallization solution, with a 500 µL 
reservoir solution. The following Hampton Research Screens were initially tested to 
determine what general conditions were most favorable for ALDH1A1 crystallization: 
Index (HR2-144), Crystal Screen (HR2-110), Crystal Screen 2 (HR2-112), Polyethylene 
Glycol 6000 (HR2-213), Sodium Chloride (HR2-219), PEG/Ion (HR2-126), and PEG/Ion 
2 (HR2-098). Promising results from these screens were further tested using the Additive 
Screen (HR2-428). For the Additive Screen, 0.2 µL of the additive screen component was 
added to the sitting drop, using the conditions identified as favorable from previous 
screens.  
 
Following optimization, the final crystallization solution contained 100 mM sodium 
BisTris, pH 6.2 – 7.5, 7 – 12% polyethylene glycol 3350 (PEG3350 from Hampton 
Research, Laguna, CA), 200 mM sodium chloride, and 5 – 10 mM ytterbium chloride. 
Protein (3 – 7 mg/mL) was crystallized primarily using the sitting drop method, but the 
hanging drop method also successfully produced crystals under the same conditions. 
Drop composition could also vary, but an equal ratio of protein volume to reservoir 
volume was preferred, and typically 2 – 3 µL protein was mix with an equal volume of 
crystallization solution. The drop was mixed by both pipetting and agitation. 
Crystallization was allowed to proceed at 22°C in an incubation chamber. Crystals also 
formed when placed in a 10°C incubation chamber. Small crystals were present within 24 
hours, while larger crystals were present in 4 – 7 days. Crystals continued to diffract well 
for 6 weeks, but beyond that timeframe, the crystals became soft, malleable, and no 
longer diffracted well. For the ALDH1A1-NADH structure, seven day old apo-crystals 
were soaked for 2 hours with crystallization solution containing 1 mM NAD
+
. Complexes 
with CM026 analogs were produced by soaking apo-crystals overnight with a 
crystallization solution containing 500 µM inhibitor and 2% DMSO. Complexes with 
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CM037 analogs were produced by soaking apo-crystals for 5 hours with a crystallization 
solution containing 500 µM CM037, 1 mM NAD
+
, and 1% DMSO. Freezing of the 
crystals occurred in crystallization solution plus 20% (v/v) ethylene glycol as well as any 
soak components (NAD
+
 or compound). Crystals were frozen in a liquid nitrogen 
cryostream, and diffraction tested on the home source Bruker D8 System. Crystals with 
good diffraction were stored in liquid nitrogen until collection. Diffraction data was 
collected at either Beamline 19-ID or 19-BM operated by the Structural Biology 
Consortium at the Advanced Photon Source, Argonne National Laboratory, Chicago, 
Illinois. Diffraction data was indexed, integrated, and scaled using either HKL2000 or 
HKL3000 program suites
156
. The CCP4 program suite
157
 was used for molecular 
replacement and refinement. For molecular replacement for the apo-ALDH1A1 structure, 
sheep ALDH1A1 (PDB Code 1BXS) was used; for all other structures, the apo-
ALDH1A1 was used. The molecular graphics application Coot
158
 was used for model 
building, and the TLSMD (Translation/Libration/Screw Motion Determination) server 
was used to determine dynamic properties of the protein
159,160
. 
 
4. Esterase High-Throughput Screen 
The high-throughput screen (HTS) was performed using an esterase reaction (Figure 15). 
The esterase assay was selected for screening because it is cofactor independent and the 
spectral properties of the monitored product (para-nitrophenol at 405 nm) are less likely 
to overlap with the absorbance characteristics of the compounds in the libraries. The 
 
Figure 15: Esterase high-throughput screen. 
The high-throughput screen used an NAD
+
-independent esterase reaction that 
monitored the formation of para-nitrophenol at a wavelength of 405 nm. 
 36 
 
substrate was prepared by adding 0.0725 g of para-nitrophenylacetate (pNPA) to 6 mL of 
DMSO; this mixture was slowing added to 94 mL of water with continuous stirring for a 
final stock concentration of 4 mM in 6% DMSO. ALDH1A1 was diluted to a 
concentration of 3.6 µM in 10 mM sodium HEPES, pH 7.5 and maintained on ice until 
added to the reaction plate. The non-selective ALDH1A1 inhibitor Aldi-1
137
 was used as 
a positive control for inhibition, with a stock concentration of 62.5 µM in a 2% DMSO 
solution and a final reaction concentration of 25 µM. To identify novel activators and 
inhibitors of ALDH1A1, a HTS of 64,000 compounds from ChemDiv Corporation (San 
Diego, CA) was carried out at the Indiana University Chemical Genomics Core Facility. 
This library contained a structurally diverse collection of drug-like compounds that 
follow Lipinski’s rule151. The HTS was performed in 384-well, clear-bottomed plates, 
monitoring the change in absorbance of p-nitrophenol at a wavelength of 405 nm. The 
final 50-µL reaction contained 730 nM ALDH1A1, 800 µM  substrate para-nitro-
phenylacetate (pNPA), 10 µM library compound, and 2% DMSO in 25 mM sodium 
HEPES, pH 7.5 at 25°C. The rate of reaction was determined by monitoring the reaction 
for 7 minutes, with prior optimization results indicating that the reaction is linear for at 
least 20 minutes. Prior to conducting the HTS, a Z factor was calculated by comparing 
the values of ALDH1A1 plus/minus the control inhibitor Aldi-1 under the conditions of 
the HTS assay, each at n = 384, using the following formula: 
𝑍 𝑓𝑎𝑐𝑡𝑜𝑟 = 1 −  
3 | 𝛿𝑝 −  𝛿𝑛 |
| 𝜇𝑝 − 𝜇𝑛 |
 
where µp and δp are the mean and standard deviation for the control (positive) reaction, 
respectively, and µn and δn are the mean and standard deviation for the inhibition 
(negative) reaction, respectively. A Z factor between 0.5 and 1.0 indicates a good assay 
that is statistically strong enough to detect inhibitors. 
 
The IU Chemical Genomics Facility provided plates containing 20 µL aliquots of each 
compound at a 25 µM concentrations in a 2% DMSO solution, for a final concentration 
of 10 μM in the 50 μL screening reaction. Columns 23 and 24 contained no compound 
and were used as assay controls. A sample reaction plate is shown in Figure 16, with 
columns 1 – 22 containing library compounds and columns 23 and 24 used as controls: 
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column 23 as a control for enzyme activity 
(positive control) and column 24 as an 
inhibition control (negative control). The 
enzyme activity control formed the basis 
to determine whether and to what degree a 
library compound had an effect on enzyme 
activity. The control for inhibition 
combined with the enzyme control 
established whether that plate was run 
successfully. If the values in these two 
columns were not significantly different, 
an error had occurred in set-up, or enzyme 
activity had decreased too much to 
identify inhibitors. For the two control columns, a multichannel pipet was used to add 
either 20 µL of a 2% DMSO solution or 20 µL of the control inhibitor Aldi-1 in a 2% 
DMSO solution. To each plate, 10 µL of 125 mM HEPES buffer was added via the Titan 
Multidrop-384 Microplate Dispenser. The Tecan Genesis or the Tecan Freedom EVO 
Robotic workstations were used to add 10 µL of a 3.6 µM ALDH1A1 enzyme solution 
followed by 10 µL of a 4 mM pNPA solution in 6% DMSO with mixing. The plates were 
centrifuged at 1000 rpm for 10 seconds and read on a Spectromax Plus 384 plate reader 
over a 7-minute period. The rate of reaction was used to determine a ratio to control for 
each compound, with control being the average of the rates of reaction for the plate 
control (positive control), column 23 (n = 16): 
𝑅𝑎𝑡𝑖𝑜 𝑡𝑜 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 =  
𝑅𝑎𝑡𝑒 𝑜𝑓 𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛 𝑤𝑖𝑡ℎ 𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑟𝑎𝑡𝑒 𝑜𝑓 𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛 𝑜𝑓 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
 
A compound was identified as an activator if its ratio to control was greater than 2 and 
was identified as an inhibitor if its ratio to control was less than 0.4. Compounds 
identified as either activators or inhibitors of ALDH1A1 esterase activity were rescreened 
using the same protocol and cutoffs to confirm the initial readings. Confirmed hits were 
grouped based on their structural properties. Compounds selected for further analysis 
 
Figure 16: Esterase HTS plate set-up. 
High-throughput screen 384-well plate. 
The open circles represent wells 
containing library compounds. Green 
circles are the enzyme control and red 
circles are the inhibition control. 
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Figure 17: Aldehyde oxidation activity assays. 
NAD
+
-dependent aldehyde oxidation reaction used to determine selectivity of hit. 
Both reactions monitored the formation of NADH at 340 nm. A) oxidation of 
propionaldehyde used with ALDH1 family members, B) oxidation of benzaldehyde 
used for ALDH3A1. 
A. 
B. 
were purchased from ChemDiv Corporation (San Diego, CA) to determine their effect on 
aldehyde oxidation. 
 
5. Aldehyde Oxidation Activity Assays for ALDH Isoenzymes 
Hits from the HTS were ordered from ChemDiv to determine if they had an effect on 
aldehyde oxidation and if they were selective for ALDH1A1 compared to ALDH2 and 
ALDH3A1. The dehydrogenase activity of the three isoenzymes was assayed by 
monitoring the production of NADH at 340 nm (molar extinction coefficient of 
6220 M
-1
·cm
-1
) on a Beckman DU-640 or Cary 300 Bio UV-Vis spectrophotometer for 2 
to 3 minutes. Under these conditions, the control reactions were linear for at least 10 
minutes. For ALDH1A1 and ALDH2, the reaction contained 100 – 200 nM enzyme, 200 
µM NAD
+
, 100 µM propionaldehyde, and 1% DMSO in 50 mM sodium BES, pH 7.5 at 
room temperature (Figure 17A). For ALDH3A1, the reaction contained 20 – 25 nM 
enzyme, 200 µM NAD
+
, 300 µM benzaldehyde, and 1% DMSO in either 100 mM 
sodium phosphate or 50 mM sodium BES at pH 7.5 at room temperature (Figure 17B). 
For most compounds, a concentration of 20 µM was used for the initial round of 
selectivity assays. However, due to solubility issues for CM307, 10 µM of compound 
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was used. Following a 2 minute incubation of enzyme, compound, and NAD
+
, the 
reaction was initiated by adding substrate. Compounds that were selective for ALDH1A1 
compared to ALDH2 and ALDH3A1 were tested on other ALDH1 isoenzymes. For 
ALDH1A2, ALDH1A3, and ALDH1B1, the reaction contained 100 – 200 nM enzyme, 
200 µM NAD
+
, and 100 µM propionaldehyde. Selectivity towards ALDH1L1 was tested 
with 500 nM enzyme, 4 mM propionaldehyde, and 500 µM NADP
+
. Selectivity towards 
ALDH4A1 was tested with 100 nM enzyme, 20 mM propionaldehyde, and 1.5 mM 
NAD
+
. Selectivity towards ALDH5A1 was tested with 100 nM enzyme, 2 mM 
propionaldehyde, and 1.5 mM NAD
+
. For all selectivity assays, reactions contained 1% 
DMSO in 50 mM sodium BES, pH 7.5 at room temperature. Following a 2 minute 
incubation of enzyme, compound, and NAD(P)
+
, the reaction was initiated by adding 
propionaldehyde, and the production of NAD(P)H was monitored at 340 nm on either a 
Beckman DU640 or Cary 300 Bio UV-Vis Spectrophotometer for 2 – 3 minutes.  
 
For compounds with over 60% inhibition at 20 µM, IC50 values for propionaldehyde 
oxidation were calculated by varying the concentration of the compound from 0 – 
200 µM.  Following a 2 minute incubation of enzyme, compound, and NAD
+
,
 
the 
reactions were initiated by adding propionaldehyde and monitored at 340 nm for 2 – 3 
minutes. Data were fit to the four parameter EC50 equation using SigmaPlot (StatSys 
v12.3). The values represent the mean/SEM of three independent experiments, with each 
experiment n = 3.  
 
6. Steady-State Enzyme Kinetics 
In order to use steady-state enzyme kinetics to characterize these compounds, we first 
needed to determine the Km values of the aldehyde substrates and cofactor NAD
+
 for 
ALDH1A1. Acetaldehyde was distilled at room temperature to remove impurities, and 
the concentration of acetaldehyde in the distillate was calculated using ALDH2. 
Acetaldehyde has a sub-micromolar Km for ALDH2 and is rapidly turned over, producing 
NADH at a constant rate until all acetaldehyde has been metabolized. At this time, the 
velocity curve flattens to a slope of zero, as no more NADH is being produced. The 
amount of acetaldehyde present at the start can be calculated from the total amount of 
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NADH produced. This method to determine the total acetaldehyde present was used for 
all reactions requiring varied concentrations of acetaldehyde. The reactions for Km 
calculations contained 100 nM ALDH1A1 in 50 mM sodium BES at pH 7.5 at room 
temperature and were monitored at 340 nm for 3 minutes. To determine the Km for the 
aldehyde substrates, we produced velocity curves, plotting increasing concentrations of 
aldehyde (0 to 2 mM) versus the velocity of the reaction, with a saturating amount of 
NAD
+
 (1.5 mM). The Km value is the aldehyde concentration where velocity is one-half 
its maximum value. A similar method was used to calculate the Km for cofactor, plotting 
increasing amounts of NAD
+
 (0 – 1.5 mM) verses velocity, with a saturating amount of 
propionaldehyde (2 mM). Data were plotted using the Simple Ligand Binding Toolbox in 
SigmaPlot (StatSys v12.3), and the values represent the mean/SEM of three experiments 
(each n = 3). 
 
Characterization of ALDH1A1 WT and ALDH1A1 G458N were performed by co-
varying acetaldehyde and NAD
+
 concentrations in reactions containing 150 – 300 nM 
enzyme, 50 – 500 µM or 20 – 200 µM acetaldehyde, and 50 – 500 µM NAD+ in 50 mM 
sodium BES, pH 7.5 at 25˚C. Reactions were initiated by adding enzyme. Data was fitted 
using the Cleland FORTRAN program
161
, while graphs were produced using SigmaPlot 
(StatSys v12.3), and the values represent the mean/SEM of three experiments (each 
n = 3).   
 
We determined the mode of inhibition of the compounds using steady-state kinetics by 
co-varying compound and substrate concentrations, with a saturating amount of the 
second substrate. The reactions contained 100 – 150 nM ALDH1A1 and 1% DMSO in 
50 mM sodium BES at pH 7.5 at room temperature. Following a 2 minute incubation of 
enzyme, NAD
+
, and compound, the reaction was initiated by adding aldehyde substrate 
and monitored at 340 nm for 3 minutes on a Beckman DU-640 spectrophotometer. To 
determine the mode of inhibition with respect to substrate acetaldehyde, acetaldehyde 
was varied from 100 – 800 µM with a fixed concentration of NAD+ at either 800 or 
1000 µM. When cofactor NAD
+
 was varied, the reactions contained 20 – 250 µM NAD+ 
and 200 µM propionaldehyde. All data were fit to competitive, noncompetitive, 
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uncompetitive, and mixed inhibition models using both single substrate-single inhibitor 
and tight binding inhibition programs in SigmaPlot (StatSys v12.3). The appropriate 
model was selected through analysis of goodness-of-fit and the residuals of those fits. 
The value represents the average of three independent experiments (each n = 3). Each 
independent experiment contained protein from a single protein prep, but at least two 
protein preps were used to generate the final values. 
 
DEAB behaved as an irreversible inhibitor for ALDH1A2 and ALDH2. For ALDH1A2, 
solutions containing 100 nM enzyme, 0.1 – 2.0 µM DEAB, and 1.5 mM NAD+ in 50 mM 
sodium BES, pH 7.5 were incubated at 25˚C. For ALDH2, solutions containing 100 nM 
enzyme, 100 – 400 nM DEAB, and 1.5 mM NAD+ in 50 mM sodium BES, pH 7.5 were 
incubated at 25˚C. At the designated time point, the remaining enzyme activity was 
determined spectrophotometrically by adding a saturating amount of propionaldehyde 
(1.0 mM) and monitoring NADH production at 340 nm on a Beckman DU-640. This 
concentration of propionaldehyde is sufficient to prevent any additional DEAB-
dependent inactivation of both ALDH1A2 and ALDH2, thereby obviating the need for 
sample dilution prior to the assay. The apparent bimolecular rate constants were 
determined using the traditional linear analysis of covalent enzyme inactivation
162
:  
ln (
𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦𝑡
𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦0
 𝑥 100) =  −𝑘′ ∗ 𝑡 
A secondary plot was generated from the above and the slope of this secondary plot 
through the origin represented the apparent bimolecular rate constant. The values 
represent the mean/SEM of three independent experiments, with ALDH2 at n = 3 and 
ALDH1A2 at n = 2. 
 
To monitor ALDH1A1 and ALDH3A1 activity using DEAB as a substrate, it was 
necessary to determine both what wavelength to monitor and the differential molar 
extinction coefficient between DEAB and NADH at that wavelength. As the reaction 
time progressed, we observed a decrease in absorbance at 360 nm due to loss of DEAB 
and an increase in absorbance at 300 nm and 340 nm due to increases in product 
formation, diethylaminobenzoic acid and NADH, respectively. The largest molar 
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extinction coefficient difference between DEAB and NADH was seen at 360 nm, and this 
wavelength was used for these kinetic assays (molar extinction coefficient of 
30160 M
-1
 cm
-1
). Molar extinction coefficient determination and kinetics for ALDH3A1 
with DEAB were performed by Dr. Bibek Parajuli. 
 
7. Wavelength Scans to Monitor DEAB Oxidation 
Wavelength scans were performed on the Cary 300 Bio UV-vis spectrophotometer to 
monitor changes in absorbance that could indicate DEAB was acting as a substrate. Scans 
were performed in 1-mL quartz cuvettes and unless otherwise noted contained 500 nM 
enzyme, 10 µM DEAB, and 200 µM NAD
+
 in 50 mM sodium BES pH 7.5 at 25˚C. To 
confirm enzyme activity, a known substrate for each enzyme was added after completion 
of the scan to verify that the enzyme and assay conditions were functional. Wavelength 
scans for ALDH4A1 and ALDH5A1 were performed by Cameron Buchman. 
 
8. Mass Spectrometry 
Complexes for analysis by mass spectrometry were formed from 2.5 – 10.0 µM of the 
ALDH isoenzyme with 10 µM DEAB with or without 100 – 500 µM NAD+ and 
incubated for 1 hour at room temperature in 10 mM HEPES, pH 7.5. Samples (0.5 – 5 
µL) were injected using an Agilent 1200SL HPLC with a flow rate of 0.3 mL/min 
consisting of 70% H2O and 30% acetonitrile with 0.1% formic acid into an Agilent 6520 
quadrupole-time of flight (Q-TOF) mass spectrometer operating in TOF mode. The 
spectra were extracted and deconvoluted using MassHunter and Bioconfirm software. All 
mass spectrometry was performed at the Mass Spectrometry Facility, Department of 
Chemistry and Chemical Biology, Indiana University, Purdue University – Indianapolis 
with the assistance of Dr. Karl Dria.  
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III. Characterization of Diethylaminobenzaldehyde 
A. Results 
1. DEAB as a Substrate for ALDH Isoenzymes  
DEAB shows a characteristic absorbance peak near 360 nm, while the oxidized product 
N,N-diethylaminobenzoic acid shows an absorbance peak at 300 nm (Figure 18). If 
DEAB is a substrate for members of the aldehyde dehydrogenase, it should be possible to 
monitor the decrease in absorbance at 360 nm and an increase in absorbance at 300 nm. 
The changes near these absorbance bands will be the convolution of the decrease of 
DEAB, increase of the acid product and the increase in NADH due to its less prominent 
absorption band at 340 nm (6220 M
-1 
cm
-1
). The extinction coefficient for DEAB at 360 
nm is 34380 M
-1 
cm
-
1, and the extinction coefficient for diethylaminobenzoic acid at 300 
nm is 20370 M
-1 
cm
-1
. In addition, there are some changes in the absorbance features over 
time, even in the absence of enzyme (Figure 19), possibly due to the interaction of the 
aldehyde with water leading to the formation of a gem diol. However, in the presence of 
five of the nine ALDH enzymes tested, there is an observable increase in the rate of 
oxidation, indicating that DEAB can act as a substrate for these isoenzymes. For 
 
 
Figure 18: Absorption characteristics of DEAB and diethylaminobenzoic acid. 
The substrate and product of the reaction absorb at different wavelengths, allowing the 
reaction to be monitored. For both diethylaminobenzaldehyde and diethylamino-
benzoic acid, 10 µM of compound was used. The green trace represents the buffer 
BES and 100 µM NAD
+
. 
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incubations between DEAB and ALDH1A1, the scan shows a drop in absorbance at 360 
nm, indicating a loss of DEAB substrate, plus an increase in absorbance at 300 nm, 
corresponding to the carboxylic acid product (Figure 20A). With 500 nM ALDH1A1, 
oxidation of a large percentage of the 10 µM DEAB had occurred in 3.5 hours. The 
strong absorption of DEAB at 360 nm partially masks NADH formation at 340 nm. 
Monitoring the change in absorbance at 360, we calculated the ALDH1A1 turnover rate 
of DEAB at 0.028 ± 0.002 per min. DEAB was turned over very rapidly by ALDH3A1 
using only 25 nM enzyme, indicating that it is a very good substrate for this isoenzyme 
(Figure 20B). However, with ALDH2 there was only a moderate change in the traces 
after 4 hours, similar to DEAB incubated in the absence of enzyme (Figure 20C). 
Wavelength scans for ALDH1A2 and ALDH4A1 were similar to ALDH2, suggesting 
that DEAB is either an extremely slow substrate or is not turned over by these three 
isoenzymes. DEAB is a very slow substrate for ALDH1B1 (Figure 20D), and the 
wavelength scans for ALDH1A3 and ALDH5A1 were similar to ALDH1B1. For all nine 
isoenzyme scans, there was no change in absorbance noted from 400 – 600 nm, and even 
after a 16 hour scan, the enzymes were still active and capable of propionaldehyde 
oxidation. Wavelength scans indicated that DEAB was turned over by ALDH3A1 much 
more rapidly than by the other ALDH isoenzymes tested. An analysis using substrate-
inhibition kinetics produced a Km of 5.6 ± 0.4 µM (Figure 21). For comparison, the Km of 
the commonly used substrate benzaldehyde is over 30-fold higher at ~300 µM (Table 4).  
 
Figure 19: Oxidation of DEAB in the absence of enzyme. 
Wavelength scans indicate that DEAB oxidizes to its acid at a slow rate in a 50 mM 
Na
+
-BES pH 7.5 at 25°C, the buffer conditions used for wavelength scan assays with 
the enzymes. No NAD
+
 is present.  The green line represents a water trace while the 
magenta line is BES alone (no DEAB). Over time, there was a decrease at 360 nm 
corresponding to DEAB and an increase at 300 nm corresponding to 
diethylaminobenzaldehyde. 
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Figure 20: Wavelength scans of ALDH isoenzymes with DEAB. 
For ALDH1A1, ALDH2, and ALDH1B1 reactions containing 500 nM enzyme, 200 
µM NAD
+
, and 10 µM DEAB were monitored from 200 – 600 nm. A) For 
ALDH1A1, a gradual decrease at 360 nm and increase at 300 nm is seen, 
corresponding to substrate lose and product formation, respectively. B) For 
ALDH3A1, the reaction contained 25 nM enzyme, 200 µM NAD
+
, and 10 µM DEAB 
and rapid DEAB oxidation occurs. C) For ALDH2, there is little change in the 
spectrographic trace after 4 hours. D) ALDH1B1 had more DEAB oxidation then 
ALDH2 but turnover was still low.  For all reactions, no absorption changes were seen 
above approximately 400 nm. 
Table 4: Kinetic parameters for ALDH3A1 oxidation of DEAB  
Substrate KM (mM) kcat (min
-1
) kcat/KM 
Benzaldehyde 280 ± 20 1400 ± 60 4.9 ± 0.3 
DEAB 5.6 ± 0.7 130 ± 20 24 ±1 
Bibek Parajuli, Ph.D. 
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2. DEAB as an Inhibitor of ALDH Isoenzymes.  
Although DEAB is a substrate for ALDH1A1, ALDH1A3, ALDH1B1, and ALDH5A1, 
it is turned over at such a slow rate it is effectively an inhibitor for the oxidation of other 
substrate aldehydes such as acetaldehyde and propionaldehyde. DEAB inhibited six 
ALDH isoenzymes tested, and all had IC50 values less than 20 µM (Figure 22 and Table 
5). Under the conditions of the experiments, it was a more potent inhibitor for ALDH1A1 
(Figure 23A, IC50 = 57 ± 5 nM) compared to the other five isoenzymes inhibited by 
DEAB. DEAB displayed a competitive mode of inhibition toward ALDH1A1 with 
respect to varied acetaldehyde with a Ki of 9.8 ± 3.1 nM (Figure 23B). During IC50 
calculations for ALDH2, it was discovered that the IC50 values were dependent on order 
of addition and incubation times, with no inhibition observed at up to 50 µM (maximum 
concentration used) when the reaction was initiated by adding enzyme, but dropped to an 
IC50 of 160 ± 30 nM following a two minute pre-incubation of enzyme with DEAB and 
NAD
+
 (Figure 24). Under these conditions, saturation with propionaldehyde did not lead 
to recovery of full enzymatic activity, suggesting that DEAB is covalently modifying 
ALDH2. Although not as apparent as with ALDH2, ALDH1A2 behaved in a similar 
manner, with the IC50 for ALDH1A2 dependent on the order of addition and exhibited 
 
Figure 21: Substrate saturation curve for ALDH3A1 with DEAB as a substrate. 
This curve represents one of three experiments, each n = 3, it to the substrate 
inhibition equation (Bibek Parajuli, Ph.D.).  
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more than a 5-fold increase without a pre-incubation with DEAB and NAD
+
. The 
apparent bimolecular rate constant of ALDH1A2 was 2900 ± 160 M
-1
s
-1
 (Figure 25), 
while ALDH2 had an apparent bimolecular rate constant of 86000 ± 4200 M
-1
s
-1
 (Figure 
26). 
 
 
 
 
 
 
 
Figure 22: Selectivity of DEAB with eight ALDH isoenzymes. 
For each enzyme, activity following treatment with 20 μM DEAB 
was compared to control activity with 1% DMSO Bar represents 
mean/SEM (n=3). 
A.                                                              B. 
 
Figure 23: Characterization of ALDH1A1 with DEAB. 
A) IC50 curve of DEAB with 150nM ALDH1A1. B) Lineweaver-Burk plot to 
determine the Ki of DEAB for ALDH1A1 with respect to varied acetaldehyde. Each 
plot represents one of three experiments, with each point representing the mean/SEM 
of three independent readings. 
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Table 5: Effect of DEAB on ALDH isoenzymes. 
 Substrate 
IC50 (μM) 
Mean/SEM Comments 
ALDH1A1 Yes 0.057 ± 0.005 
Competitive Tight Inhibition 
Ki = 10 ± 3 nM 
ALDH1A2 No 1.2 ± 0.1 
 
Covalent Inhibitor 
Apparent Bimolecular Rate Constant  
2900 ± 160 M
-1
 s
-1 
ALDH1A3 
Yes 
(slow) 
3.0 ± 0.3  
ALDH1B1 
Yes 
(slow) 
1.2 ± 0.1  
ALDH1L1 No NI*  
ALDH2 No 0.16 ± 0.03 
Covalent Inhibitor 
Apparent Bimolecular Rate Constant 
86000 ± 4200 M
-1
 s
-1
 
ALDH3A1 Yes NA# Km = 5.6 μM 
ALDH4A1 No NI*  
ALDH5A1 
Yes 
(slow) 
13 ± 0.5  
*NI denotes no detectable inhibition.    #NA denotes not applicable as an inhibitor. 
ALDH3A1 Km determined by Bibek Parajuli, Ph.D. ALDH4A1 and ALDH5A1 
substrate analysis and ALDH5A1 IC50 performed by Cameron Buchman. 
 
  
 
Figure 24: ALDH2 and DEAB. 
With a 2 min incubation of ALDH2 with DEAB and NAD
+
, DEAB is a potent 
inhibitor with an IC50 = 160 nM. Without an incubation period, no inhibition was seen 
at up to 50 µM DEAB. 
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B. 
A.  
 
Figure 25: Time-dependent inhibition of human ALDH1A2 with DEAB. 
A) Plot of ln (% activity) vs. time with 6 doses of DEAB. The slopes (-m) of these 
lines were used to generate the secondary plot. B) Secondary plot of –k’ versus DEAB 
concentration for ALDH1A2. The bimolecular rate constant for inhibition was 
calculated from the slope of this line. Each set of plots represents one of three 
experiments, each n = 2. 
 
 
 
B. 
 50 
 
A 
 
Figure 26: Time-dependent inhibition of human ALDH2 with DEAB. 
A) Plot of ln (% activity) vs. time with 5 doses of DEAB. The slopes (-m) of these 
lines were used to generate the secondary plot. B) Secondary plot of –k’ versus DEAB 
concentration for ALDH2. The bimolecular rate constant for inhibition was calculated 
from the slope of this line. Each set of plots represents one of three experiments, each 
n = 3. 
 
B. 
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Figure 27: Modification of human ALDH2 with DEAB. 
Deconvoluted spectrum of A) ALDH2, B) ALDH2 incubated with 2-fold molar 
excess of DEAB, and C) ALDH2 incubated with 2-fold molar excess of DEAB and 
saturating NAD
+
. 
3. Mass Spectrometry of ALDH-DEAB Complexes. 
Mass spectrometry was used to determine whether DEAB was covalently binding to the 
ALDH enzymes. Quadrupole TOF MS of ALDH1A1, ALDH1A2, ALDH1B1, and 
ALDH2 confirmed that there was an increase in mass of 175 Da, corresponding to DEAB 
binding with the loss of two protons. With 5 µM ALDH2 alone (Figure 27A) or 
incubated with 10 µM DEAB without NAD
+
 (Figure 27B), there was a major peak at a 
mass of 54445 Da plus a much smaller peak at 54357 Da, a difference of 87 Da likely 
corresponding to loss of the N-terminal serine during protein production. ALDH2 
incubated with both DEAB and 500 µM NAD
+
 resulted in a major peak at 54620 Da and 
much smaller peaks at 54533 Da, 54445 Da, and 54357 Da (Figure 27C). The peaks at 
54620 Da and 54533 Da represent a shift of 176 Da from 54445 Da and 54357 Da, 
respectively, and correspond to DEAB binding to the two major ALDH2 species present 
in the sample. A similar shift was seen using 2.5 µM ALDH1B1, 10 µM DEAB, and 500 
µM NAD
+
 (data not shown). ALDH1B1 alone or incubated with DEAB yielded a major 
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Figure 28: Modification of human ALDH1A1 with DEAB. 
Deconvoluted spectrum of A) ALDH1A1, B) ALDH1A1 incubated with 10-fold 
molar excess of DEAB, and C) ALDH1A1 incubated with 10-fold molar excess of 
DEAB and saturating NAD+. 
peak at 56592 Da and a much smaller peak at 57200 Da; this latter peak may represent an 
enzyme species modified by two glutathione molecules. However, incubation of 
ALDH1B1, DEAB, and NAD
+
 shifted the major peak to 56768 Da plus a minor peak at 
57375 Da, both corresponding to DEAB bound to the two ALDH1B1 species present, 
and a smaller peak at 56592 Da, corresponding to unmodified protein. Both the ALDH2 
and ALDH1B1 data indicate that NAD
+
 must be present for DEAB to modify the 
enzyme. After a one hour incubation with a 2- to 4-fold molar excess of DEAB, most of 
the enzyme present had been modified. DEAB also covalently modifies ALDH1A1 in the 
presence of NAD
+
 but is not complete (Figure 28). These shifts in peaks correspond to 
DEAB binding with a loss of two protons, similar to what is seen with ALDH1A1 and a 
known substrate benzaldehyde. Using 5 µM ALDH1A1, 1.5 mM NAD
+
, and 2.5 mM 
benzaldehyde, there is a 104 Da shift corresponding to the substrate binding to 
ALDH1A1 with the loss of two protons in the presence of enzyme, cofactor, and 
substrate (Figure 29). Association of DEAB to ALDH1A1, ALDH1B1, and ALDH2 was 
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Figure 29: Modification of human ALDH1A1 with benzaldehyde. 
Deconvoluted spectrum of A) ALDH1A1, B) ALDH1A1 incubated with 500-fold 
molar excess of benzaldehyde, and C) ALDH1A1 incubated with 500-fold molar 
excess of benzaldehyde and saturating NAD
+
. 
dependent on NAD
+
, but the requirement for NAD
+
 was not absolute for ALDH1A2.  
Using 5.0 µM ALDH1A2, 10 µM DEAB, and 500 µM NAD
+
, enzyme alone yielded a 
major peak at 56592 Da and a much smaller peak at 56830 Da (Figure 30A). When 
ALDH1A2 is incubated with DEAB, the major peak is still at 56592 Da but a large peak 
is also seen at 56768 Da, corresponding to DEAB binding to approximately one-third of 
the ALDH1A2 present, with smaller peaks at 56830 Da and 57007 Da (Figure 30B). 
Following incubation of ALDH1A2, DEAB, and NAD
+
, the major peak was seen at 
56768 Da, with smaller peaks at 56592 Da and 57006 Da (Figure 30C). These results 
imply that DEAB may bind to ALDH1A2 independent of the presence of coenzyme. 
However, it may be possible that oxidized coenzyme co-purifies with ALDH1A2. To 
determine whether NAD
+
 is present from the ALDH1A2 protein purification, 500 µM 
propionaldehyde was added to 18 µM ALDH1A2 without additional NAD
+
 and 
monitored for 15 minutes. There was no change at 340 nm, indicating that NADH is not 
being produced in this reaction. This suggests that NAD
+
 is, at a minimum, not present at 
the molar ratio levels suggested by mass spectrometry, since reactions using only 5 µM 
NAD
+
 produce an observable change at 340 nm. To confirm covalent modification and 
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Figure 30: Modification of human ALDH1A2 with DEAB. 
Deconvoluted spectrum of A) ALDH1A2, B) ALDH1A2 incubated with 2-fold molar 
excess of DEAB, and C) ALDH1A2 incubated with 2-fold molar excess of DEAB and 
saturating NAD+. 
investigate the requirement for NAD
+
 to inactivate ALDH2 and ALDH1A2, the enzymes 
were incubated in the presence of DEAB with and without NAD
+
 and then dialyzed for 4 
hours against a 4000-fold excess of buffer. Relative to control samples incubated in the 
absence of DEAB, neither the ALDH2 nor the ALDH1A2 samples regained enzymatic 
activity when DEAB and NAD
+
 were present in the incubation, consistent with 
irreversible, covalent modification (Figure 31). In contrast to the level of inactivation 
observed with DEAB and NAD
+
, incubation of enzyme plus DEAB alone, resulted in 
only partial inactivation of both ALDH2 and ALDH1A2. Dialysis had no impact on the 
level of inactivation for ALDH2, but the ALDH1A2 sample recovered 75% of the control 
activity, suggesting the latter modification is, in part, reversible (Figure 31). ALDH1L1, 
ALDH3A1, ALDH4A1 and ALDH5A1 were not examined in this manner due to limited 
quantities of enzyme available.  
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B. Discussion 
A number of isoenzymes in the aldehyde dehydrogenase superfamily have been linked to 
both normal and cancer stem cells. The Aldefluor Assay relies on their aldehyde 
oxidation abilities to identify and segregate stem cells with high levels of ALDH activity. 
Inhibition of ALDHs by DEAB, an aldehyde, is used as a control. The concept of 
substrates as inhibitors is not new. A number of organophosphorus compounds are esters 
that inhibit cholinesterase by acetylating the enzyme in a process similar to its normal 
substrate acetylcholine.  As discussed by Aldridge, the only difference between a 
substrate (i.e. acetylcholine) and an inhibitor (i.e. dimethylphosphates) is the rate of 
reaction
163
. Here, we have shown that DEAB is both a substrate and an inhibitor for 
certain ALDH isoenzymes and that the rate of reaction, namely hydrolysis, determines 
whether the compound behaves as a classic substrate (ALDH3A1), as a covalent 
inhibitor, (ALDH2 and ALDH1A2), or as an intermediate between substrate and inhibitor 
(ALDH1A1, ALDH1A3, ALDH1B1, and ALDH5A1). We propose that differences in 
residues at the substrate binding sites of the isoenzymes are capable of stabilizing the 
acyl-enzyme intermediate to varying degrees. In ALDH3A1, little to no stabilization 
 
Figure 31: Effects of dialysis on DEAB-induced inhibition. 
ALDH1A2 and ALDH2 were pre-incubated for 30 minutes with DEAB in the 
presence or absence of NAD
+
. Solutions were dialyzed for 4 hours against a 4000-
fold excess of buffer and the activity post-dialysis compared to the activity levels 
prior to dialysis. Bars represent mean/SEM (n=3) (performed by Cameron Buchman). 
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Figure 32: Proposed mechanism of action of DEAB on ALDH enzymes. 
Residue numbering based on ALDH2. 
 
occurs and DEAB is quickly turned over, resulting in a low micromolar Km. For ALDH2 
and ALDH1A2, the acyl-enzyme is very stable and little observable turnover occurs, thus 
mimicking a covalent inhibitor. However, we do believe these two enzymes are capable 
of eventually oxidizing DEAB at an extremely low rate. We propose that structural 
features within their respective active sites are capable of stabilizing a resonance structure 
intermediate (Figure 32).  
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Based on the kinetic and mass spectrometry data, we propose that DEAB functions as a 
substrate for all enzymes through the hydride transfer step, but that the acyl-enzyme 
intermediate is slowed for hydrolysis by a resonance structure available to the thioester 
intermediate due to the lone pair of electrons on the para-diethylamino substituent  
(Figure 32). The addition of the lone pair into the aromatic ring resonance promotes the 
formation of a quinoid-like structure where the extra electrons now reside on the carbonyl 
oxygen atom resulting in stabilization by the oxy-anion hole comprised of the peptide 
amide nitrogen of the catalytic nucleophile and the side chain amide nitrogen of the 
residue equivalent to Asn169 in ALDH2. The intermediate stabilized in this manner 
makes the carbonyl carbon less susceptible to attack by a hydroxyl ion. The extent that 
this resonance structure forms and the duration of its stabilization would appear to differ 
between the various isoenzymes with which DEAB forms productive interactions.  
 
The fact that DEAB is an excellent substrate for ALDH3A1 is not altogether surprising, 
since the enzyme is known to prefer aromatic substrates over linear aliphatic 
substrates
164,165
. It is interesting that even for ALDH3A1, the kcat is lower for DEAB than 
for benzaldehyde by an order of magnitude, making DEAB, by definition, a slow 
substrate. Thus, only the fact that the Km for DEAB is approximately 50-fold lower than 
for benzaldehyde places the catalytic efficiency for DEAB amongst the best for known 
substrates. For acetaldehyde and benzaldehyde, hydride transfer is known to be rate-
limiting for catalysis in ALDH3A1
42
, implying that either hydride transfer is 11-fold 
slower for DEAB or another step has become rate-limiting.  We suggest that acyl-enzyme 
hydrolysis has become rate-limiting due to the potential for resonance stabilization of the 
acyl-enzyme intermediate and the fact that the electronic properties of DEAB should 
promote easier extraction of the hydride ion from the thiohemiacetal. Measurements of 
the isotope effects or stopped-flow analyses will be necessary to distinguish between 
these or other mechanistic possibilities for ALDH3A1. However, it is clear that the acyl-
enzyme intermediate formed between ALDH3A1 and DEAB is the shortest lived of any 
ALDH acyl-enzyme species tested by at least 3-orders of magnitude. The short life-time 
may be influenced by the curved nature of the enzyme’s substrate-binding site166, which 
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likely distorts the planar conformations required to maintain the aromatic quinoid 
resonance state (see Figure 12 for comparisons of ALDH substrate-binding sites). 
 
DEAB is a good to excellent inhibitor for all but three of the ALDH isoenzymes 
examined, with IC50 values ranging between 57 nM to 13 μM. The most potent inhibition 
by DEAB is toward ALDH1A1, followed by ALDH2, ALDH1A2, ALDH1B1, 
ALDH1A3 and ALDH5A1. However, the relative order for enzymatic turnover follows 
the order ALDH1A1 > ALDH1B1, ALDH1A3, ALDH5A1 > ALDH1A2, ALDH2. Thus, 
it would seem that the two properties of DEAB, inhibition vs substrate, are not directly 
correlated. DEAB demonstrates the most potent inhibition for ALDH1A1 with an IC50 of 
57 nM and exhibits a competitive mode of inhibition toward acetaldehyde with a Ki of 10 
nM. Consequently, despite the low turnover of this complex (0.028 min
-1
), these 
properties give rise to a pseudo-bimolecular rate constant of approximately 47,000 M
-1
s
-1
, 
which is within a factor of two of the value obtained for DEAB inactivation of ALDH2 at 
86,000 M
-1 
s
-1
.  Both these values imply a rapid association between enzyme and DEAB.  
ALDH1A2 is 20- to 30-fold slower, correlating with its 10- to 100-fold higher IC50 value. 
The interactions between DEAB and ALDH1A3 or ALDH1B1 are similar to ALDH1A2, 
although these enzymes do show very slow turnover of their respective enzyme-DEAB 
complexes.  
 
An inspection of the respective active site structures fails to identify consistent 
differences in residues lining the substrate sites that correlate with all the features of 
DEAB interactions
167
 
166
. ALDH1A1 is the most wide open substrate binding site which 
is best described as a flattened funnel shape, due to Gly substitutions at positions 125 and 
458 and Val at positions 174 and 460
166
. The ALDH1A2, ALDH1A3 and ALDH1B1 
enzymes have substrate sites more similar to the cylindrical site in ALDH2
166
, and 
perhaps these sites better constrain the aromatic system to remain planar, thereby 
increasing the residency time of the quinoid intermediate and slowing hydrolysis. The 
active site structure of ALDH5A1 (PDB code 2W8R
168
) is next most similar to ALDH2, 
but its low reactivity toward DEAB may be due to the presence of two characteristic 
arginine residues near the middle and outer regions of the substrate site, R213 and R334. 
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Presumably, the binding site in ALDH5A1 does not stabilize the acyl-enzyme 
intermediate sufficiently to prevent turnover. The failure of DEAB to inhibit ALDH1L1 
and ALDH4A1 suggests that elements of the substrate binding site in these isoenzymes 
are incompatible with formation of a productive thiohemiacetal intermediate with DEAB 
in the first place. ALDH1L1 has a very narrow active site surrounding the catalytic 
nucleophile, which may exclude aromatic substrates from its active site. In agreement 
with this observation, aromatic aldehydes are poor substrates for ALDH1L1. In the case 
of ALDH4A1 (PDB code 4LH2
169
), it is the outer region of the substrate binding site that 
is narrowed, which may prevent DEAB association.  
 
DEAB possesses all the characteristics of a substrate for many ALDH isoenzymes, 
especially ALDH3A1. However, its particular electronic properties give rise to a stalled 
acyl-enzyme intermediate in ALDH isoenzymes that can stabilize its electronic resonance 
structure, making DEAB a mechanism-based inhibitor for ALDH2 and ALDH1A2, a 
very slow substrate for ALDH1A3, ALDH1B1 and ALDH5A1, a slow substrate for 
ALDH1A1, and an excellent substrate for ALDH3A1.  In contrast, DEAB is neither a 
substrate nor an inhibitor for ALDH1L1 or ALDH4A1. The broad and varied nature of 
the interaction between DEAB and ALDH isoenzymes suggests that its use as an 
inhibitor or competitive substrate in the Aldefluor Assay should be interpreted with 
caution with respect to which particular ALDH isoenzymes contribute to the observed 
signal in the flow-cytometry assay. 
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IV. Discovery of Novel, Selective Inhibitors of ALDH1A1 
A. Results 
1. X-ray Crystallography of apo-ALDH1A1 and ALDH1A1-NADH Complex 
To better understand target specificity and provide a structural context for the mechanism 
underlying how a compound inhibits ALDH1A1, it was necessary to determine the 
structure of ALDH1A1 using X-ray crystallography. To accomplish this objective, we 
first needed to crystallize human ALDH1A1. The structure of sheep ALDH1A1 was 
determined roughly 15 years ago
148,149
. Although the sheep and human enzymes share 
approximately 90% sequence identity, the conditions used to crystallize the sheep 
enzyme did not successfully crystallize the human enzyme. To determine crystallization 
conditions for human ALDH1A1, a number of Hampton Research screens were used. 
These screens contain a diverse range of reagents to facilitate discovery of conditions in 
which the protein begins to crystallize, rather than simply staying in solution or 
precipitating out. Only the Index Screen (HR2-144) generated positive results, with five 
conditions producing crystalline needle clusters (Figure 33A): (1.) 200 mM sodium 
chloride, 100 mM BisTris pH 6.5, 25% PEG3350, (2.) 200 mM sodium chloride, 100 
mM HEPES pH 7.5, 25% PEG3350, (3.) 200 mM sodium chloride, 100 mM Tris pH 8.5, 
25% PEG3350, (4.) 200 mM ammonium acetate, 100 mM BisTris pH 6.5, 25% 
PEG3350, and (5.) 200 mM sodium formate, 20% PEG3350. The first four conditions 
were successfully replicated, and these conditions were further optimized to produce 
multiple, small needle clusters. Next, the Additive Screen (HR2-428) was used with each 
of the four conditions above to identify small molecule(s) that might aid in the formation 
  A.                B.             C. 
 
Figure 33: Evolution of ALDH1A1 crystallization conditions. 
A) Needle cluster of crystalline ALDH1A1 enzyme produced from five conditions in 
Hampton Research Index Screen. B) Small crystals that formed in presence of yttrium 
chloride. C) Final crystal produced following optimization with ytterbium chloride.  
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of crystals suitable for X-ray structural analysis. The salt yttrium chloride produced small 
crystals in the two conditions that used the buffer BisTris, PEG3350, and either sodium 
chloride or ammonium acetate (Figure 33B). However, further optimization with yttrium 
chloride did not improve crystal formation. Yttrium is a trivalent ion with an ionic radius 
of 0.9 Å. Others ions of similar size were tested, including gold (III) chloride, palladium 
(II) chloride, thulium (III) chloride, lutetium (III) chloride, ytterbium (III) chloride, and 
samarium (III) chloride. Ytterbium (III) chloride (YbCl3) produced large, single crystals 
exhibiting strong X-ray diffraction; it is a trivalent ion and with a radius of 0.858 Å, it is 
only slightly smaller than yttrium. YbCl3 with ammonium acetate produced large, cube-
shaped crystals, while YbCl3 with sodium chloride produced tetragonal crystals, with the 
unequal edge at least four times longer than the lengths of the other two sides (Figure 
33C). The cube-shaped crystals were more difficult to produce and generated X-ray 
diffraction data indicating a more disordered crystal. Therefore, the conditions that 
produced tetragonal-shaped crystals were deemed the best for X-ray crystallography 
structure determination. For human ALDH1A1, these conditions are 100 mM sodium 
BisTris, pH 6.2 - 7.5, 7 - 12 % PEG3350, 200 mM NaCl, 5 - 10 mM YbCl3, and 
3 - 5 mg/mL enzyme.  
 
A similar approach was taken to determine crystallization conditions for the co-crystals 
of ALDH1A1 with its cofactor NAD
+
. The Index Screen identified similar conditions as 
found with enzyme alone. Follow-up with the Additive Screen indicated nearly half of 
the 96 additives aided crystal formation. However, further optimization of numerous 
conditions did not improve crystal size, and the crystals produced did not diffract as 
expected for a protein. To determine the structure of ALDH1A1 bound to its cofactor, 
apo-enzyme crystals were soaked for two hours with 1 mM NAD
+
.  
 
The structure of human ALDH1A1 had not been previously reported, but was expected to 
be similar to both the human ALDH2 enzyme (PDB code 3N80), with which ALDH1A1 
shares about 70% sequence identity, and the sheep ALDH1A1 (PDB code 1BXS), with 
over 90% sequence identity. We solved the structure of human ALDH1A1 N121S in its 
apo-enzyme form to a resolution of 1.75 Å (Figure 34, Table 6, PDB Code 4WJ9). The 
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enzyme’s structure is similar to other ALDH enzymes and contains all the structural 
features that characterize the ALDH superfamily. The structure of wild-type ALDH1A1 
with NADH was determined to a resolution of 2.1 Å (Figure 35, Table 6, PDB Code 
4WB9). Comparison of the structure of ALDH1A1 (PDB Code 4WB9), ALDH2 (PDB 
Code 10O2), and ALDH3A1 (PDB Code 4L2O) with cofactor illustrates the difficulty of 
developing selective inhibitors for ALDH1A1 that target the cofactor binding site. Of the 
three isoenzymes compared, ALDH3A1 is the least similar both by structural topology 
and sequence identity, as is expected based on its ability to utilize both NAD
+
 and 
NADP
+
, and these differences are most obvious near the adenosine ribose and 
pyrophosphate binding site. However, as shown in Figure 36, there is a high degree of 
similarity between the cofactor binding sites of ALDH1A1 and ALDH2, supporting our 
hypothesis that selection of an assay independent of the cofactor binding site would aid 
development of selective inhibitors for the ALDH1/2 class of enzymes.  
 Table 6: Data collection and refinement statistics. 
Data Collection 
Apo-ALDH1A1 
N121S (PDB: 4WJ9) 
ALDH1A1-NADH 
WT (PDB: 4WB9) 
Space Group P422 P422 
Cell Dimensions 
  
a, b, c (Å) 109, 109, 83 109, 109, 83 
Α, β, γ (°) 90, 90, 90 90, 90, 90 
Resolution (Å) 50 – 1.75 50 – 2.1 
R
merge
 0.056(0.59) 0.09(0.52) 
I/σ
i
 31.5 (3.9) 17.8 (4.9) 
Completeness (%) 99 (97) 99 (100) 
Redundancy 9.6 (8.5) 8.3 (7.9) 
Refinement   
No. of Reflections 48,862 29,814 
R
work
 / R
free
 0.19 / 0.23 0.18 / 0.23 
No. of Atoms 4087 4102 
Protein 3836 3837 
Ligand/Ion 2 50 
Water 249 215 
R.M.S. Deviations   
Bond Lengths (Å) 0.010 0.017 
Bond Angles (°) 1.24 1.8 
Numbers in parenthesis represent values of highest resolution shell. 
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A.                                                                  B. 
 
Figure 34: Structure of human ALDH1A1 (N121S) apo-enzyme. 
A) Ribbon representation of an ALDH1A1 monomer showing the location of cysteine 
303 in the active site plus the location of ALDH1A1 N121S SNP used for the HTS. B) 
Ribbon representation of the structure of the homotetrameric ALDH1A1 with each 
monomer colored separately (PDB 4WJ9).  
C. 
A.                                                            B. 
 
Figure 35: Structure of ALDH1A1 (WT) with reduced cofactor NADH. 
The location of the active site Cys-303 is shown in red. A) Location of NADH at 
cofactor binding site of one monomer of ALDH1A1. B) Electron density maps of 
NADH with the original Fo – Fc in green contoured at 2.5 standard deviations and the 
final 2Fo – Fc map in grey contoured at 1.0 standard deviations C) Surface rendition of 
NADH near the active site Cys-303 (PDB 4WB9). 
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2. Esterase High-Throughput Screen 
A high-throughput screen (HTS) was used to discover novel activators and inhibitors for 
ALDH1A1. For the HTS, we used the inherent NAD
+
-independent
 
esterase activity of 
ALDH1A1 to identify compounds capable of altering enzyme activity, instead of the 
standard NAD
+
-dependent aldehyde oxidation assay. This approach minimized 
interference from compounds that absorb light at a wavelength similar to the reduced 
cofactor NADH. It also minimized identification of compounds that bind to the cofactor 
binding site. The cofactor binding site is highly conserved amongst the members of the 
ALDH superfamily. As seen in Figure 36, there is a high degree of similarity between the 
structures of ALDH1A1-NADH and ALDH2-NADH, and it is highly likely that such 
compounds would not be selective for ALDH1A1.  
 
The Z-factor for the HTS comparing ALDH1A1 plus/minus inhibitor (Aldi-1) under 
screening conditions was 0.67 (n = 384), indicating inhibitors can be identified from 
single assays. As shown in Figure 37, there is a clear separation between the control 
reaction containing enzyme and substrate (ES Control) represented in blue, and the 
inhibitor control reaction containing enzyme, substrate plus an ALDH1A1 inhibitor (ESI 
control) represented in red. Also, the average value for ALDH1A1 with control inhibitor 
 
 
Figure 36: Comparison of the cofactor binding sites of ALDH1A1 and ALDH2. 
Overlap of the structure of ALDH1A1-NADH, in blue, with the structure of ALDH2-
NADH, in grey.  
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Figure 37: Z-factor determination for HTS esterase screen. 
Each point represents the rate of change in absorbance at 405 nm of a reaction. The x-
axis is the column (1 – 24) on the 384-well plate of the reaction. The blue data points 
represent the enzyme + substrate (ES) control, with an average value of 4.086; the red 
is enzyme + substrate + inhibitor, with an average value of 0.697; the open circles are 
the no enzyme control (blank). The lines represent 3x standard deviation from ES 
control (blue lines), ESI control (red lines), and blank (black lines). Each condition 
(ES, ESI, blank) performed on a separate plate with n = 384.  
was similar to the no enzyme, blank control (mean rate of change of 0.70 vs 0.60), 
indicating our inhibition control (25 µM Aldi-1, IC50 = 2.2 µM
137
) strongly inhibited 
ALDH1A1. For the HTS, we used an ALDH1A1 protein with a known SNP at residue 
121. This N121S “mutant” in the open reading frame was cloned by the Weiner group152 
and utilized for all their published work on ALDH1A1. The enzyme is active and 
behaved similarly to ALDH1A1 WT (Km of 12 µM vs 15 µM, respectively, with identical 
kcat/Km values at 2.7 min
-1
 ·µM
-1
 for the substrate propionaldehyde). A comparison of the 
respective alpha-carbons in the structure of the N121S apo-enzyme and those of the wild-
type ALDH1A1 structure complexed with NADH generated an RMSD of 0.2 Å, 
consistent with a high degree of functional and structural similarity. The side chains of 
Ser and Asn both form similar hydrogen bonding interactions with Tyr297. The screen 
used a saturating amount of the esterase substrate pNPA (Km = 5 µM
170
). Each plate 
contained a control column with enzyme and substrate (ES control), and the average (n = 
16) of this intra-plate control served as the basis to determine whether a compound 
modified esterase activity. An activator was defined as having 2-fold or higher esterase 
activity compared to this control, while an inhibitor had 40% or less activity. Each plate 
also contained a positive control for inhibition (ESI control) using the inhibitor Aldi-1. 
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Figure 38: Representative plate from HTS. 
Each point represents one well, with the x-axis the column (1-24) on the plate and the 
y-axis, the rate of change measured at wavelength 405 nm. Column 23 is the ES 
control, with an average value of 3.05 (n=16). Column 24 is the inhibition (ESI) 
control containing 25 µM Aldi-1. For this plate, an activator had a value ≥ 6.1 while 
an inhibitor had a value ≤ 1.22. Lines are 3x standard deviation, blue for ES and red 
for ESI. On this plate, we identified 3 activators (P14, N16, M19) and 1 inhibitor 
(D12) out of 352 compounds, with labeling based on their row and column on 384-
well plate. 
The initial round of the in vitro esterase-based screen of 64,000 compounds yielded 631 
compounds that activated ALDH1A1 and 278 compounds that inhibited ALDH1A1. A 
sample plate from the first round of screening is shown in Figure 38, illustrating 3 
activators and 1 inhibitor out of 352 compounds tested. Following rescreening of the 909 
compounds identified in the first round under identical conditions, nearly 75% did not 
meet these same selection criteria during the second, validation assay set. After two 
rounds, we identified 241 activators and 15 inhibitors of ALDH1A1 esterase activity 
(Supplementary Tables 1 and 2). 
 
3. Selectivity of Compounds for ALDH1A1 Aldehyde Oxidation 
From the HTS, we identified 256 compounds that either activated or inhibited ALDH1A1 
esterase activity to the levels of our selection criteria. All compounds had molecular 
masses between 250 and 500 Da. The 241 activators were classified into 17 groups based 
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on their structural similarities. Over 65% of the esterase activators fell into nine structural 
classes, with one class containing 78 hits. There were 22 structurally unique compounds. 
The HTS identified only 15 esterase inhibitors, 2 structurally similar compounds and 13 
structurally unique compounds. Of the 256 hits, 67 have been analyzed further to 
determine their effect on aldehyde oxidation and selectivity for ALDH1A1, 57 esterase 
activators and 10 esterase inhibitors (Figure 39). Of the 15 esterase inhibitors identified 
by HTS, only 7 were commercially available without requiring customized synthesis. 
However, close analogs of three others were purchased and analyzed: (1) hit 3343-2924 
was substituted with 2188-3302 (CM310), (2) hit C699-0615 was substituted with C699-
0244 (CM306), and (3) hit K788-2754 was substituted with K938-0803 (CM307). The 
effects of the hits on aldehyde oxidation were tested using the standard assays performed 
in our laboratory to study ALDH1A1, ALDH2, and ALDH3A1. For ALDH1A1 and 
ALDH2, the 100 µM propionaldehyde used is near or at saturation (ALDH1A1 Km =15 
µM and ALDH2 Km < 1 µM). For ALDH3A1, the concentration of benzaldehyde used 
was set at its Km. None of the 67 compounds activated aldehyde oxidation by ALDH1A1, 
ALDH2, or ALDH3A1 by more than 20%. However, of the 57 esterase activators 
examined at 20 µM, 28 inhibited ALDH1A1 propionaldehyde oxidation by at least 50%. 
Of the 10 esterase inhibitors tested at 20 µM, 4 compounds also inhibited ALDH1A1 
propionaldehyde oxidation at least 50%, but 2 inhibitors (CM302 and CM303) also 
exhibited at least 50% inhibition of ALDH2 and therefore were not selective for 
ALDH1A1. To a limited degree, CM302 also inhibited ALDH3A1, but none of the 
remaining 66 hits altered ALDH3A1 benzaldehyde oxidation more than 20% from 
control. Based on the selectivity assays of 67 esterase hits, 30 compounds selectively 
inhibited ALDH1A1 compared to ALDH2 and ALDH3A1, while 2 compounds inhibited 
both ALDH1A1 and ALDH2 at least 50% but not ALDH3A1  (Figure 39). Therefore, the 
HTS for esterase activity successfully identified selective inhibitors for ALDH1A1 
aldehyde oxidation. 
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Figure 39: Effect on aldehyde oxidation of hit compounds from HTS. 
The activity of 67 compounds (20 μM except [CM307] = 10 μM) identified via HTS 
was tested on three ALDH isoenzymes. Mean/SEM (n = 3) 
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Figure 39, continued. Effect on aldehyde oxidation of hit compounds from HTS. The 
activity of 67 compounds (20 μM except [CM307] = 10 μM) identified via HTS was 
tested on three ALDH isoenzymes. Mean/SEM (n = 3). 
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IC50 values were determined for compounds that inhibited propionaldehyde oxidation at 
least 60% at 20 µM concentration, with the most potent inhibitors and their IC50 values 
shown in Figure 40 and Table 7. Of the 57 esterase activators, 17 were structurally 
similar (CM022-031, CM051-057) with all but one (CM024) inhibiting ALDH1A1 at 
20 µM concentration. Based on IC50 values, the most potent inhibitors selective for 
ALDH1A1 were CM038, CM039, and two structural analogs, CM053 and CM055, with 
all four hits having IC50 values less than 500 nM. CM302 was a potent inhibitor of both 
ALDH1A1 and ALDH2, with IC50 values of 1.0 ± 0.1 µM and 2.2 ± 0.3 µM, 
respectively. To a limited extent, CM302 also inhibited ALDH3A1, but with an IC50 
A.                                                               B. 
 
Figure 40: IC50 curves and structures of the four most potent ALDH1A1 inhibitors. 
Representative IC50 curves and structures for the three most potent ALDH1A1 
inhibitors based on IC50 values: A) CM053, B) CM055, C) CM038, and D) CM039. 
Each point represents the mean/SEM for three readings. The IC50 values represent the 
mean of three independent assays. 
C.                                                               D. 
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value greater than 10-fold higher compared to ALDH1A1 and ALDH2. In comparison, 
the non-selective inhibitor Aldi-1, which was used as a control during the esterase HTS, 
has an IC50 value of 2.2 µM for ALDH1A1
137
. As previously discussed, DEAB is a 
nonselective ALDH1/2 inhibitor used as a control for the Aldefluor Assay (Stemcell 
Technologies, Vancouver, Canada), a flow cytometry assay commonly used to identify 
stem cells based on ALDH activity. DEAB has an IC50 value of approximately 60 nM 
under these same conditions, but is also a potent inhibitor of other ALDH isoenzymes
127
.  
 
Two classes of compounds identified in the HTS have been analyzed further to determine 
whether they could progress from hit to lead compounds in the search for selective 
inhibitors of ALDH1A1. CM026, in the same structural class as CM053 and CM055, and 
CM037 emerged from the HTS as ALDH1A1 esterase activators, but both compounds 
inhibited aldehyde oxidation and were selective for ALDH1A1 compared to ALDH2 and 
ALDH3A1. These two classes of compounds were further explored via steady-state 
enzyme kinetics, structural-activity relationship (SAR), X-ray crystallography, and cell 
culture. 
 
4. Steady-State Kinetics Optimization 
In order to perform steady-state kinetics, it was first necessary to calculate the Km values 
for NAD
+
, propionaldehyde, and acetaldehyde to determine the range over which to vary 
these substrates (Figure 41). For steady-state kinetics, their values should vary 
approximately 10-fold, with the Km near the middle of the range. For NAD
+
, the 
calculated Km value was 50 µM. Propionaldehyde is commonly used as a substrate for 
ALDH1A1 and was used for both selectivity and IC50 calculations. However, its 
calculated Km of 15 µM would have required varying propionaldehyde in the range of 5 – 
50 µM, a range too small to accurately detect differences in the NADH produced with 
our spectrophotometers. Instead, acetaldehyde (Km = 180 µM) was used, allowing for a 
larger range of substrate concentrations (100 – 800 µM) that could be monitored on a 
spectrophotometer. 
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Table 7:  IC50 values and structures of the top 19 compounds that inhibit ALDH1A1. 
Compound 
IC50  [µM] Structure  
Compound 
IC50  [µM] Structure 
CM001* 
1.1 ± 0.1 
 
 
CM045* 
2.5 ± 0.5  
 
CM009* 
5.3 ± 0.3 
 
 
CM047* 
0.31 ± 0.03  
 
CM010* 
1.3 ± 0.1  
 
 
CM053 
0.21 ± 0.04 
 
CM020 
0.45 ± 0.10 
 
 
CM055 
0.24 ± 0.04 
 
CM025 
2.1 ± 0.7 
 
 
CM056 
5.4 ± 0.8 
 
CM026 
0.80 ± 0.06 
 
 
CM057 
0.92 ± 0.2 
 
CM028 
2.0 ± 0.1 
 
 
CM302 
1.1 ± 0.1 
 
CM037 
4.6 ± 0.8 
 
 
CM306 
3.5 ± 0.6 
 
CM038 
0.26 ± 0.01 
 
 
CM307 
0.57 ± 0.09 
 
CM039 
0.41 ± 0.01 
 
   
Each value represents mean/SEM for three independent assays, each n = 3. Values 
calculated using 100 µM propionaldehyde and 200 µM NAD
+
. An asterisk (*) 
indicates less than 70% maximum inhibition. 
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Figure 41: Calculation of Km’s for steady-state kinetics with ALDH1A1. 
A) Km of cofactor NAD
+
.  B) Km of substrate propionaldehyde, and C) Km of substrate 
acetaldehyde. 
A. 
 B. 
C. 
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5. Characterization of the CM037 Class of Compounds 
CM037 is a selective inhibitor for ALDH1A1 with a molecular weight of 431.6 Daltons 
(Figure 42A). At a concentration of 20 µM, CM037 had no effect on seven other human 
ALDH isoenzymes (ALDH1A2, ALDH1A3, ALDH1B1, ALDH2, ALDH3A1, 
ALDH4A1, and ALDH5A1) as well as the carboxyl-terminal, ALDH domain of rat 
ALDH1L1 (Figure 42B). Higher concentrations were not tested due to the absorbance 
properties of CM037, which interferes at 340 nm. At 20 µM, ALDH1A3 was inhibited 
approximately 25% while ALDH1A1 had 80% inhibition at this same concentration; this 
A.      B. 
 
C.    D. 
 
Figure 42: Characterization of CM037, a selective inhibitor of ALDH1A1. 
A) The structure of CM037 with a molecular weight of 431.6.5 Daltons. B) Selectivity 
of 20 µM of CM037 with respect to six ALDH isoenzyme. C) IC50 of CM037 with 
ALDH1A1. D) Lineweaver-Burk representation of competitive inhibition for CM037 
(0 – 800 nM) at fixed concentration of NAD+ (800 µM) verses varied acetaldehyde 
(100 – 800 µM).  The IC50 curves and Lineweaver-Burk plots represent one of three 
experiments performed for each condition, with each point the mean/SEM of three 
data points at each concentration. 
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concentration had little to no effect on the other isoenzymes. CM037 had good potency 
towards ALDH1A1 with an IC50 = 4.6 ± 0.8 µM (Figure 42C). CM037 has a competitive 
mode of inhibition with respect to varied acetaldehyde, with a Ki of 0.23 ± 0.06 µM 
(Figure 42D).  
 
Although it had some structural similarity to 
CM039, no analogs of CM037 were identified in 
the HTS. To better understand the role of 
particular chemical groups, the selectivity and 
potency of ten compounds structurally similar to 
CM037 were tested. Of particular interest was the 
role of CM037’s ester group. As an ester, it is 
possible CM037 is a substrate for ALDH1A1, and 
in a manner similar to what was seen with DEAB, the ester substrate is turned over at 
such a slow rate that it inhibits aldehyde oxidation. SAR was performed using CM037 
analogs to determine the effect of structural changes to both selectivity and potency. 
CM037a had an identical R1 group but the ester group of R2 was replaced with a primary 
amide. The IC50 value for the amide is 5 times higher than the ester (23 µM vs 4.6 µM) 
(Figure 44), indicating that an amide could not replace the ester functional group. Nine of 
the analogs contained the identical fused three-ring structure as CM037, with various R1 
and R2 groups (Figure 45), while the tenth analog was similar to CM039. None of the ten 
compounds had any effect on ALDH3A1. However, there was great variability in the 
effect these compounds had on the three ALDH1A subfamily members (Figure 45). Four 
analogs had identical R2 groups to CM037, maintaining the ester group (CM037b, 
CM037c, CM037g, and CM037j). At a compound concentration of 20 µM, only one 
compound (CM037g) inhibited ALDH1A1 more than 50%. CM037g replaces the propyl 
pyrrolidine with an ethanol. This change had little effect on potency towards ALDH1A1, 
having an IC50 only slightly lower than CM037 (3.3 µM vs. 4.6 µM, Figure 44). 
However, this R1 change resulted in ALDH1A3 inhibition increasing from 20% with 
CM037 to 70% with CM037g, indicating that the R1 group is involved in isoenzyme 
selectivity with respect to ALDH1A3. For the other three esters, the pyrrolidine group 
 
Figure 43: Basic structure of 
CM037 Analogs. 
 
 76 
 
three carbons removed from the core structure was replaced with a phenyl group closer to 
the core structure. At 20 µM concentration, none of these three compounds inhibited 
ALDH1A1 more than 50%, indicating a longer linker may be needed to inhibit 
ALDH1A1. However, the opposite was seen with the other members of the ALDH1A 
subfamily as both CM037b and CM037j had an increase in inhibition of ALDH1A2 and 
ALDH1A3. Only one non-ester analog (CM037e), with a carboxylic acid group at the R1 
position, inhibited ALDH1A1 more than 50% at the tested concentration.   
 
 
  
 
Figure 44: IC50 Curves for CM037 and two of its analogs. 
The parent compound CM037, an ester, is shown in black (IC50 = 4.6 µM). An ester 
analog CM037g, shown in red, is slightly more potent than the parent compound (IC50 
= 3.3 µM). The amide CM037a, shown in blue, is less potent (IC50 = 23 µM) Each 
point represents the mean/SEM of three readings, with the IC50 values the mean/SEM 
of three independent experiments. 
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Figure 45: CM037 and its analogs. 
The effect on aldehyde oxidation activity of ten CM037 analogs on three ALDH1A 
isoenzymes. The reactions used 20 µM compound and each bar represents mean/SEM 
(n = 3).  
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6. Characterization of the CM026 Class of Compounds  
CM026 is a selective inhibitor for ALDH1A1 with 
a molecular weight of 442.5 Daltons (Figure 46). 
At a concentration of 20 µM, CM026 had no effect 
on seven other human ALDH isoenzymes 
(ALDH1A2, ALDH1A3, ALDH1B1, ALDH2, 
ALDH3A1, ALDH4A1, and ALDH5A1) as well as 
the carboxyl-terminal ALDH domain of rat 
ALDH1L1 (Figure 47A). At a concentration of 
100 µM compound, CM026 modestly increased 
aldehyde oxidation catalyzed by ALDH1A2, ALDH1A3, and ALDH1B1, but 20 µM 
CM026 had values similar to control. For an initial hit compound, CM026 had good 
potency towards ALDH1A1 with an IC50 = 0.80 ± 0.06 µM (Figure 47B). Complete 
inhibition of ALDH1A1 was not observed, with concentrations above 20 µM leveling off 
between 80 and 90% inhibition. CM026 has a noncompetitive partial mode of inhibition 
with respect to varied acetaldehyde, with a Ki of 0.80 ± 0.16 µM and β = 0.15 ± 0.03 
(Figure 48A), indicating that maximum inhibition was 0.15Vmax. With respect to varied 
NAD
+
, CM026 had an uncompetitive partial mode of inhibition, with a Ki of 0.72 ± 0.03 
µM and β = 0.10 ± 0.03 (Figure 48B).  
 
Figure 46: Structure of CM026. 
 
 
 
 
A.     B. 
 
Figure 47: Selectivity and potency of CM026. 
A) Selectivity of 20 µM CM026 with respect to nine ALDH isoenzymes. B). IC50 
curve of CM026 with ALDH1A1. The IC50 curve represent one of three experiments 
performed, with each point the mean/SEM of three data points at each concentration. 
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The HTS identified 77 compounds that were structurally similar to CM026, with the 
basic xanthine structure shown in Figure 49. These compounds share this core structure 
with two commonly used compounds, theophylline and caffeine. However, neither 
theophylline nor caffeine affected ALDH1A1 aldehyde oxidation activity at 
concentrations up to 250 µM, indicating that larger substituents at the R1 and/or R2 
positions are necessary for ALDH1A1 inhibition (Figure 50). Seventeen members of this 
class of compounds have been tested further, enabling us to examine their structural 
activity relationship (SAR). Unlike traditional 
SAR, because these compounds were identified 
in the HTS, all 17 hits were known to bind to 
ALDH1A1 and affect the enzyme’s esterase 
activity. All inhibited ALDH1A1 to some degree 
while having little to no effect on ALDH1A2, 
ALDH1A3, ALDH1B1, ALDH2, and ALDH3A1 
(Table 8). At 100 µM, some compounds activated 
A.    B. 
 
Figure 48: Mode of Inhibition for CM026, a selective inhibitor of ALDH1A1. 
A) Lineweaver-Burk representation of noncompetitive inhibition for CM026 
(0 - 3 µM) verses varied acetaldehyde (100 – 800 µM) at fixed concentration of NAD+ 
(800 µM). B) Lineweaver-Burk representation of uncompetitive inhibition for CM026 
(0 – 3 µM) verses varied NAD+ (25 – 200 µM) at fixed concentration of 
propionaldehyde (200 µM). Lineweaver-Burk plots represent one of three experiments 
performed, with each point the mean/SEM of three data points at each concentration. 
 
Figure 49: General structure of 
CM026 analogs. 
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the aldehyde oxidation of some of the other three ALDH1 isoenzymes tested, similar to 
the activation seen with CM026, but at 20 µM any activation was less than 10%. CM053 
was the most potent analog examined, with an IC50 = 210 ± 40 nM and a 
Ki = 96 ± 14 nM, with noncompetitive tight inhibition compared to varied substrate 
acetaldehyde. Unlike CM026, complete inhibition was observed with CM053. CM028 
shares the same R2 group as CM053 but the isopentyl group at R1 has been replaced with 
a phenylpropyl group. CM028 is less potent, with an IC50 = 2.0 ± 0.1 µM and exhibits a 
competitive mode of inhibition with respect to acetaldehyde with a Ki = 240 ± 40 nM.  
 
 
  
 
Figure 50: Common structural analogs of CM026. 
The structures and effects of theophylline and caffeine on ALDH1A1. Each value is 
mean/SEM, with n = 3. 
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Table 8: SAR for CM026 Analogs. 
    R1                  
 IC50 in μM (SE) 
R2 
ALDH 
1A1 
ALDH 
1A2 
ALDH 
1A3 
ALDH
2 
ALDH 
1B1 
ALDH 
3A1 
CM022   
5.2* 
(0.8) 
>100 NI(A) NI NI NI 
CM023 
  
14* 
(2) 
NI NI(A) NI NI >100 
CM024   
>20 NI >100 NI >100 NI 
CM025 
  
2.1 
(0.7) 
NI NI(A) NI >100 NI(A) 
CM026 
  
0.80 
(0.06) 
NI(A) NI(A) NI NI(A) NI(A) 
CM027 
  
6.1 
(1.1) 
NI NI NI NI NI 
CM028 
  
2.0 
(0.1) 
NI NI >100 >100 NI 
CM029 
  
8.4 
(1.0) 
NI NI(A) NI NI NI 
CM030 
  
>20 NI NI NI NI NI 
CM031  
 
>20 >100 >20 >100 >100 NI(A) 
CM051 
  
>20 NI(A) NI(A) NI NI NI 
CM052 
 
 
>20 >100 NI(A) NI NI(A) NI(A) 
CM053 
  
0.21 
(0.04) 
NI NI(A) NI NI NI(A) 
CM054 
  
3.4* 
(0.7) 
>100 NI(A) >100 >100 NI 
CM055 
  
0.24 
(0.04) 
NI(A) NI(A) NI NI NI 
CM056 
  
5.8 
(1.2) 
NI NI >100 >100 NI 
CM057 
  
0.92 
(0.2) 
NI >100 >100 >100 NI 
 At 100 µM compound, NI stands for no inhibition and NI(A) indicates no inhibition but 
activation.  * indicates < 70% maximum inhibition. 
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7. X-ray Crystallography of ALDH1A1 with CM026, CM053, and CM037 
To determine the mechanism that underlies the ability of these compounds to selectively 
inhibit ALDH1A1, X-ray crystallography was used to determine the structure of the 
enzyme-compound complexes. For CM026 and CM037, the naturally occurring N121S 
polymorphic variant of ALDH1A1 was used
167
, while ALDH1A1 WT was used for the 
structure with bound CM053. A comparison of the respective alpha carbons in the 
structure of the N121S∙CM026 to those in the WT∙CM053 generated an RMSD of 0.12Å, 
indicating a high degree of similarity between WT and the N121S mutant as expected 
since the two have very similar kinetic behavior
167
. For CM026 analogs, apo-ALDH1A1 
crystals were soaked overnight in a crystallization solution containing 500 μM compound 
and 2% DMSO. Structures of the ALDH1A1-CM026 complex and the ALDH1A1-
CM053 complex were solved to resolutions of 1.80 Å and 1.95 Å, respectively (Table 9). 
Table 9: Data collection and refinement statistics. 
Data Collection 
ALDH1A1- 
CM026 
PDB 4WP7 
ALDH1A1- 
CM053 
PDB 4WPN 
ALDH1A1- 
CM037 
PDB 4X4L 
Space Group P422 P422 P422 
Cell Dimensions 
  
 
a, b, c (Å) 109, 109, 83 109, 109, 83 109, 109, 83 
Α, β, γ (°) 90, 90, 90 90, 90, 90 90, 90, 90 
Resolution (Å) 50 – 1.80 50 – 1.95 50 – 1.85 
R
merge
 0.082(0.59) 0.11(0.66) 0.058 (0.70) 
I/σ
i
 22.7 (4.7) 18.3 (3.7) 27.4 (3.3) 
Completeness (%) 99 (100) 99 (100) 99 (100) 
Redundancy 11.7 (11.7) 9.3 (6.9) 8.5 (8.8) 
Refinement    
No. of Reflections 44544 35048 40517 
R
work
 / R
free
 0.19 / 0.22 0.19 / 0.24 0.20 / 0.23 
No. of Atoms 4109 4080 4066 
Protein 3833 3858 3806 
Ligand/Ion 35 33 80 
Water 241 189 180 
R.M.S. Deviations    
Bond Lengths (Å) 0.008 0.009 0.010 
Bond Angles (°) 1.28 1.30 0.135 
Numbers in parenthesis represent values of highest resolution shell. 
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CM026 binds near the solvent exposed exit of the substrate-binding site (Figure 51, PDB 
Code 4WP7). The xanthine ring lies parallel to and approximately 3.6 Å from Tyr297, 
creating a hydrophobic pi-stacking interaction. Four residues form hydrogen bonds with 
CM026; the xanthine ring interacts with His293, Cys302, and Gly458, while Trp178 
interacts with the ketone group on R2. The isopentyl group of R1 projects towards 
Cys303 and fills the hydrophobic space bounded by Phe171 and Phe466. CM053 differs 
from CM026 only in its R2 group, which can form hydrogen bonds with two residues, 
Trp178 and Val460 (Figure 52, PDB Code 4WPN). For CM037, apo-ALDH1A1 crystals 
were soaked for 5 hours in a solution containing 500 μM compound and 1 mM NAD+ 
with 1% DMSO. CM037 binds at a similar location to the CM026 compounds, but its 
A. 
 
Figure 51: Structure of ALDH1A1 with CM026. 
A) CM026 binds in the active site near cysteine 303, shown in red. The location of 
Gly458 is shown in yellow. B) Two-dimensional representation of the key hydrogen 
bonds, illustrated with red dashed lines, and hydrophobic interactions, illustrated with 
black arcs, between ALDH1A1 and CM026. C) The electron density maps of CM026, 
with the original Fo – Fc map in green contoured at 2.5 standard deviations and the 
final 2Fo – Fc map in grey contoured at 1.0 standard deviations (PDB Code 4WP7). 
 
B.                                                                   C. 
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long axis is oriented almost orthogonal to that of CM026 and CM053 (Figure 53A). Most 
of the tricyclic ring of CM037 is in a hydrophobic pocket formed by Phe171, Val460, and 
Phe466 with a potential hydrogen bond between the ring system’s carbonyl oxygen atom 
and the side chain of Cys302 (Figure 53B). The biggest structural adaptation to CM037 
binding is the movement of Trp178 away from the substrate-binding site to accommodate 
the benzyl ring of CM037 (Figure 53C). This conformational movement appears to be 
dynamic and impacts the observed electron density for both the benzyl group of CM037 
and of Trp178. Trp178 is well ordered in all other determined structures of human 
ALDH1A1, including our CM026 and CM053 structures, but has weak density for the 
benzyl moiety of the indole ring in this complex (Figure 53D). We would suggest that 
optimization of CM037 could be achieved by altering the thiophene and benzyl ring 
systems to alleviate these steric conflicts. 
 
To better understand the selectivity of these compounds for ALDH1A1, we compared the 
structure of human ALDH1A1 against human ALDH2 (PDB code 1CW3), human 
ALDH3A1 (PDB code 3SZA), and human ALDH4A1 (PDB code 3V9G) and identified a 
critical glycine (Gly458) that is present near the xanthine ring binding site in ALDH1A1. 
This glycine is replaced by larger amino acid side chains in the other three structures 
A.                                                                   B. 
 
Figure 52: Structure of human ALDH1A1 with CM053. 
A) Two dimensional representation of the key hydrogen bonds, illustrated with red 
dashed lines, and hydrophobic interactions, illustrated with black arcs, between 
ALDH1A1 and CM053. B) The electron density maps of CM053 with the original 
Fo – Fc map in green contoured at 2.5 standard deviations and the final 2Fo – Fc map in 
grey contoured at 1.0 standard deviations (PDB Code 4WPN). 
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examined, as well as in sheep ALDH1A1. In rat ALDH1A2 (PDB code 1BI9), which 
shares 97% sequence identity to human ALDH1A2, this location is part of a small 
disordered loop not observed in the crystal structure
171
. Using sequence alignments of the 
human genes, Gly458 in ALDH1A1 is replaced by an asparagine in ALDH1A2, 
ALDH1A3, and ALDH1B1, an aspartate in ALDH2, and an isoleucine in ALDH3A1 
(Figure 54A). As shown in Figure 54B, these side chains would interfere with the 
position of the xanthine ring, effectively eliminating the ability of these analogs to bind to 
any human isoenzyme but ALDH1A1. 
 
 
  
A.                                                            B. 
 
Figure 53: Structure of ALDH1A1 N121S with CM037. 
(A) CM037 binds in the active site near cysteine 303, shown in red. The location of 
Gly458 is shown in green. (B) Two-dimensional representation of the hydrophobic 
interactions, illustrated with black arcs, between ALDH1A1 and CM037. (C) Binding 
of CM037 induces structural changes in ALDH1A1 (in blue) compared to apo-
ALDH1A1 (in gray), particularly at W178. NADH binding (in cyan), induces 
conformational changes at the cofactor binding site, as seen here with E269. (D) The 
electron density maps of CM037, with the original Fo – Fc map in green contoured at 2 
standard deviations and the final 2Fo – Fc map in grey contoured at 1.0 standard 
deviations. Figures A, C and D generated in Pymol and Figure B  in ChemDraw. 
C.                                                           D. 
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Figure 54: Structural basis of selectivity of CM026 for ALDH1A1. 
A) Multiple sequence alignment in the region of ALDH1A1 Gly-458 to the mature form of 
ALDH2.  B) Structure of ALDH1A1 (blue) with bound CM026 compared to ALDH2 (green) 
and ALDH3A1 (grey) indicating that a bulky amino acid such as the Asp of ALDH2 and Ile 
of ALDH3A1 would clash with CM026 and prevent the compound from inhibiting the 
enzyme. Sequence alignment was performed using NCBI delta-BLAST, while structural 
alignment was performed using least square fit (LSQ) in Coot. 
A. 
B. 
 87 
 
8. Characterization of ALDH1A1 G458N Mutant 
To confirm whether Gly458 in ALDH1A1 directly impacts the selectivity of CM026 
analogs for ALDH1A1, we mutated the glycine at this position to asparagine, as found in 
ALDH1A2 and ALDH1A3. We determined the kinetic parameters for acetaldehyde 
oxidation for both the wild-type and G458N enzymes (Table 10). This mutation did not 
dramatically affect the enzyme’s catalytic efficiency for aldehyde oxidation. However, 
when Gly458 is mutated to asparagine, CM026 no longer inhibits the enzyme at 
concentrations up to 100 µM, and none of the CM026 analogs inhibited the mutant more 
than 25% (Figure 55). CM037 also does not inhibit G458N. However, DEAB and 
CM302, a non-selective inhibitor identified in the HTS, both inhibit G458N, exhibiting 
IC50 values of 0.52 ± 0.10 µM  and 3.1 ± 0.3 µM respectively, compared to 0.057 ± 0.005 
µM  and 1.0 ± 0.1 µM, respectively for ALDH1A1 WT (Table 10). These data support 
the hypothesis that the substrate-binding site and in particular Gly458 determine the 
selectivity of the CM026 class of compounds for ALDH1A1, and that the bulkier side 
chains at this position in ALDH1A2, ALDH1A3, ALDH1B1, ALDH2, and ALDH3A1 
occludes their binding to other ALDH isoenzymes.  
 
Figure 55: Selectivity of compounds for WT vs G458N mutant. 
For CM026 and its analogs, 100 µM of compound was used. For CM037 and CM302, 
20 µM of compound was used. Each value is mean/SEM, with n = 3. 
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  A. ALDH1A1               B. ALDH2                             C. ALDH3A1 
  
Figure 56: Surface topography of the cofactor binding site for 3 ALDH isoenzymes. 
A) ALDH1A1 (PDB 4WB9), B) ALDH2 (PDB 1O02), and C) ALDH3A1 (PDB 
4L2O). The orange sphere in ALDH1A1 and ALDH2 represent cations, Yb for 
ALDH1A1 and Mg for ALDH2 that are present during crystallization. 
 
B. Discussion 
Aldehyde dehydrogenases contribute to a variety of biological processes and disease 
states. ALDH1A1, in particular, has been linked to such diverse diseases as cancer, 
Parkinson’s disease, obesity, and cataracts. Therefore, selective inhibitors of ALDH1A1 
would be of tremendous value to understanding the roles of this enzyme in both normal 
and disease processes. However, great structural and functional similarity exists, 
especially within the ALDH1/2 family, with five members sharing approximately 70% 
protein sequence identity plus significant overlap in substrate utilization. To date, there 
are no ALDH1A1-selective inhibitors commercially available. Although comparisons of 
available ALDH structures indicate a high degree of overlap, distinct surface 
topographies exist that may enable selective inhibitors to be developed. Comparison of 
the structures of human ALDH1A1, ALDH2, and ALDH3A1 indicate they exhibit a high 
 
Table 10: Kinetic parameters of ALDH1A1 WT and mutant G458N. 
K
M
Acetaldehyde
  
(µM) 
k
cat
 / K
M
 
(min
-1
 · µM
-1
) 
K
I
CM026
 
(µM) 
K
I
CM037
 
(µM) 
K
I
CM302 
(µM) 
K
I
DEAB 
(µM) 
WT 177±19 0.18±0.02 0.80±0.16 4.6±0.8 1.0±0.1 0.057±0.005 
G458N 86±2 0.21±0.02 NI NI 3.1±0.3 0.52±0.10 
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degree of structural similarities, particularly within their coenzyme binding sites (Figure 
56). However, there exist distinct differences within their substrate binding sites that 
could be exploited to discover selective compounds targeting the individual isoenzymes 
(Figure 12). These structural features support our screening approach to avoid identifying 
compounds that interact at the cofactor binding site, as they are less likely to be selective 
for ALDH1/2 class members. It is possible that a number of our esterase activators that 
had no effect on aldehyde oxidation acted at the cofactor binding site, activating the 
esterase reaction similar to NAD
+
. However, the near saturating levels of NAD
+
 used in 
the assays would minimize their effect on aldehyde oxidation. If a compound did bind at 
the cofactor binding site, only an extremely potent or covalent modulator would be 
identified under these conditions.  
 
The esterase screen used in this study was modeled after a previously reported screen for 
ALDH3A1 inhibitors that successfully identified two classes of selective ALDH3A1 
inhibitors capable of increasing mafosphamide sensitivity in cancer cells
106,136,166
. By 
adapting this assay to ALDH1A1, we screened a 64,000 compound library and following 
one round, identified over 900 compounds. Rescreening of these compounds under 
identical conditions resulted in 256 confirmed hits that modified ALDH1A1 esterase 
activity. Therefore, the effect on esterase activity of <30% of the identified 
activators/inhibitors identified in round one were successfully repeated in round two. 
Although these replicability results may seem low, HTS are inherently noisy and produce 
many false positives that are eliminated in the second round. As shown in Figure 37, 
simply calculating the Z-factor produced outliers despite identical conditions within one 
plate. Some reasons for poor replicability include inaccuracies in compound 
concentration, spectral interference from the compounds, errors in robot pipetting, and 
debris or bubbles in the well that interfered with the reading. The second round of 
screening is designed to remove these false positives from consideration, conserving both 
time and resources. Since the HTS identified 256 compounds, the large number of false 
positives from round one was not a concern. In addition, the data can always be revisited 
at a later date to investigate compounds eliminated in this manner. 
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We examined the effect on dehydrogenase activity of 67 of the 256 compounds identified 
via the esterase HTS and found that 30 selectively inhibited ALDH1A1 at least 50% but 
had little to no effect on ALDH2 or ALDH3A1. One compound inhibited both 
ALDH1A1 and ALDH2, while a second inhibited ALDH1A1, ALDH2, and ALDH3A1, 
although ALDH3A1 was only modestly inhibited (40%) versus over 90% inhibition of 
ALDH1A1 and ALDH2. Therefore, nearly 50% of the esterase modifiers also altered 
aldehyde oxidation, and most of the compounds did so selectively for ALDH1A1 
compared to two other ALDH’s. These results indicate that the esterase HTS is well 
suited for reliably identifying inhibitors of ALDH1A1 aldehyde oxidation activity. 
However, no confirmed activators of aldehyde oxidation activity have been identified. 
 
Of the 57 esterase activators tested, none activated the aldehyde oxidation reaction of 
ALDH1A1, but nearly half inhibited it. The esterase reaction is independent of NAD
+
, 
but the presence of either NAD
+
 or NADH will increase the rate of ester hydrolysis, 
depending on assay conditions
170,172
. The substrate and cofactor binding sites are linked 
to the active site by a tunnel through the enzyme. For ester hydrolysis, the substrate can 
likely enter the active site via either end of this tunnel. To activate esterase activity, it is 
proposed that cofactor binding slows transit of the ester substrate out of the tunnel, 
increasing the number of productive encounters with the active site nucleophile and 
possibly by directly activating the nucleophile (Figure 35C)
140
. Compounds that function 
as esterase activators but dehydrogenase inhibitors likely bind to the substrate-binding 
end of this tunnel, as illustrated by Hit-2 in Figure 57. In a manner similar to activation 
via cofactor binding, compound binding slows the transit of pNPA out of the active site 
tunnel and increases the likelihood of a productive encounter with the active site cysteine. 
However, the effect these esterase activators have on the NAD
+
-dependent aldehyde 
oxidation reaction is the opposite. Binding of the compound and cofactor alters access to 
the active site at both ends, and therefore, depending on the structure of the compound 
and the size of the substrate, could inhibit dehydrogenase activity. However, as seen with 
the ALDH2 activator Alda-1, a compound that binds at the substrate binding end of the 
active site tunnel could also result in a dehydrogenase activator, depending on binding 
position, location relative to the active site residues and substrate size
140
. It is possible 
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that a number of our esterase activators that had no effect on aldehyde oxidation acted at 
the cofactor binding site, activating the esterase reaction like NAD
+
/NADH (Hit-1 in 
Figure 57). However, the levels of NAD
+
 used in the assays (approximately 4 x Km) 
might minimize their effect on aldehyde oxidation, no longer binding to the enzyme in 
the presence of NAD
+
, as illustrated by Hit-1 in Figure 57. If a compound did bind at the 
cofactor site, only an extremely potent or covalent modulator would be identified under 
these conditions.  
 
Of the 241 esterase activators identified, 78 were structural analogs with a common 
xanthine ring core structure. Of these 78 compounds, 17 (CM022-031 and CM051-057) 
were tested further to determine their effect on aldehyde oxidation, with 16 selectively 
inhibiting ALDH1A1 at least 50% at a compound concentration of 20 μM compared to 
ALDH1A2, ALDH1A3, ALDH1B1, ALDH2 and ALDH3A1. At 100 μM concentration, 
 
Figure 57: Esterase activators as inhibitors of aldehyde oxidation. 
The active site of ALDH1A1 is within a tunnel. For the NAD
+
-independent esterase 
reaction, substrate can enter via either side and a compound that binds at either end 
(NAD
+
, Hit-1, Hit-2) may possibly activate the esterase reaction. For the NAD
+
-
dependent aldehyde oxidation reaction, Hit-2, a compound that activated esterase 
reaction could inhibit the oxidation reaction by blocking access to the active site. 
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some CM026 analogs activated other members of the ALDH1/2 family, mostly 
ALDH1A3, although with just a single dose, it is not known whether these results 
represent enzyme activation or something else is occurring to increase absorbance at 340 
nm. The esterase HTS also produced eight other structural groups that contained seven or 
more analogs. As a consequence, 65% of the HTS esterase hits could be classified into 
nine structural categories (Table 11). An additional eight structural groups contained 2 – 
6 analogs each plus 22 structurally unique compounds. As the majority of esterase 
activators, including a number of structurally unique compounds and classes of 
compounds, have yet to be tested, it is probable that at least one ALDH1A1 aldehyde 
oxidation activator is present. An analog of Alda-1 (CM021) showed modest activation 
of the mutant ALDH1A1 N121S, but did not activate WT enzyme. Of the 15 esterase 
inhibitors identified in the HTS, only two were structurally similar. The effect on 
aldehyde oxidation of ten esterase inhibitors has been further examined, with four 
inhibiting ALDH1A1 at least 50% at a concentration of 20 µM. CM302 was a 
nonselective inhibitor, inhibiting ALDH1A1, ALDH2, and ALDH3A1, but it was a 
particularly potent inhibitor for the ALDH1/2 family. CM303 inhibited ALDH1A1 and 
ALDH2 but not ALDH3A1, while both CM306 and CM307 inhibited ALDH1A1 but not 
ALDH2 nor ALDH3A1. Additional work is needed to determine the effect of CM303, 
CM306, and CM307 on other members of the ALDH1 family.   
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Table 11: Structural classes of hit compounds. 
Structure 
HTS 
Hits 
Dehydrogenase Activity 
Tested Results 
 
78 17 16 Inhibitors 
 
20 3 CM001 
 
10 1 No effect 
 
9 0  
 
13 1 No effect 
 
11 4 3 Inhibitors 
 
8 3 CM047 
 
7 4 CM010 
 
7 0  
Results of nine structural classes of esterase modulators representing 65% of 
the compounds identified from the esterase HTS.  
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Results from kinetic studies indicated that CM026 displayed a noncompetitive partial 
mode of inhibition with respect to varied substrate acetaldehyde and an uncompetitive 
partial mode of inhibition with respect to the cofactor NAD
+
. In a classical one-substrate 
system, a noncompetitive inhibitor binds to both the free enzyme and the enzyme-
substrate species, forming the enzyme-substrate-inhibitor (ESI) complex. An 
uncompetitive inhibitor binds only to the enzyme-substrate species, forming the ESI 
complex. With complete inhibition, the ESI complex is inactive, while partial inhibition 
indicates the ESI complex retains activity, although at a decreased rate of product 
formation. However, ALDH1A1 aldehyde oxidation is a two-substrate system; the 
aldehyde itself and the cofactor NAD
+
 are both considered substrates. A schematic of the 
steady-state kinetic results is shown in Figure 58. The kinetic results indicate that CM026 
binds to the enzyme-NAD
+
 and enzyme-NADH complexes. It may be possible that the 
enzyme-NAD
+
-inhibitor complex is able to complete a cycle. As a partial inhibitor 
retaining approximately 15% the activity of uninhibited enzyme, either the enzyme-
NAD
+
-substrate-CM026 complex and/or the binding of CM026 to the enzyme-NADH 
 
 
Figure 58: Schematic representation of CM026 inhibition of ALDH1A1.  
CM026 was noncompetitive with respect to varied acetaldehyde with saturating NAD
+
 
and uncompetitive with respect to varied NAD
+
 and saturating propionaldehyde 
indicating that CM026 can bind to either the enzyme-NAD complex or the enzyme-
NADH complex. As a partial inhibitor, the enzyme remains active in the presence of 
CM026. However, the rate of product formation is much slower.   
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complex has much lower activity than control. In the presence of CM026, the order of the 
release of the products and inhibitor has not been determined, but it is probable that the 
acid product leaves first followed by either CM026 or the reduced cofactor. Although 
kinetics indicate that CM026 only binds to certain enzyme-NAD(H) species, 
crystallographic results using high concentrations of the compound show it can bind to 
the free enzyme. The more potent CM026 analog, CM053 displayed noncompetitive tight 
binding inhibition compared to varied substrate acetaldehyde. In a reaction, an inhibitor 
can exist in two general phases: free inhibitor (Ifree) and inhibitor bound to an enzyme 
(EI), with multiple species of the EI complex possible. In standard inhibition calculations, 
the amount of inhibitor (I) greatly surpasses the amount of enzyme (E), and therefore 
when determining the total amount of I (Itotal) in the system, EI can be disregarded 
because it is so small in comparison to Ifree. However, for inhibitors that bind tightly to 
the enzyme, steady-state kinetics will require much lower concentrations of the inhibitor 
and a significant portion of inhibitor will be found bound to the enzyme. Therefore, EI 
cannot be disregarded in the calculations. For CM053, the mode of inhibition kinetics 
used 150 nM enzyme and a maximum of 300 nM inhibitor. Unlike CM026, binding of 
CM053 will ultimately produce an inactive enzyme. CM028 contains a larger side chain 
at R1 compared to CM053, replacing an isopentyl group with a phenylpropyl group and 
exhibits competitive tight inhibition with respect to acetaldehyde.  
 
There were 77 compounds in the initial screening results that were structurally similar to 
CM026. We tested 17 members of this compound class. Unlike traditional SAR, this 
SAR only contained compounds known to bind to ALDH1A1, as they all modified the 
enzyme’s esterase activity (Table 8). Halogens on either R-group were not well tolerated 
and only less potent inhibitors possessed a halogen. This is particularly obvious with the 
R1 group as it projects into a hydrophobic pocket formed by two phenylalanines (F171 
and F466). Less clear with the R1 group is why a linear butyl group was not favored but a 
branching isopentyl group was found in 3 of the 4 most potent inhibitors, based on their 
IC50 values. For potent inhibition of aldehyde oxidation, the R2 group must have 
hydrogen bonding capability. The three compounds with sub-micromolar IC50 values 
contain amide groups, with the carbonyl carbon six atoms removed from the xanthine 
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ring. CM055 and CM026 are the second and third most potent analogs, respectively, and 
they share a common R2 group. They differ in their R1 group, with CM026 possessing an 
isopentyl group while CM055 has a larger hydrophobic 3-methylbenzyl group, which 
may bind tighter in the R1 hydrophobic pocket and decrease the IC50 value nearly 4-fold. 
However, there is a limit to the size of the hydrophobic group on R1. CM053 and CM028 
share the same R2 group but CM053, the most potent inhibitor, has an isopentyl group at 
R1 while CM028 has a phenylpropyl group. This difference in the R1 group results in a 
nearly 10-fold increase in IC50 values between CM053 and CM028. It is possible that the 
methylbenzyl group at R1 (seen in CM055) combined with the 1-methylpiperidine 4-
carboxyamide group at R2 (seen in CM053) would be a more potent inhibitor than 
CM053, but no compounds with a similar structure were included in the HTS library. 
 
CM037 was a competitive tight inhibitor with respect to varied acetaldehyde, with a 
Ki = 230 nM, and uncompetitive with respect to NAD
+
. The schematic for ALDH1A1 
inhibition by CM037 is shown in Figure 59. Unlike CM026 and CM053, there is no 
crystallographic evidence to indicate that CM037 binds to the free enzyme. As a 
competitive inhibitor, binding of CM037 and acetaldehyde is mutually exclusive, 
 
 
Figure 59: Schematic representation of CM037 inhibition of ALDH1A1 
CM037 is a competitive inhibitor with respect to acetaldehyde and uncompetitive with 
respect to NAD
+
. The predominant pathway is CM037 binding to the enzyme-NAD’ 
complex. However, inhibition is still present with saturating aldehydes, and therefore 
CM037 can likely bind to the enzyme-NADH complex.  
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resulting in an inactive enzyme. However, even in the presence of saturating aldehyde, 
CM037 still inhibits to some extent. As seen with CM026, CM037 was uncompetitive 
with respect to varied NAD 
+
 and likely binds weakly to the enzyme-NADH complex, as 
the Ki value with respect to varied NAD
+
 and saturating propionaldehyde was at least 20-
fold weaker than with respect to varied acetaldehyde and saturating NAD
+
. CM037 is an 
ester and it is possible that it is a substrate for ALDH1A1 (Figure 60). In a manner 
similar to inhibition of ALDH1A1 by DEAB, this ester may be turned over at a slow rate, 
therefore appearing as an inhibitor. It is also possible that the carboxylic acid product acts 
as an inhibitor, with either the product remaining bound to the enzyme (slow turnover 
rate) or the product released only to rebind and inhibit the enzyme, although preliminary 
results indicate the acid product does not inhibit the enzyme. However, structural data 
shows that the ester is still intact after a five hour incubation with NAD
+
, an activator of 
esterase activity. Also, structural data does not indicate that CM037 is binding in an 
orientation that would support a substrate as inhibitor mechanism. SAR with CM037 
indicates that the ester functional group is important for ALDH1A1 inhibition. Replacing 
the ester group with an amide resulted in a 5-fold increase in IC50 value, suggesting that 
CM037 may inhibit by acting as a substrate. The only non-ester analog that inhibited 
ALDH1A1 at a similar level to CM037 was the carboxylic acid CM037e. Although the 
carboxylic acid functional group of CM037e is on R1, whereas the carboxylic acid 
functional group for the CM037 product would be on R2, these results suggest that the 
esterase product may be able to bind to and inhibit ALDH1A1. The substituent on R1 is 
important for isoenzyme selectivity within the ALDH1A subfamily. CM037 does not 
inhibit ALDH1A2 or ALDH1A3 more than 20% at a concentration of 20 µM. However, 
 
Figure 60: Possible hydrolysis of CM037 by ALDHs. 
CM037 is an ester that possibly acts as a substrate for ALDH1A1, producing ethanol 
and a carboxylic acid. 
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replacing the propyl pyrrolidine group with either an ethanol group (CM037g) or a 
phenyl group one or two carbons removed from the core three-ring structure (CM037b, 
CM037j), greatly increased ALDH1A2 and ALDH1A3 inhibition. CM037b, CM037c 
and CM037j, which all contain phenyl groups on R1, were not strong inhibitors of 
ALDH1A1. Either a longer, more flexible linker is required for binding or the aromatic 
ring interferes with compound binding.  
 
As shown in Figure 61, ALDH1A1 possesses a large, funnel shaped opening leading to 
the active site, whereas ALDH2 has a much more constricted, cylindrical shaped 
opening. ALDH3A1 possesses a wider inner vestibule near the catalytic nucleophile, with 
a much narrower and curved entryway. The cylindrical entry to ALDH2 sterically 
occludes the binding of the CM026 class of inhibitors in large part due to the side chain 
present at the position equivalent to Gly458. Like daidzin, both the CM026 and CM037 
classes of compounds are planar, multi-ringed structures that adopt binding modes that 
take advantage of the topological characteristics unique to the ALDH isoenzyme toward 
 ALDH1A1 (PDB 4WJ9)          ALDH2 (PDB ICW3)            ALDH3A1 (PDB 3SZA) 
 
Figure 61: Comparison of the active site topography of human ALDHs. 
The three isoenzymes were aligned using LSQ in Coot and the surface figures 
generated via Pymol. The active site cysteine is shown in red for all three isoenzymes. 
In ALDH1A1, Gly458 is shown in yellow. For ALDH2 and ALDH3A1, the amino 
acid at the equivalent position as ALDH1A1 G458 is also shown in yellow (ALDH2 
Asp457, ALDH3A1 Ile394). 
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which they demonstrate selectivity, and neither of these types of compounds can be 
accommodated in the curved and more sterically restricted substrate binding site of 
ALDH3A1. Daidzin is a strong inhibitor of ALDH2 but it also inhibits ALDH1A1
147
. 
Comparison of the binding of daidzin to ALDH2 (PDB Code 2VLE
173
) with CM026 
binding to ALDH1A1 indicate that they bind in a similar location but in a different 
orientation. This near perpendicular difference in orientation enables CM026 to inhibit 
ALDH1A1 but not ALDH2 due to steric hindrance of Asp474 of ALDH2, while daidzin 
inhibits both isoenzymes (Figure 62A). Although CM026 and CM037 have little 
compound similarity, they utilize the same regions of the active site of ALDH1A1, with 
both capitalizing on the presence of the small binding pocket created by the presence of 
Gly458 (Figure 62B). Sequence alignment of the other 18 human ALDH isoenzymes 
indicate that the only other family member that has a glycine in this position is 
ALDH16A1. However, the function of ALDH16A1 is unknown, and the protein has a 
three residue deletion in the active site loop that eliminates the conserved Cys 
nucleophile, suggesting this protein may lack aldehyde dehydrogenase activity
36
. 
Analysis of the G458N mutant indicates that the presence of a non-glycine residue at this 
A.                                                                          B. 
 
Figure 62: Comparison of compound binding to ALDH isoenzymes. 
A) Comparison of ALDH1A1-CM026 to ALDH2-daidzin with ALDH1A1, shown in 
light blue with CM026 in dark blue, and ALDH2, shown in light green with daidzin in 
dark green. The active site cysteine is shown in red for both isoenzymes. B) 
Comparison of CM026 and CM037 binding to ALDH1A1 illustrating that both 
classes utilize similar surface features of ALDH1A1. Daidzin-ALDH2 (PDB 2VLE). 
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position does not adversely affect either substrate kinetics or inhibition by the non-
selective compounds DEAB and CM302. Consequently, our screening protocol 
successfully exploited a unique structural feature found primarily in primate ALDH1A1s, 
which further validates the use of the esterase activity as a screening tool for ALDH 
isoenzymes. 
 
Unlike DEAB, both the CM026 and CM037 classes of compounds were selective for 
ALDH1A1, and our next question was to determine if they can produce a physiological 
effect in cells. For a compound to have an effect in the cell, it must have certain 
characteristics in order to reach its protein destination. First, it must be able to pass 
through the cell membrane and enter the cell. Next, the compound must not be 
inactivated or exported from the cell by active transporters too quickly. Third, it must 
modulate the activity of its target with minimal off-target effects. Finally, the compound 
itself or any of its metabolic by-products must not exceed toxicity thresholds
174
. If any or 
all of these characteristics are not present, even the most potent in vitro modulators will 
fail in cell culture.  
 
The next step in the development of the CM026 and CM037 classes of compounds was to 
determine whether these compounds could produce a desired biological effect in cell 
culture For this step, we recruited two cancer researchers: Dr. Daniela Matei at Indiana 
University School of Medicine and Dr. Ronald Buckanovich at the University of 
Michigan School of Medicine. In both laboratories, the effects of the CM026 and CM037 
classes of compounds on ovarian cancer (OC) cell models were tested. OC cells form 
cellular aggregates, or spheroids, that facilitate metastasis by serving as vehicles for 
dissemination, while protecting the cells from the extracellular, peritoneal 
environment
175,176
 Dr. Matei has shown that ALDH1A1 is over-expressed in spheroids 
compared to cellular monolayers using both OC cell lines and primary cells, and that 
ALDH1A1 mRNA and protein levels increased with each successive spheroid 
generation
101
. These results indicate that the protein is not simply a biomarker but is 
important for cellular aggregation and/or cancer stem cell survivability. In a dose-
dependent manner, the Matei group showed that CM037 was able to disrupt spheroid 
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formation and decrease cell viability by targeting ALDH
+
 cell populations (Figure 63). 
Via the Wnt signaling pathway, the ALDH1A1 gene is a direct target of β-catenin, a 
transcription factor linked to stem cell self-renewal, survivability, and as discovered by 
Matei et al, the formation of OC spheroids. Following inhibition of ALDH1A1, the 
downstream effects of ALDH1A1 inhibition that disrupt spheroid formation are not 
known, as the role of this enzyme in stem cell maintenance, self-renewal, and/or 
survivability in general are still unclear. CM037 and other selective small molecule 
inhibitors of ALDH1A1 should increase our understanding of these processes. ALDHs 
are also involved in increasing cellular resistance to various chemotherapeutics, and 
CM037 increased cellular sensitivity to cisplatin in a dose-dependent manner
101
. These 
results with OC cells indicate that CM037 is capable of entering a cell and inducing a 
phenotypic change. Therefore, CM037 represents a potent first-generation selective 
inhibitor of ALDH1A1 that should be further developed and modified to improve 
potency and selectivity. 
 
Figure 63: The effect of CM037 in ovarian cancer cells. 
Dose-dependent decrease following 3-day CM037 treatment in A) spheroid formation 
and B) ALDH
+
 cells (modified from Condello et al 
101
). 
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The CM026 class of compounds has been less successful in cell culture. Tested by the 
Matei lab along with CM037, CM026 did not disrupt spheroid formation. In unpublished 
work from the Buckanovich lab, neither CM027 nor CM053, two analogs of CM026, 
altered cellular proliferation in OC cells, while CM037 did so in a dose dependent 
fashion (Figure 64). Why the CM026 analogs are ineffective in cell culture are not 
known. The CM026 analogs tested had low partition coefficients (logP) values, an 
estimate of the compound’s lipophilicity, and therefore its cell membrane permeability. 
All compounds had logP values less than 5, in accordance with Lipinski’s Rule of 5151. 
However, the three CM026 analogs tested in cell culture, CM026, CM027, and CM053 
had estimated logP values of 1.99, 2.25, and 1.75, respectively, based on ChemDiv 
calculations (www.chemdiv.com). These values indicate that the compounds may be too 
hydrophilic to be efficiently taken up by the cell. Of the CM026 class of compounds 
tested, CM057 had an IC50 < 1 µM and an estimated logP of 3.44, and may serve as a 
 
Figure 64: Effect of various compounds on the proliferation of OC cell. 
A2780DK, an ovarian cancer cell line, was plated with an initial cell count of 500,000 
cells. Following a 2-day treatment with ALDH1 inhibitors, cellular proliferation was 
determined by counting the number of viable cells. Compounds 6737540 and CM010 
inhibit the ALDH1A subfamily, and CM027, CM037, and CM053 are selective for 
ALDH1A1. 6737540 is a University of Michigan compound developed by Ronald 
Buckanovich and used here as a control (bars represent mean/SEM; unpublished data). 
A. 
B. 
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good representative of this class in cell culture. However, maximum solubility in DMSO 
is approximately 10 mM, and CM057 was not tested in cell culture due to limitations on 
maximum compound concentration. It may be possible to use a different solvent to 
achieve higher concentrations for CM057. Another approach is to test the remaining 
CM026 analogs identified in the HTS that have higher logP values. The logP values of 
this class ranged from 1.71 to 4.92, so ample variability exists to determine whether the 
inability of the CM026 class of compounds to alter cellular phenotype is simply due to 
the compounds not getting into the cells. In comparison to CM026, CM037’s logP value 
was 4.02 and likely could easily enter the cell. However, CM037 solubility has become 
an issue moving forward from a cell culture model to an animal model, as it is far less 
soluble in the required aqueous solutions. Other possible reasons for why the CM026 
analogs have no effect in cell culture include: 1. the compound is taken up by the cell but 
it is quickly metabolized into an inactive form, 2. the compound is taken up by the cell 
but is actively transported back out of the cell, 3. the compound binds to another 
macromolecule and is not available to inhibit ALDH1A1, and 4. the compound is 
ineffective against ALDH1A1 in a cellular environment. Additional cell culture studies 
are needed to determine why this potent class of ALDH1A1 inhibitors is ineffective in 
the cellular environment. Although cell culture data with the CM037 class is much more 
promising, the CM026 class cannot be eliminated. The results from the Buckanovich lab 
also revealed that CM010, another compound discovered in the HTS, reduces cell 
proliferation in a dose-dependent manner (Figure 64). CM010 is not selective for 
ALDH1A1, inhibiting the other two ALDH1A subfamily members, but has no effect on 
ALDH2 or ALDH3A1. As CM010 was more potent in this model compared to CM037, it 
may either be a more effective inhibitor of ALDH1A1 in cells or the combined inhibition 
of multiple ALDH1A isoenzymes by CM010 was more effective in blocking 
proliferation of the cancer cells. Therefore, all three classes of compounds (CM010, 
CM026, and CM037) still remain excellent starting points for the development of 
ALDH1A and ALDH1A1 selective compounds.  
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V. Conclusion and Future Directions 
Members of the aldehyde dehydrogenase superfamily of enzymes are critical for normal 
biological processes. ALDH1A1 has also been linked to a wide variety of diseases 
including obesity, cancer, and neurodegeneration. Small molecule probes are needed to 
study the role of this enzyme in both normal and disease states, but due to the high degree 
of structural and functional overlap within the ALDH1/2 family, targeted drug 
development has proven to be difficult. At this time, there are no commercially available 
small molecules that selectively modulate ALDH1A1 activity compared to other ALDH 
isoenzymes. The goal of our study was to discover and characterize ALDH1A1-specific 
inhibitors. 
  
Our results with DEAB indicate that the substrate-as-inhibitor type of compounds may 
not represent good candidates for the development of selective ALDH inhibitors due to 
the high degree of substrate overlap amongst ALDH superfamily members, particularly 
within the ALDH1/2 family. A number of ALDH superfamily members are capable of 
the oxidation of DEAB to its corresponding carboxylic acid, but with great variation in 
the rate of the reaction. DEAB is a potent inhibitor of ALDH1A1, but it also inhibits most 
of the ALDH1/2 family members and in the process is metabolized to its carboxylic acid 
and removed from the system, allowing for short-term, reversible inhibition. This overlap 
of inhibition may be of minimum concern if a short-term knockdown of global ALDH1/2 
activity is desired. However, DEAB is rapidly turned over by ALDH3A1, and the 
presence of even modest levels of this enzyme could hinder the use of DEAB in a system 
or tissue-type with high levels of ALDH3A1 expression. Analogs of DEAB could be 
developed that are not metabolized as rapidly by ALDH3A1. To better design these 
analogs, the structures of DEAB with multiple ALDH isoenzymes are needed to 
determine how the compound binds and which residues are involved in stabilizing the 
acyl-enzyme intermediate. As ALDH3A1 prefers aromatic substrates like DEAB and 
benzaldehyde compared to the linear aliphatic aldehydes preferred by the ALDH1/2 
family, structural data could facilitate the development of DEAB analogs that are no 
longer substrates for ALDH3A1. However, due to the high level of structural and 
functional overlap within the ALDH1/2 family, it will likely be very difficult to develop 
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DEAB analogs that are selective towards one isoenzyme. DEAB is a potent, reversible 
ALDH1/2 inhibitor, but it is not a valid candidate for the development of inhibitors 
selective for a particular isoenzyme. Therefore, new classes of compounds are needed. 
  
To discover selective activators and inhibitors for ALDH1A1, an in vitro esterase-based 
high-throughput screen (HTS) was performed. From a 64,000 compound library, 256 
compounds were identified as hits capable of altering ALDH1A1’s esterase activity. We 
have further examined 67 compounds and discovered approximately 50% also inhibited 
aldehyde oxidation. These results indicate that the esterase screen is a valid option for 
identifying ALDH1A1 aldehyde oxidation modulators.  
  
We further characterized two classes of compounds from the HTS in detail, CM026 and 
CM037, using steady-state kinetics, structure-activity-relationship, X-ray crystallographic 
structural data, and cell culture studies. Currently CM037 is the most promising and is 
capable of inducing a phenotypic change in two ovarian cancer cell lines (Condello 
et al
101
 and Buchanovich et al, unpublished). As CM037 progresses from hit to lead 
compound, additional pharmacokinetic studies are needed to determine if CM037 can 
become an effective drug. These studies will address CM037’s absorption, distribution, 
metabolism, and excretion (ADME) properties
174
. CM037 is an ester and even if CM037 
is not a substrate of ALDH1A1, other esterases exist in the cell that will likely hydrolyze 
the compound. Microsomal stability assays will aid in better understanding the clearance 
rate of the compound. Toxicity studies in mice are in the early stages by the Matei lab. 
One problem with these toxicity studies has been solubility issues of CM037 in an 
aqueous solution, and therefore DMSO has been needed at a higher percentage than 
desired, causing temporary discomfort to the mice. With doses at 30 mg/kg or below, 
there have been no apparent effects on the mice. Additional pharmacokinetic and 
pharmacodynamics studies are needed in mice to determine the LD50 (dose required to 
kill one-half of the animals), the rate of compound elimination from the body, optimal 
route of administration, and other drug ADME characteristics. CM037 has an in vitro 
IC50 value of approximately 5 μM, and cell culture results had EC50 values in the 20 – 50 
μM range. In its current form, CM037 does not represent an ideal drug, but modifications 
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could increase potency and improve solubility while maintaining selectivity for 
ALDH1A1. Therefore, CM037 represents an excellent choice for further drug 
development. 
 
Since CM026 and its analogs represented nearly 25% of both the 256 hits identified in 
the esterase HTS and the 67 compounds analyzed further for their effect on aldehyde 
oxidation, this class of compounds was studied the most. Kinetic studies showed that this 
class contains potent, selective, reversible ALDH1A1 inhibitors. Structural data enabled 
us to determine where the compounds bind and why they are selective for ALDH1A1 
compared to other ALDH1/2 family members. Unfortunately, cell culture data was less 
promising, as the compounds selected for cell culture studies had little to no effect on 
cellular phenotype, viability, or proliferation. However, it is possible that the compounds 
have little effect on cells because they are too hydrophilic and simply are not getting into 
the cells. Of the 17 CM026 analogs tested, CM057 represents the most promising 
compound for possible cell culture studies. CM057 has a sub-micromolar IC50 and an 
estimated clogP value of 3.44, similar to CM037 and is more hydrophobic than the other 
CM026 analogs tested in cell culture. Because CM057 is less soluble in DMSO than the 
other CM026 analogs, it was not explored further, but this characteristic may make it 
more promising for future in vivo testing. If CM057 solubility issues continue to be 
problematic, there exists a great deal of diversity amongst the nearly 75 CM026 analogs 
identified in the HTS, and compounds that both inhibit ALDH1A1 aldehyde oxidation 
and are cell permeable likely exist. Structural data, SAR results, and estimated logP 
values will help determine which hits represent the best candidates for further 
development of the CM026 class of compounds. Unfortunately, a negative result still 
does not confirm that the compound is ineffective in cell culture. Solubility or 
permeability issues, inactivation of the compound, and/or rapid removal of the compound 
from the cell will also produce negative results. Regardless, by testing a variety of 
CM026 analogs of varying logP values, we should be able to determine if this class of 
compounds represents a potential candidate for the development of selective ALDH1A1 
inhibitors.  
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The CM026 and CM037 classes of compounds represented 18 of the 67 compounds 
further analyzed and 13 of the 32 hits that inhibited ALDH1A1, leaving 19 compounds 
yet to be analyzed in detail that are known to inhibit ALDH1A1. CM302 and CM303 
inhibited both ALDH1A1 esterase and dehydrogenase activities but were not selective for 
ALDH1A1 compared to other ALDH isoenzymes tested. However, if a short term 
inhibition of ALDH1/2 activity, irrespective of any specific isoenzyme, is desired, both 
of these compounds represent new classes of compounds with this capability. Unlike 
DEAB, CM302 has an added feature in that it also partially inhibits ALDH3A1 and 
possibly ALDH5A1, and may represent an ideal candidate for drug development 
targeting cells that overexpress both ALDH1A1 and ALDH3A1. The esterase activator 
CM010 is a selective inhibitor of the ALDH1A subfamily, and results from the 
Buchanovich lab at the University of Michigan indicate that this compound decreases cell 
proliferation. Similar to CM037, CM010’s in vivo EC50 was in the 20 – 50 µM range with 
an in vitro IC50 in the low micromolar range, but unlike CM037, complete inhibition was 
not seen under the assay conditions used. Additional modifications are needed to improve 
the potency of CM010. Very little has been done on the remaining 16 compounds, but all 
are selective for ALDH1A1 compared to ALDH2 and ALDH3A1. The most promising of 
these unexplored compounds are CM020, CM038, CM039, CM047, and CM307, as all 
have sub-micromolar IC50’s. Although CM039 has some structural resemblance to 
CM037, the remaining compounds are all structurally unique, and each could represent a 
new class of ALDH1A1 inhibitors. Further kinetic and cell culture work is needed to 
determine if any or all of these compounds should be pursued as potential hits. Additional 
work is also needed to characterize all classes of compounds identified in the HTS. 
Although most of the 15 esterase inhibitors have been examined, with 4 of 10 also 
inhibiting aldehyde oxidation, much more work is needed on the esterase activators. 
Based on the results of the HTS compounds tested to date, almost half of these activators 
will likely modify ALDH1A1 dehydrogenase activity, and most will inhibit the enzyme 
selectively, generating even more candidates for the development of selective ALDH1A1 
inhibitors.  
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The HTS identified 241 compounds that activated ALDH1A1 esterase activity, but upon 
examination of 57 of these activators, none activated the enzyme’s aldehyde oxidation 
activity. One compound, CM021 exhibited a modest increase of ALDH1A1 N121S 
activity, but did not activate ALDH1A1 WT. CM021 is a structural analog to Alda-1, an 
ALDH2 activator identified by coupling aldehyde oxidation to an NADH-dependent 
reaction
75
, indicating that the HTS is capable of identifying activators. Although an 
activator of aldehyde oxidation was not in the first 57 esterase activators analyzed, it is 
still probable that at least one exists within the compounds remaining to be analyzed. 
 
Our study has identified and characterized multiple classes of compounds that inhibit 
ALDH1A1, including some that exhibit promising anti-cancer properties in cell culture 
studies. ALDH1A1 inhibition likely induces this phenotype by changing the levels of 
various retinoids, and therefore alters various cell growth and differentiation pathways. 
Although our goal was to develop selective ALDH1A1 compounds, we have also 
discovered and characterized compounds that inhibit the ALDH1A subfamily and 
multiple members of the ALDH1/2 family. Each compound class could serve as a 
scaffold to design drugs that target the ALDH1/2 family of enzymes, the ALDH1A 
subfamily, or ALDH1A1 specifically. For inhibition of the ALDH1/2 family, reversible 
inhibition by CM302 and CM303 would be preferred to minimize the long-term 
consequences of such a global reduction in enzyme activity, including the build-up of 
toxic aldehydes that would occur with an irreversible inhibitor. Short-term, reversible 
inhibition of ALDH1A activity, as seen with CM010, may be ideal to minimize the 
cancer stem cell characteristics identified as contributing to more aggressive and fatal 
cancers. In combination with other drugs, inhibition of ALDH1A may prevent CSC 
proliferation and enable complete destruction of the cancer. Long-term inhibition of 
ALDH1A may not be desired due to the critical role of this subfamily in a number of cell 
growth and differentiation pathways. Finally, for selective inhibition of ALDH1A1, both 
the CM026 and CM037 classes of compounds can serve as a scaffold for the continued 
development of drugs targeting this enzyme. Initially, these ALDH1A1-selective 
compounds would be of great use as chemical tools for deciphering the role of this 
enzyme in multiple biological pathways, both in normal and disease states. With the use 
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of various “–omics”, including metabolomics and proteomics, as well as other biological 
tools, it is possible to decipher the downstream effects of ALDH1A1 activity on various 
biological processes. By increasing our knowledge of the processes involved, we can 
better understand the physiological roles of ALDH1A1 and determine which steps to 
target for drug development. If ALDH1A1 is discovered to be a potential target for 
chemotherapeutics, these selective ALDH1A1 inhibitors again represent a potential 
starting point for drug development. By precisely targeting ALDH1A1, the development 
of more potent, longer lasting covalent inhibitors may be possible, as other similar ALDH 
isoenzymes could minimize the build-up of toxic aldehydes. Regardless of the degree of 
selectivity desired, from ALDH1A1-selective to a global inhibition of multiple ALDH 
enzymes, the compounds identified in this study represent an excellent starting point for 
the development of ALDH1A1 inhibitors.    
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Supplementary Table 1: Activators of ALDH1A1 esterase activity. 
ChemDiv catalog number and structure of the 241 compounds that activated ALDH1A1 
esterase activity in the HTS. The ratio to control value for the initial screen (1) and 
verification screen (2) are shown. The names of the compounds whose effect on aldehyde 
oxidation have been tested are shown as CM0XX below the ChemDiv number.  
Chem 
Div 
Structure 
Ratio to 
Control 
1 2 
2188- 
3777 
 
2.1 2.9 
3238- 
0138 
 
CM052 
 
7.5 5.1 
3238- 
0120 
 
4.5 4.3 
3277- 
0112 
 
CM046 
 
4.0 2.4 
3335- 
0338 
 
3.2 2.2 
3332- 
1185 
 
4.8 3.6 
3332- 
1195 
 5.7 4.6 
3334- 
4922 
 4.1 3.6 
3334- 
4625 
 
2.1 2.0 
Chem 
Div 
Structure 
Ratio to 
Control 
1 2 
3339- 
3595 
 
7.3 4.0 
3473- 
1281 
 
4.8 4.9 
3544- 
1012 
 
CM003 
 
2.4 2.3 
3544- 
1018 
 
2.4 2.0 
3635- 
1425 
 
2.7 2.1 
3750- 
0067 
 
4.0 3.0 
3771- 
7523 
 
13 4.8 
3909- 
9107 
 
6.7 4.3 
3909- 
9109 
 
3.1 2.5 
3909- 
9113 
 
2.3 2.6 
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Chem 
Div 
Structure 
Ratio to 
Control 
1 2 
3909- 
9114 
 
3.4 3.5 
3932- 
0079 
 
9.9 7.0 
3909- 
9134 
 
5.5 5.3 
3993- 
1905 
 
2.4 2.2 
3993- 
1906 
 
11 10 
3909- 
9877 
 
2.3 2.2 
4049- 
0294 
 
4.7 2.5 
4052- 
2657 
 
7.4 4.8 
4112- 
0771 
 
CM001 
 
4.9 5.1 
4112- 
0824 
 
6.6 6.5 
4236- 
0892 
 
2.3 2.0 
Chem 
Div 
Structure 
Ratio to 
Control 
1 2 
4181- 
1899 
 
CM008 
 
2.1 2.3 
4236- 
0953 
 
3.9 14 
4281- 
0310 
 
CM022 
 
23 16 
4358- 
4339 
 
CM016 
 
2.2 2.0 
4472- 
0052 
 
2.7 6.6 
4552- 
5135 
 
CM032 
 
2.0 3.5 
4555- 
0196 
 
2.1 2.1 
4554- 
6912 
 
4.5 2.6 
4555- 
3401 
 
3.0 2.4 
4554- 
6941 
 
3.4 2.8 
4555- 
0120 
 
2.9 2.3 
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Chem 
Div 
Structure 
Ratio to 
Control 
1 2 
4554- 
6856 
 
3.1 2.3 
4554- 
6933 
 
2.9 2.3 
4555- 
3107 
 
8.2 4.9 
4780- 
0024 
 
CM033 
 
3.8 2.9 
4903- 
2108 
 
2.0 2.4 
4903- 
2155 
 
CM002 
 
3.1 2.8 
4903- 
2156 
 
3.1 3.2 
5055- 
7414 
 
3.1 2.6 
5067- 
0687 
 
8.3 6.3 
5067- 
0952 
 
CM014  
4.2 4.5 
5067- 
0859 
 
12 12 
Chem 
Div 
Structure 
Ratio to 
Control 
1 2 
5183- 
0418 
 
2.3 2.5 
5186- 
0442 
 
5.5 2.2 
5228- 
0312 
 
12 7.0 
5339- 
0215 
 
4.8 3.5 
5339- 
0193 
 
5.8 2.4 
5339- 
0551 
 
CM051 
 
5.3 5.1 
5519- 
0751 
 
3.8 2.2 
5521- 
0170 
 
CM034 
 
2.7 2.1 
5519- 
0629 
 
CM010 
 
2.6 2.3 
5591- 
1893 
 
CM047 
 
8.2 13 
5611- 
1897 
 
2.3 2.5 
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Chem 
Div 
Structure 
Ratio to 
Control 
1 2 
5591- 
1925 
 
8.6 3.1 
5591- 
0588 
 
CM006 
 
2.6 2.5 
5611- 
1894 
 
CM004 
 
5.4 5.2 
5611- 
1978 
 
CM005 
 
4.3 3.6 
5665- 
0118 
 
CM019 
 
3.6 3.6 
5672- 
0068 
 
2.3 2.0 
5611- 
1984 
 
3.0 2.6 
5611- 
1987 
 
5.3 5.7 
5664- 
0379 
 
CM035 
 
2.5 4.0 
5720- 
0005 
 
2.5 2.4 
5922- 
0026 
 
7.6 6.2 
Chem 
Div 
Structure 
Ratio to 
Control 
1 2 
5922- 
0032 
 
6.5 6.1 
5922- 
0076 
 
CM036 
 
3.1 2.6 
5941- 
1237 
 
CM023 
 
3.0 2.3 
5946- 
0003 
 
4.9 3.8 
6049- 
1331 
 
8.0 3.8 
6049- 
1282 
 
CM013 
 
3.7 3.1 
6049- 
0440 
 
2.1 2.2 
6049- 
2856 
 
3.6 3.2 
6049- 
2858 
 
3.1 2.8 
6113- 
1671 
 
9.5 6.7 
6113- 
2682 
 
14 9.7 
6228- 
1380 
 
CM048 
 
3.9 2.8 
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Chem 
Div 
Structure 
Ratio to 
Control 
1 2 
6216- 
0194 
 
2.4 2.1 
6434- 
3636 
 
2.1 2.2 
6434- 
3680 
 
8.1 11 
6434- 
3637 
 
2.6 2.3 
6434- 
3686 
 
CM049  
2.1 5.9 
6434- 
3639 
 
2.2 2.1 
6434- 
3695 
 
5.4 7.3 
6434- 
3640 
 
2.4 2.2 
6434- 
3707 
 
8.5 9.7 
6434- 
3720 
 
3.5 4.2 
6434- 
3629 
 
2.5 2.5 
Chem 
Div 
Structure 
Ratio to 
Control 
1 2 
6434- 
3678 
 
5.2 4.8 
6434- 
3679 
 
8.6 10 
6466- 
1761 
 
4.5 3.7 
6618- 
0004 
 
6.7 5.6 
6466- 
1795 
 
CM015 
 
3.6 2.7 
6481- 
7344 
 
3.0 2.2 
7287- 
0518 
 
2.5 2.4 
7287- 
0519 
 
CM009  
3.2 2.3 
8003- 
0397 
 
CM050 
 
3.1 3.6 
7202- 
2296 
 
CM007 
 
3.1 4.1 
8009- 
0196 
 
2.7 2.2 
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Chem 
Div 
Structure 
Ratio to 
Control 
1 2 
8009- 
2086 
 
9.3 4.5 
8012- 
8719 
 
3.6 2.3 
8013- 
5620 
 
3.3 2.1 
8013- 
5576 
 
3.7 3.9 
A001- 
5851 
 
6.7 4.1 
8015- 
3130 
 
5.1 2.1 
C066- 
0331 
 
2.9 2.9 
C066- 
0314 
 
2.3 2.1 
C077- 
0019 
 
2.6 2.6 
C085- 
2100 
 
2.7 2.1 
C109- 
0828 
 
2.8 2.2 
Chem 
Div 
Structure 
Ratio to 
Control 
1 2 
C109- 
0868 
 
CM020 
 
2.2 2.1 
C123- 
0492 
 
CM021 
 
6.3 4.5 
C156- 
0107 
 
CM018  
3.6 3.4 
C174- 
0133 
 
CM043 
 
3.7 2.3 
C174- 
0218 
 
CM011 
 
3.7 3.1 
C174- 
0331 
 
CM012 
 
2.7 2.5 
C174- 
0222 
 
2.2 2.3 
C187- 
0019 
 
3.2 2.6 
C200- 
0216 
 
2.9 2.5 
C200- 
1296 
 
4.0 2.1 
C269- 
0038 
 
8.7 2.3 
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Chem 
Div 
Structure 
Ratio to 
Control 
1 2 
C303- 
0270 
 
4.4 2.1 
C303- 
0317 
 
3.5 2.0 
C305- 
0458 
 
3.3 2.6 
C361- 
0197 
 
CM044 
 
6.3 2.1 
C366- 
0190 
 
CM045 
 
3.5 2.1 
C429- 
0235 
 
2.7 2.3 
C378- 
0506 
 
4.8 2.2 
C429- 
0223 
 
3.2 2.6 
C386- 
0528 
 
3.5 3.2 
C434- 
0076 
 
CM017 
 
3.5 2.6 
C470- 
0068 
 
CM024  
4.4 2.0 
Chem 
Div 
Structure 
Ratio to 
Control 
1 2 
C470- 
0085 
 
11 7.1 
C470- 
0125 
 
2.3 2.0 
C470- 
0665 
 
6.8 2.9 
C470- 
0728 
 
4.2 2.5 
C470- 
0070 
 
3.9 2.6 
C470- 
0242 
 
5.8 4.9 
C470- 
0315 
 
2.9 2.1 
C470- 
0057 
 
2.7 2.5 
C470- 
0325 
 
CM025 
 
2.2 2.4 
C470- 
0645 
 
CM054 
 
4.5 3.0 
C470- 
0667 
 
CM026 
 
8.3 5.2 
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Chem 
Div 
Structure 
Ratio to 
Control 
1 2 
C470- 
0730 
 
15 8.4 
C470- 
0075 
 
2.6 2.2 
C470- 
0089 
 
6.4 2.5 
C470- 
0216 
 
8.0 4.2 
C470- 
0243 
 
9.6 7.5 
C470- 
0262 
 
CM055 
 
16 13 
C470- 
0646 
 
CM053 
 
14 11 
C470- 
0654 
 
CM056 
 
6.3 4.3 
C470- 
0668 
 
4.6 3.9 
C470- 
0077 
 
9.6 5.2 
C470- 
0094 
 
10 3.7 
Chem 
Div 
Structure 
Ratio to 
Control 
1 2 
C470- 
0197 
 
20 2.3 
C470- 
0244 
 
3.2 2.0 
C470- 
0264 
 
14 4.3 
C470- 
0317 
 
7.7 6.1 
C470- 
0334 
 
7.1 5.3 
C470- 
0647 
 
3.9 2.7 
C470- 
0720 
 
9.2 9.3 
C470- 
0489 
 
CM027 
 
3.8 4.0 
C470- 
0245 
 
11 9.9 
C470- 
0048 
 
3.5 2.8 
C470- 
0648 
 
3.9 2.5 
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Chem 
Div 
Structure 
Ratio to 
Control 
1 2 
C470- 
0721 
 
CM028 
 
8.0 5.3 
C470- 
0246 
 
CM029 
 
2.4 2.6 
C470- 
0061 
 
9.8 5.0 
C470- 
0657 
 
CM030 
 
2.5 2.3 
C470- 
0723 
 
6.1 3.5 
C470- 
0248 
 
4.1 2.5 
C470- 
0051 
 
2.0 2.3 
C470- 
0064 
 
2.9 2.7 
C470- 
0650 
 
CM057 
 
7.6 4.5 
C470- 
0658 
 
13 7.7 
C470- 
0725 
 
7.1 5.0 
Chem 
Div 
Structure 
Ratio to 
Control 
1 2 
C470- 
0204 
 
2.3 2.1 
C470- 
0249 
 
16 12 
C470- 
0312 
 
2.2 4.1 
C470- 
0053 
 
2.9 4.3 
C470- 
0065 
 
CM031 
 
3.6 2.3 
C470- 
0662 
 
7.0 2.4 
C470- 
0482 
 
18 10 
C470- 
0726 
 
9.1 2.7 
C593- 
0746 
 
3.4 2.5 
C598- 
0399 
 
17 3.5 
C598- 
0444 
 
3.6 2.9 
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Chem 
Div 
Structure 
Ratio to 
Control 
1 2 
C629- 
0095 
 
5.8 3.4 
C629- 
0084 
 
4.9 3.3 
C629- 
0100 
 
CM038 
 
3.3 2.4 
C660- 
0239 
 
7.7 3.6 
C692- 
0206 
 
2.7 2.1 
C692- 
0425 
 
3.5 2.5 
C692- 
0426 
 
6.4 2.3 
C692- 
0428 
 
3.2 2.6 
C692- 
0319 
 
4.4 2.3 
C692- 
0248 
 
5.2 2.8 
C692- 
0333 
 
3.2 2.5 
Chem 
Div 
Structure 
Ratio to 
Control 
1 2 
C720- 
0002 
 
5.8 4.1 
K263- 
0587 
 
CM037 
 
2.2 2.0 
K284- 
1521 
 
4.3 2.1 
K284- 
1536 
 
7.9 4.8 
K284- 
7015 
 
6.9 2.1 
K297- 
0386 
 
3.2 2.6 
K409- 
0004 
 
2.2 2.1 
K643- 
0219 
 
8.4 3.8 
K781- 
5423 
 
CM039 
 
3.5 2.1 
K781- 
5628 
 
8.4 4.0 
K783- 
4550 
 
3.5 2.2 
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Chem 
Div 
Structure 
Ratio to 
Control 
1 2 
K784- 
6532 
 
4.1 2.0 
K784- 
5336 
 
4.5 2.8 
K784- 
9658 
 
6.0 3.2 
K784- 
8446 
 
2.5 2.6 
K784- 
9612 
 
2.2 2.4 
K784- 
9804 
 
3.6 3.9 
K785- 
0143 
 
CM040 
 
3.4 3.6 
K785- 
0281 
 
3.9 3.7 
K785- 
0289 
 
2.4 2.5 
K784- 
9808 
 
4.8 4.7 
K785- 
0189 
 
2.3 2.2 
Chem 
Div 
Structure 
Ratio to 
Control 
1 2 
K786- 
9188 
 
CM042 
 
2.4 2.2 
K786- 
9836 
 
CM041 
 
2.1 2.1 
K788- 
0894 
 
5.5 2.6 
K788- 
6942 
 
2.3 2.6 
K788- 
1286 
 
6.0 3.1 
K788- 
8259 
 
4.1 3.5 
K788- 
7993 
 
2.6 2.5 
K894- 
1589 
 
3.2 2.2 
K913- 
0047 
 
3.4 2.2 
K913- 
0222 
 
4.2 2.3 
K913- 
0335 
 
3.7 2.7 
K913- 
0043 
 
3.8 2.5 
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Supplementary Table 2: Inhibitors of ALDH1A1 esterase activity. 
ChemDiv catalog number and structure of the 15 compounds that inhibited ALDH1A1 
esterase activity in the HTS. The ratio to control value for the initial screen (1) and 
verification screen (2) are shown. The names of the compounds whose effect on aldehyde 
oxidation have been tested are shown as CM3XX below the Chem Div number. For three 
HTS compounds, close analogs of the compounds were used due to non-availability of hit 
compound. 
Chem 
Div 
Structure 
Ratio to 
Control 
1 2 
3343-
2924 
 
0.4 0.5 
2188-
3271 
 
CM310  
Analog to 
3343-
2924 
3998-
0079 
 
0.0 0.5 
5311-
0360 
 
CM301 
 
0.4 0.3 
8008-
9631 
 
CM308 
 
0.3 0.3 
8008-
0704 
 
CM309 
 
0.0 0.0 
8011-
8027 
 
CM302 
 
0.4 0.5 
8013-
9940 
 
0.3 0.5 
C189-
0365 
 
0.3 0.5 
Chem 
Div 
Structure 
Ratio to 
Control 
1 2 
C226-
4110 
 
CM303 
 
0.4 0.4 
C226-
4114 
 
0.3 0.5 
C521-
0306 
 
0.3 0.5 
C548-
3890 
 
CM304 
 
0.4 0.1 
C638-
0449 
 
CM305  
0.3 0.4 
C699-
0515 
 
0.4 0.4 
C699-
0244 
 
CM306  
Analog to 
C699-
0515 
K788-
2754 
 
0.5 0.5 
K938-
0803 
 
CM307  
Analog to 
K788-
2754 
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